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Summary 
Hereditary spastic paraplegias (HSPs) are a large group of inherited neurodegenerative 
disorders characterised by a progressive spasticity and weakness of the lower limbs. 
Additional symptoms variably occur and define so-called complicated forms of the disease. 
HSPs exhibit a very high genetic and clinical variability, with at least 84 loci identified and 67 
known causative genes. They can be inherited in autosomal dominant, autosomal recessive, 
and X-linked manner. However, they all share a common trait: a progressive length-
dependent distal axonopathy of the motor neurons that form the corticospinal tracts. 
The use of whole exome sequencing (WES) has dramatically increased the speed of gene 
discovery in HSP. This technique granted the conjunct identification of the five genes 
described here, which are responsible for causing different forms of spastic paraplegia: 
SPG28, SPG46, SPG26, SPG54 and SPG58. These genes are respectively involved in 
mitochondrial function, different aspects of lipid metabolism and RNA metabolism. 
The in-depth study of SPG58 shows how mutations in KIF1C alter the cellular localization of 
KIF1C protein and affect endogenous protein levels if mutations locate to the ATP-binding 
domain.  This work also elucidates that KIF1C interacts with known RNA-binding proteins 
(RBPs) and that it also binds RNA directly and is thus itself an RBP. Transcripts bound to 
KIF1C correspond to genes involved in key mechanisms of cell cycle and gene regulation and 
in various aspects of RNA metabolism. In addition to the enrichment of ribosomal RNAs, 
KIF1C also interacts with ribosomal proteins and influences cellular ribosome distribution. 
This suggests that KIF1C might have a role in the regulation and or transport of ribosomes. 
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Synopsis 
I. Hereditary Spastic Paraplegias 
HSPs are a diverse group of inherited neurodegenerative disorders characterized by 
progressive spasticity and weakness of the lower limbs. Although they are overall rare with a 
prevalence of about 4 - 6 per 100.000 individuals (1), they are among the most 
heterogeneous Mendelian diseases. Up to date, at least 84 different loci have been 
associated with HSPs and 67 corresponding spastic paraplegia genes (SPG) have been 
identified (2) (Figure 1). 
All Mendelian modes of inheritance: autosomal dominant, autosomal recessive and X-linked 
have been described in HSP. SPG4 is by far the most common subtype and mutations in the 
associated SPAST gene explain about 50% of autosomal dominant HSP cases. The majority of 
the remaining subtypes are rare and individually account for less than 5% of cases. Clinically, 
HSPs are classified into pure and complex forms depending on the absence or presence of 
additional signs and symptoms. Common complicating features comprise peripheral 
neuropathy, muscle atrophy, cerebellar ataxia, mental retardation and/or dementia, 
epilepsy, optic neuropathy, deafness, and many others (3).  Complicated forms therefore 
phenotypically overlap with other neurodegenerative disorders such as amyotrophic lateral 
sclerosis (ALS), hereditary cerebellar ataxias, Charcot-Marie Tooth (CMT) disease, epileptic 
encephalopathies, and others (4–6). These phenotypic overlap-syndromes further increase 
the genetic heterogeneity of HSP and related disorders.  
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Figure 1. Overview over known 
HSP loci and genes. HSP loci are 
named by the acronym SPG (Spastic 
Paraplegia Gene), followed by a 
number. All modes of inheritance 
occur: X-linked (yellow), autosomal 
dominant (green) and autosomal 
recessive (orange). Reference: 
Schule, R. and L. Schols, Genetics of 
Hereditary Spastic Paraplegias (HSP), in 
Movement disorder genetics, S.A. 
Schneider and J.M.T. Brás, Editors. 2015, Springer Berlin Heidelberg: New York, NY. p. 353-385. 
 
Due to poor phenotype-genotype correlation and the extraordinary genetic heterogeneity, 
molecular diagnostic testing in HSP based on single-gene analysis has posed a huge challenge 
in clinical practice. Identification of novel disease genes required large pedigrees to allow 
meaningful linkage analysis, followed by often time consuming screening of candidate genes 
by Sanger sequencing or related techniques. The advent of Next Generation Sequencing 
(NGS) technology has revolutionized both diagnostic testing as well as research-based gene 
identification studies. This has led to an exponential increase in the number of newly 
identified HSP genes (Figure 2). Moreover, unbiased screenings of HSP genes in large cohorts 
of patients have led to a broadening of the phenotypic spectrum of many HSP subtypes, thus 
even increasing the phenotypic overlap with other hereditary neurodegenerative disorders. 
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Figure 2. Number of HSP genes published by 
year. Bars represent the number of HSP genes 
published per year (not cumulative). First WES 
publications came out in 2011. 
 
In spite of their high clinical and genetic variability, all HSPs share a common pathological 
hallmark in form of a progressive length-dependent distal axonopathy of the motor neurons 
that comprise the corticospinal tracts. Identification of disease genes in HSP has thus not 
only clinical applications but offers a chance to identify pathways that are important for axon 
formation and maintenance. Several cellular processes and pathways with its responsible 
proteins have been identified in HSP pathogenesis (Figure 3). For instance SPAST (SPG4) and 
KIF5A (SPG10) are involved in axonal transport (7, 8); ATL1 (SPG3) and REEP1 (SPG31) in 
endoplasmic reticulum membrane modelling and shaping (9); PARAPLEGIN (SPG7) is 
essential for mitochondrial function (10); AP5Z1 (SPG48), MARS (SPG70) and NT5C2 (SPG65) 
are involved in DNA repair and nucleotide metabolism (11, 12); SPATACSIN (SPG11) and 
SPASTIZIN (SPG15) in autophagy (13); CYP7B1 (SPG5), B4GALNT1 (SPG26), DDHD1 (SPG28) 
FA2H (SPG35), GBA2 (SPG46), DDHD2 (SPG54) are all involved in diverse aspects of lipid 
metabolism (14–19); NIPA1 (SPG6) and SPARTIN (SPG20) in cellular signalling for protein 
morphogenesis (20); and the family of adaptors AP4 (SPG47,50-52) or Strumpellin (SPG8) 
(part of the WASH complex) are involved in endosome membrane trafficking and vesicle 
formation (21).  
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Figure 3. Network of HSP-associated proteins based on protein-protein interactions and functional 
annotations. The iRefScape plugin in Cytoscape was used to generate a protein-protein interaction 
map based on iRefIndex (includes BIND, BioGRID, CORUM, DIP, HPRD, InnateDB, IntAct, MatrixDB, 
MINT, MPact, MPIDB and MPPI). The resulting network was then uploaded to Gephi and clustered by 
modularity. Clusters were functionally annotated using ConsensusPathDB; over-representation 
analysis for pathways and GO terms was performed and the resulting significant pathways/terms for 
each cluster were then overlaid manually onto the network. Reprinted with permission from Dana 
Bis, University of Miami. 
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The huge variety of functional mechanisms involved makes the heterogeneity of the disease 
very tangible. However there are still cases to be solved and therefore it is plausible that 
other important pathways, such as RNA metabolism, could also be altered in HSP 
pathogenesis. The continuous discovery of new HSP genes has shed light into the overall 
picture of this network and it is helping to link existing affected pathways, which improves 
the way we can address and understand the disease. 
 
II. Gene identification in HSPs 
In spite of the large number of genes already identified in HSP, mutations in these genes still 
only explain about 70% of autosomal dominant and less than half of autosomal recessive 
and sporadic cases (22). We therefore employed a WES-based approach to identify novel 
genes causing autosomal recessive HSP.  
Our centre runs one of the largest HSP specialty clinics in the world and has collected 
detailed clinical data and biomaterials of > 1000 HSP cases, including 544 simplex cases with 
HSP, 115 families with multiplex recessive HSP and 557 autosomal dominant pedigrees. 
From this cohort we selected multiplex recessive families, where several affected and 
unaffected family members were available, in which Sanger sequencing based approaches 
had so far failed to provide a genetic diagnosis. WES was carried out at the Hussman 
Institute for Human Genomics at the University of Miami Miller School of Medicine 
(collaboration: Stephan Zuchner). Data were then analysed using the web-based 
GEM.app/Genesis platform developed by the Zuchner lab (23). Resulting exome variants 
were filtered for allele frequency in public databases and GEM.app/Genesis, segregation 
pattern, variant ontology, and genotyping quality; resulting variants were then prioritized 
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based on conservation across species and predicted effect on protein function. In ~27% of 
families we identified pathogenic mutations in known autosomal recessive genes associated 
with HSP and related disorders. In the remaining families we created shortlists of candidate 
genes, typically between 1 and 20 genes per family. Sanger sequencing in additional family 
members was then performed to evaluate the segregation pattern within the family and 
thus reject variants based on failed co-segregation with the disease. The resulting final 
candidate gene lists were then intersected across families both within our own cohort as 
well as with candidate genes obtained by international collaborators. In genes mutated in 
two or more families with a similar phenotype additional genetic as well as functional 
evidence was then obtained as detailed below.  
SPG28 
WES in two brothers of Turkish origin and consanguineous family background revealed a 
homozygous truncating mutation (c.1874delT) in the DDHD1 gene. Both affected siblings in 
Family THI26002 showed progressive spastic gait developing since adolescence, complicated 
by a mild cerebellar oculomotor phenotype in one of them. Sanger segregation confirmed 
co-segregation of the mutation with the disease. Identification of two additional HSP families 
with truncating DDHD1 mutations led to our joint identification of DDHD1 as a novel HSP 
gene (SPG28) (17) (paper attached). DDHD1 is a phospholipase that hydrolyses phosphatidic 
acid (PA) and is transiently associated with cytosolic membranes. We demonstrated that 
DDHD1 causes mitochondrial dysfunction, including reduced respiration and ATP production. 
As PA is a natural substrate for DDHD1 it can be speculated that the mitochondrial 
bioenergetic dysfunction observed in DDHD1 deficiency, might be a result of an 
accumulation of PA in the mitochondria (24). Mitochondrial dysfunction could also result 
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from an altered mitochondrial morphogenesis, as in Paraplegin mutations (25) or from a 
mitochondrial respiratory impairment, due to increased reactive oxygen species (ROS) as 
observed in SPG28 cells. Such overproduction of ROS could play a role in neuronal 
degeneration, as previously suggested for HSP pathophysiology (26). 
SPG46 
In a Turkish family (F18310) with consanguineous family background and two siblings 
affected by spastic ataxia we were able to narrow down the candidate gene list carrying rare 
homozygous coding variants to 22 genes. GBA2 was the only gene harbouring a truncating 
mutation. Sanger sequencing confirmed that both affected siblings in this family carried the 
nonsense homozygous mutation c.700C>T (p.Arg234*) in the GBA2 gene. A targeted query 
of GBA2 across the GEM.app/Genesis database pointed us to a Belgian family (de Jonghe 
group, Antwerp) with a similar phenotype also carrying two truncating GBA2 alleles, thus 
adding genetic evidence towards the pathogenicity of GBA2 variants. Finally, collaboration 
with additional partners allowed us to increase the total number of GBA2 families to four 
and publish our findings in the American Journal of Human genetics (19) (paper attached). 
Affected SPG46 family members presented a complex HSP phenotype characterized by 
cerebral and cerebellar atrophy, thinning of the corpus callosum, cataract and 
hypogonadism in males.  
GBA2 is a non-lysosomal glucosylceramidase that hydrolyses glucosylceramide into glucose 
and ceramide. It also catalyses the reverse reaction by adding glucose to diverse lipid 
substrates (27). GBA2 is thus involved in key aspects of sphingolipid metabolism. It 
synthetises various signalling molecules and plasma membrane components which are 
essential for composition and dynamics of membranes (28). GBA2 localises to the 
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endoplasmic reticulum (ER) and the cell surface, where ceramide molecules produced by this 
enzyme are used to synthetize sphingomyelin (29).  
Pathogenic GBA2 mutations resulted in a complete loss of enzymatic function in both 
untransformed leukocytes and lymphoblasts from affected SPG46 patients (19). Loss of -
glucosylceramidase activity thus suggests a link between glucosylceramide metabolism and 
HSP pathogenesis.  
SPG26 
Three out of 10 siblings of Family THI26004 were affected by childhood onset cognitive 
disability, followed about a decade later by a predominantly lower limb spastic tetraparesis 
with pseudobulbar dysarthria, and organic psychosis. The family originated from a small 
village in former Yugoslavia, making a founder mutation likely. Exome sequencing in one 
affected sibling yielded possible biallelic variants in a total of 3 candidate genes (2 with 
potentially compound heterozygous and 1 with homozygous changes), including a 
homozygous missense mutation in B4GALNT1 (c.1298A>C, p.N433A). We matched these 
disease gene candidates with results from our collaborators and were able to identify a total 
of seven families with mutations in the B4GALNT1 gene (14) (paper attached). 
B4GALNT1 encodes the enzyme β-1,4-N-acetyl-galactosaminyl transferase 1 which is 
involved in the biosynthesis of complex gangliosides. Gangliosides belong to the large family 
of glycosphingolipids, components of the synaptic plasma membrane involved in synaptic 
plasticity, signal transduction and endocytosis, which are essential for CNS development 
(30). B4GALNT1 catalyses the transfer of N-acetyl-galactosamine into ganglioside mono- and 
di- sialic acid 3 (GM3, GD3) and globotriaosylceramide, therefore mutations in B4GALNT1 
will lead to a deficit of gangliosides G[M/D/T]3 and globotriaosylceramide. Concomitantly, 
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the B4galnt1 -/- mouse resembles to a certain extent the gait phenotype seen in SPG26. Lack 
of complex gangliosides in SPG26 might reduce myelination in the spinal cord, thus resulting 
in degeneration due to increased unmyelinated fibres (31).  
SPG54 
Following the same strategy of WES and Sanger confirmation in family THI26003 we were 
able to identify DDHD2 as the gene causing spastic paraplegia 54 (SPG54) (32) (paper 
attached). The SPG54 phenotype is characterized by early onset of spasticity, mental 
retardation, short stature and dysgenesis of the corpus callosum. Sequencing results 
revealed that both affected siblings in THI26003, a consanguineous family from Azerbaijan, 
presented a homozygous nonsense variant in DDHD2 (c.859C4T, p.Arg287*). The transcript 
containing this early stop codon produces – if it escapes nonsense mediated decay - a 
protein lacking the DDHD catalytic domain. This domain ensures membrane localization, 
phosphoinositide binding and homo-oligomerization; loss of this domain therefore likely 
leads to a loss of crucial DDHD2 functions. DDHD2 is phospholipase, and like DDHD1, also 
possesses phospholipase A1 activity to catalyse phosphatidic acid (PA) and other 
phospholipids (33). PA is an essential structural component of biological membranes, it is 
involved in lipid signalling and it is also a substrate for the biosynthesis of triacylglycerols and 
phosphoglycerols (34). A cytosolic and membrane-associated pool of DDHD2 localises to the 
ER-Golgi intermediate compartment (ERGIC). This pool may be involved in membrane 
trafficking because DDHD2 overexpression leads to Golgi dispersion and ERGIC enlargement 
(35). DDHD2 involvement in lipid metabolism and Golgi-ER membrane trafﬁcking highlight 
the importance of these mechanisms for motor neuron maintenance and sheds light into the 
complex network of HSP pathogenesis.  
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SPG58 
Lastly, WES of the index patient of family THI26001 permitted the identification of two 
compound heterozygous missense mutations in KIF1C c.[305G>C];[527C>T], 
p.[Gly102Ala];[Pro176Leu]. Sanger sequencing of this German family confirmed co-
segregation of these variants with the disease. The other two affected siblings also carried 
both heterozygous missense mutations, while each of the parents presented one of the 
heterozygous mutations. Targeted analysis of KIF1C in the Genesis/GEMapp database 
allowed identification of Family IHG25215, of Turkish origin and consanguineous family 
background, also carrying mutations in KIF1C. The less severely affected brother of this 
family ported the heterozygous missense variant c.901A>G, p.Arg301Gly whereas the 
severely affected brother carried the variant in homozygous state. The identification of these 
three different missense mutations in these two families and their later characterization 
allowed us to conclude that mutations in KIF1C cause spastic paraplegia type 58 (SPG58) (36) 
(paper attached). Therefore we defined SPG58 as a new form of spastic paraplegia which can 
be complicated by cervical dystonia and cerebellar ataxia.  
 
III. KIF1C, what is known?  
Prior to KIF1C involvement in human neurodegeneration, diverse functions for the motor 
had been described. These included retrograde vesicle transport from Golgi apparatus to the 
endoplasmic reticulum in mouse fibroblast cells (37), regulation of podosome dynamics in 
primary human macrophages (38), control of pericentrosomal localization and anterograde 
transport of Rab6 secretory vesicles in hippocampal neurons, when interacting with BICDR-1 
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(39), and transport of α5β1-integrins to stabilize trailing focal adhesions in migrating human 
RPE1 cells (40). 
Recent investigations also describe how the role of KIF1C in podosome formation and 
maintenance in human macrophages is influenced by microtubule acetylation (41), and 
induced by protein kinase C (PKC) which prompts KIF1C to translocate to the cell periphery in 
a CLASP dependent manner (42). Furthermore, KIF1C has been reported to transport Rab6A-
vesicles and influence Golgi’s membrane organization through its direct binding with Rab6A 
via both its motor and C-terminus domain, which causes a reduction in KIF1C motility (43).  
In spite of this broad and diverse functional spectrum, KIF1C had never been reported as an 
axonal transporter nor had it been linked to neurodegeneration. Therefore, a different 
approach was needed to tackle KIF1C role in motor neurons and its involvement in SPG58 
pathogenesis. 
 
IV. Characterization of SPG58 mutations  
Analysis of mRNA expression levels of KIF1C in all members of family THI26001 revealed that 
expression did not differ significantly between the compound heterozygous affected siblings 
and the heterozygous parents. In contrast, analysis of protein levels showed a reduction of 
about 50% in all carriers of the c.305G>C mutation when compared to controls or the 
heterozygous mother (carrier of c.527C>T change) (36) (paper attached). The c.305G>C allele 
therefore likely translates into a protein that is recognized as non-functional and is therefore 
targeted for degradation.  
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KIF1C belongs to the super family of kinesins, and has been defined as a retrograde (37) and 
anterograde (40) microtubule-based transporter. All mutations found in our HSP families 
reside in the protein’s motor domain; more precisely they are located at the ATP-binding 
domain (p.G102A), the Loop 8 microtubule-binding domain (p.P176L) and the Loop 12 
microtubule-binding domain (p.R301G). Therefore, mutations within these locations will 
likely affect processivity of KIF1C. KIF1C is expressed ubiquitously and is sparsely distributed 
in the cytoplasm, accumulating around the nucleus and the centrosome. When 
overexpressed in COS-7 cells, we found that KIF1CWT tended to redistribute to the cell 
periphery and accumulate at the verges of cellular protrusions. However, overexpressed 
mutant KIF1CG102A or KIF1CR301G failed to reach the tips of cellular processes, showing instead 
a non-specific cytoplasmic localisation. Overexpressed KIF1CP176L surprisingly showed a 
distribution comparable to that of KIF1CWT (36). Patients simultaneously express two 
pathogenic KIF1C alleles; in the case of family THI26001 the affected siblings carry both the 
P176L and the G102A mutation, while the unaffected parents carry only one mutation in 
combination with a wildtype allele. To mimic this situation in cell culture we therefore 
performed double-overexpression of different KIF1C alleles. The mis-localisation of the 
mutant KIF1CG102A can be almost completely rescued by simultaneous overexpression of 
KIF1CWT. In contrast, KIF1CP176L fails to rescue the mis-localisation caused by expression of 
mutant KIF1CG102A allele (36). We hypothesize that this might be explained by a reduced 
microtubule binding affinity of the KIF1CP176L allele. Therefore the KIF1CP176L allele, despite its 
putatively normal mobility, fails to make up for KIF1CG102A’s motility defect in dimeric state. 
The transport deficit caused by KIF1C mutations likely translates into a lack of cargo delivery 
at the verge of cellular processes (i.e. at the synapse in neurons) essential for synapse 
maintenance and cell survival in motor neurons. 
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V. Determination of KIF1C function  
With whom does KIF1C interact? 
To better understand KIF1C function we decided to look for interaction partners, because 
identification of new protein interactors may shed light on previously unknown functional 
pathways. To this end we immunoprecipitated KIF1C complexes in HEK293T cells 
overexpressing KIF1CWT or KIF1CMUT (G102A, P176L) (manuscript attached). Mass 
spectrometry analysis of a protein band of about 70 KDa revealed the presence of several 
RNA-binding proteins: PABPC1 (PABP), IGF2BP1 (IMP-1), IGF2BP3 (IMP-3) and HSPA8, all of 
them known to be involved in a certain aspect of RNA metabolism (44–46). Mutual 
interactions between KIF1C and candidates PABP, IMP-1 or HSPA8 could be confirmed by 
western-blotting of co-immunoprecipitated complexes in HEK293T cells. Moreover, 
immunofluorescent (IF) imaging of fibroblast-like COS-7 cells and neuron-like SH-SY5Y cells 
confirmed the co-localisation of KIF1C with all three putative novel interaction partners. In 
addition, quantitative analysis of KIF1C complexes demonstrated that mutations in the KIF1C 
motor domain (KIF1CG102A, KIF1CP176L, KIF1CR301G) have no effect on binding properties, at 
least in an overexpression setting.  
KIF1C binds RNA 
The fact that PABP, IMP-1 and HSPA8 are known RNA-binding proteins raised the question of 
whether KIF1C might as well share that role. The way we addressed this possibility, with an 
RNAse-mediated IP, permitted to elucidate that KIF1C-PABP interaction is RNA dependent. 
Co-Immunoprecipitation (CO-IP) of HA-tagged fusion protein KIF1C-HA with PABP in 
HEK293T lysates demonstrated that the mutual interaction diminishes with increasing 
concentrations of RNAse I, an enzyme that hydrolyses single-stranded RNA to nucleoside 3'-
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monophosphates. This outcome was not compromised by an under-representation of PABP, 
because mutual CO-IP of fusion proteins KIF1C-HA and PABP-GFP was likewise RNAse-
sensitive. Moreover, CO-IP of endogenous KIF1C and PABP in HeLa lysates was equally 
abolished after RNAse I addition (manuscript attached). Consistency of these results proved 
that PABP-KIF1C interaction is RNA-mediated and suggested that KIF1C could bind RNA 
directly and thus be an RBP itself. 
To test this hypothesis and identify potential transcripts bound to KIF1C we performed an 
individual-nucleotide resolution crosslinked immunoprecipitation (iCLIP) (47) in HEK293T 
cells transiently expressing the fusion protein KIF1C-mCherry. The iCLIP protocol notably 
includes an UV-light irradiation step, which leads to formation of covalent bonds at sites of 
protein-RNA interaction, thus specifically preserving direct protein-RNA interactions during 
the following rigorous washing and purification steps (48). iCLIP interactions are therefore 
highly specific. This procedure permitted detection of positive RNA signal and isolation of 
RNA fragments ranging between 250-450bp (retro-transcribed to cDNA) which were bound 
to KIF1C. 
Analysis of RNA transcripts bound to KIF1C 
Recovered RNA fragments were used to create a cDNA library that was submitted to high-
throughput sequencing and resulted in an average of 157 million read-pairs. Later alignment 
with Galaxy, a web-based genome analysis tool (49), mapped an average of 48 million read-
pairs to the genome. Subsequent analysis with PIPE-CLIP, a tool that provides data 
processing and statistical analysis to determine candidate protein-RNA cross-linking regions 
(50), showed that the transcripts mapped to a total of 515 unique genes (manuscript 
attached). The top four genes represented by transcripts with the highest peak scores were 
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KIF1C, HYDIN (hydrocephalus inducing protein homologue) and two ribosomal DNA genes: 
RNA45S5 from which the ribosomal 28S, 5.8S, and 18S subunits are transcribed, and RNA5-
8S5 that encodes the ribosomal 5S subunit.  
Validation of transcripts found after iCLIP data analysis was performed using recovered RNA 
from an RNA-IP of HEK293T lysates (from both endogenous and KIF1C overexpressed 
conditions) and quantitative PCR. For this purpose we chose five genes KIF1C, HYDIN, HFM1, 
PDE3 & RAPGEF, all of which were among the 10 highest scoring genes in the analysis. The 
assay proved not only the presence of the five genes in the KIF1C-IP sample but also their 
over-representation in comparison to the input sample, thus confirming the results from 
iCLIP data analysis. 
To uncover functional connections of bound transcripts and analyse functionally over-
represented pathways we used DAVID (51), a web resource that allows annotation of genes 
with terms derived from multiple databases including GO terms, KEGG and Panther 
pathways, BioGrid and many more,  and constructed a network of overrepresented 
pathways in Cytoscape. Strongly enriched functions include RNA/DNA binding, RNA 
processing and splicing, gene expression and cell cycle. These results reflect the importance 
of KIF1C as an RBP in RNA metabolism and its involvement in further key cellular functions; 
none of which had been previously described for KIF1C. 
KIF1C interacts with Ribosomes 
The strong over-representation of RNA-related functional pathways among of transcripts 
bound to KIF1C, plus the enrichment of rRNA transcripts, suggested that KIF1C might 
cooperate with ribosomes. Therefore we studied the interaction between KIF1C and the 
ribosomal protein S6 (RPS6), a ribosomal marker that has been previously used to measure 
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dendritic mRNA transport in form of RNA granules in hippocampal neurons (52).  
Immunofluorescent imaging revealed that KIF1CWT overexpression induces a ribosomal 
recruitment to the cell periphery and accumulation at the tips of cellular processes; whereas 
KIF1CG102A overexpression causes a redistribution of ribosomes to the cytoplasm. Ribosomal 
localization thereby strictly follows the localization pattern of overexpressed KIF1C. 
Moreover KIF1C-ribosome interaction is supported by the mutual co-immunoprecipitation of 
KIF1C and RPS6, as shown by western blotting (manuscript attached). These findings strongly 
suggest that KIF1C interacts with ribosomes and strengthen our hypothesis that KIF1C is an 
axonal transporter for ribosomes in neurons that might be involved in maintenance and 
regulation of synaptic translation through transport and regulation of local protein 
translation. 
 
VI. Conclusion 
Gene discovery in HSPs has progressed enormously over the last few years thanks to the use 
of whole-exome sequencing in clinical practice. This technique facilitated the discovery of 
five distinct spastic paraplegia genes during the course of this study: SPG28, SPG46, SPG26, 
SPG54 and SPG58, respectively involved in mitochondrial function, different aspects of lipid 
metabolism and RNA metabolism. 
SPG58 mutations located in the motor domain provoke a change in KIF1C distribution and 
impact protein stability if the mutation localises to the ATP-binding domain. KIF1C directly 
binds RNA as well as RNA-binding proteins. Transcripts bound to KIF1C map preferentially to 
RNA-related cellular processes and ribosomal components are strongly enriched among 
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KIF1C-bound transcripts. Overexpression of KIF1C recruits ribosomes to the tips of cellular 
processes, a distribution that is lost when overexpressing mutant KIF1C.  
In conclusion we hypothesize that KIF1C transports ribosomes along the axons and is 
involved in regulation of local protein translation at the synapse. Alteration of RNA transport 
and regulation of translation, caused by mutations in RNA-binding proteins, is increasingly 
recognized as an important pathogenic mechanism in other neurological and 
neurodegenerative diseases such as ALS and Fronto-Temporal Dementia (FTD) (53), however 
it would be the first case in HSP pathogenesis.  
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Alteration of Fatty-Acid-Metabolizing Enzymes
Affects Mitochondrial Form and Function
in Hereditary Spastic Paraplegia
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Mohamed Yahyaoui,12 Ibrahim Al Abdulkareem,9 Stephan Zuchner,20 Atsushi Yamashita,23
Ali Benomar,12,24 Cyril Goizet,6,22 Alexandra Durr,1,2,3,11 Joseph G. Gleeson,25 Frederic Darios,1,2,3
Alexis Brice,1,2,3,11,* and Giovanni Stevanin1,2,3,4,11,*
Hereditary spastic paraplegia (HSP) is considered one of the most heterogeneous groups of neurological disorders, both clinically and
genetically. The disease comprises pure and complex forms that clinically include slowly progressive lower-limb spasticity resulting
from degeneration of the corticospinal tract. At least 48 loci accounting for these diseases have been mapped to date, and mutations
have been identified in 22 genes, most of which play a role in intracellular trafficking. Here, we identified mutations in two functionally
related genes (DDHD1 andCYP2U1) in individuals with autosomal-recessive forms of HSP by using either the classical positional cloning
or a combination of whole-genome linkage mapping and next-generation sequencing. Interestingly, three subjects with CYP2U1muta-
tions presented with a thin corpus callosum, white-matter abnormalities, and/or calcification of the basal ganglia. These genes code for
two enzymes involved in fatty-acidmetabolism, and we have demonstrated in human cells that the HSP pathophysiology includes alter-
ation of mitochondrial architecture and bioenergetics with increased oxidative stress. Our combined results focus attention on lipid
metabolism as a critical HSP pathway with a deleterious impact on mitochondrial bioenergetic function.Introduction
Hereditary spastic paraplegia (HSP), also known as Stru¨m-
pell-Lorrain disease, is recognized as one of the most clin-
ically and genetically heterogeneous groups of inherited
neurodegenerative disorders. These disorders are mainly
characterized by slowly progressive lower-limb spasticity
that worsens over time. The symptoms are the conse-
quence of corticospinal-tract degeneration.1–3 Affected
subjects are clinically classified according to the absence
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The American Joucomplex HSP) of additional neurological or extraneurolog-
ical signs. This clinical heterogeneity partially underlies
the large genetic heterogeneity of this group of disorders;
at least 48 loci have been mapped to date and account
for all classical modes of inheritance.4,5 So far, mutations
have been identified in 22 genes,5 most of which play
a role in intracellular trafficking.6–8
Autosomal-recessive HSP (AR-HSP) is less common than
the autosomal-dominant form, except in countries with
a high rate of consanguinity.9,10 It is more often associated
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disease can be due to mutations in SPG5/CYP7B1 (MIM
603711), SPG7/PGN (MIM 602783), and SPG30/KIF1A
(MIM 601255) or can be linked to SPG28 (MIM
609340).11–15 Mutations in SPG11/KIAA1840 (MIM
610844) account for ~20% of the autosomal-recessive
(AR) forms,16 but many genes remain to be discovered
given that 60% of AR-HSP is still genetically unex-
plained.5
Here, we report the identification of causative mutations
in two genes after the use of next-generation sequencing
focused on all exons of the SPG28 interval, as well as
linkage mapping combined with systematic candidate-
gene analysis in SPG49, identified in this study. These
combined approaches enabled us to identify in individuals
from three families four truncating mutations in DDHD1
(MIM 614603), encoding for a phosphatidic-acid (PA)-
preferring phospholipase A1. In subjects from five different
families, we also found five mutations in CYP2U1 (MIM
610670), encoding a P450 hydroxylase. We demonstrate
in human cells that the pathophysiology of SPG28 and
SPG49 includes alteration of mitochondrial architecture
and bioenergetics with increased oxidative stress.Subjects and Methods
Subjects
Ninety-nine index individuals from families affected by AR-HSP
and without identified mutations in SPG11, SPG5, and SPG7,
were included in this study and originated mainly from France,
Italy, the Middle East, and North Africa. This study was approved
by the local Bioethics Committee (approval number 03-12-07
from the Comite´ Consultatif pour la Protection des Personnes et
la Recherche Biome´dicale Paris-Necker to A. Durr and A. Brice).
Written informed consent was signed by all index persons and
by 39 additional participating members of the families before
blood samples were collected for DNA extraction. All clinical eval-
uations included a full medical history and examination, estima-
tion of the age of onset, observation of additional neurological
signs, electroneuromyographic studies, and, when possible, brain
MRI and/or computed-tomography (CT) scans.
Next-Generation Sequencing in Family FSP445
After exclusion of large genomic rearrangements in the SPG28
linkage interval by comparative genomic hybridization (CGH) in
subjects FSP445-V.3 and FSP445-V.1 by chromosome-14-specific
385K NimbleGen arrays (data not shown), targeted enrichment
and next-generation sequencing were performed on the DNA of
individual FSP445-V.3 from the original SPG28-affected family.11
Enrichment of all 723 exons in chr14: 49,100,775–55,305,189
was performed by hybridization of shotgun fragment libraries to
a custom Roche NimbleGenmicroarray according to the manufac-
turer’s recommendations. Threemicrograms of amplified enriched
DNA was used as input for massively parallel sequencing on
a Roche 454-GS-FLX sequencer with Titanium reagents. Sequence
data were then aligned with hg18 human genome as a reference.
In total, 285,704 reads were obtained with an average length of
399 bp; 283,483 (99%) of those reads could be mapped, and
68% of them were on target. From the total of 723 enriched
regions, 689 (95%) were covered entirely, and 99% of targeted1052 The American Journal of Human Genetics 91, 1051–1064, Decebases were covered at least 103 (95% of all captured exons were
covered entirely). The real coverage of enriched regions was
803. Variants with fewer than three reads or accounting for less
than 25% of all reads were excluded from the analysis. A total of
1,062 variations were identified. We excluded known validated
SNPs present in dbSNP and the HapMap database. As expected,
88 of the remaining 239 variants were homozygous in this disease:
17 were intergenic, 63 were intronic, and 8, including 2 exonic
variants, were in the mRNA.
Genome-wide Scan in Family FSP719
Exclusion of linkage to some of the most common AR-HSP-
associated loci (SPG5, SPG15 [MIM 270700], SPG24 [MIM
607584], SPG28, SPG30, and SPG32 [MIM 611252]) and of muta-
tions in SPG7 and SPG11 was performed prior to this study (data
not shown).
A genome scan with 6,090 SNP markers (LINKAGE_V panel,
Illumina) covering all chromosomes was performed on family
FSP719. Genotypes were generated with BeadStudio software
(Illumina) and analyzed with MERLIN 1.0,17 and all family
members were considered. An AR inheritance, a penetrance of
95% without phenocopy, a disease allele frequency of 0.00001,
equal allele frequencies for each marker, and equal male-female
recombination rates were considered.
Linked and uninformative regions were explored by genotyping
of 47 additional microsatellite markers in all family members. PCR
amplicons were resolved on an ABI 3730 sequencer with the use
of fluorescent primers, and the results were analyzed with
GeneMapper 4 (Applied Biosystems). We manually constructed
haplotypes by minimizing the number of recombination events.
Genetic distances were taken from the MAP-O-MAT consortium.
Candidate-Gene Analysis
After exclusion of large genomic rearrangements by CGH in one
person of SPG49-linked family FSP1015 (data not shown), all
coding exons of genes in the SPG49 candidate interval, including
flanking splicing sites and at least 50 bp of intronic sequence on
each side,were analyzedbydirect sequencing (primers are available
from the authors upon request) with BigDye Chemistry (Applied
Biosystems). The sequence products were run on an ABI 3730
sequencer, and electrophoretic profiles were compared with the
reference hg18 sequence with the use of SeqScape 2.5 (Applied
Biosystems).
Mutation screening of DDHD1 (RefSeq accession number
NM_030637.2; hg19) and CYP2U1 (RefSeq NM_183075.2; hg19)
was performed in 96 index cases by classical Sanger sequencing
(primers and PCR conditions are available upon request).
The effects of mutations and amino acid conservation in other
species were analyzed with ALAMUT 2.2 (Interactive Biosoftware),
PolyPhen-2, and MutationTaster.18,19
Rearrangement Analysis
Exon deletions or duplications in CYP2U1 and DDHD1 were
explored by quantitative multiplex PCR of short fragments
(QMPSF; primers and PCR conditions are available from the
authors upon request) and analyzed with GeneMapper 4.
Investigation of Mitochondrial Energetics and
Oxidative Stress
The mitochondrial respiratory rate was measured in lym-
phocytes and fibroblasts grown in RPMI 1640 medium andmber 7, 2012
DMEM, respectively, both of which contained 5 mM glucose and
2 mM glutamine (Glutamax) supplemented with 10% fetal
bovine serum (PAA), 100 U/ml penicillin, and 100 U/ml of
streptomycin. All experiments were performed with the same
number of flask divisions in culture between cases and controls.
For the lymphoblast cells (nonadherent), respiration was
measured in real time on 1 3 106 cells per ml by polarography,
with the use of the Hansatech Oxygraph system (Oxy 1,
Hansatech), at 37C in growth medium containing glucose and
glutamine as energy substrates. We assessed respiratory coupling
by adding oligomycin, a specific inhibitor of mitochondrial
F1F0-ATPsynthase, in the cuvette of the oxygraph. The coupl-
ing of mitochondrial respiration with ADP phosphoryla-
tion was evaluated by the ratio of the routine respiratory rate to
the rate measured in the presence of oligomycin (at steady
state). Respiration was expressed as ngatom O per min per one
million cells. Each cell culture was assayed at least three
times (minimum of three different cultures according to the
sample). For the fibroblasts, respiration was assayed on 96-well
plates with the extracellular flux analyzer XF96 (Seahorse
Bioscience).
The amount of mitochondria was compared on protein extracts
from lymphoblastoid cell lines by immunoblot analysis according
to standard procedures20 and by labeling of actin C4 (Abcam,
1/1,000) and TOM20 (BD Biosciences, 1/1,000). The total cellular
ATP content and the mitochondrial contribution to cellular ATP
production were measured by bioluminescence with the ATP
Roche assay Kit II on 1 3 106 cells as described elsewhere.21 The
concentration of reactive oxygen species was measured with
the CMH2DCFDA fluorescent probe on a fluorometer (SAFAS) as
previously reported.21
The measurement of respiratory-chain-enzyme activities was
performed spectrophotometrically with standardized techniques
as described previously.22 In brief, fibroblasts and lymphoblasts
of affected and control subjects were grown in DMEM or RPMI
and harvested at 70% confluency. We performed cell- and mito-
chondrial-membrane disruption by freezing the cells in liquid
nitrogen, thawing them at room temperature, and subsequent
sonication. Total protein content was measured with the bicin-
choninic acid assay, and maximal activities of respiratory-chain
complex I (NADH: ubiquinone oxidoreductase), complex II
(succinate dehydrogenase), complex III (ubiquinol cytochrome
c reductase), and complex IV (cytochrome c oxydase) were
assayed at 30C and expressed as nmol/min/mg of protein. Mito-
chondrial transmembrane electric potential (Dc) was measured
on a fluorometer (SAFAS Xenius) with the potentiometric dye
tetramethylrhodamine methyl esther (TMRM) obtained from
Invitrogen as previously detailed.23mRNA-Expression Analysis
Total RNA was extracted from various tissues and different devel-
opment stages of four wild-type c57bl6 mice with the RNeasy
Mini kit (QIAGEN) and was used for generating cDNA with the
Superscript III First-Strand Synthesis SuperMix for quantitative
RT-PCR (Invitrogen). Real-time quantitative expression analysis
of DDHD1, CYP2U1, and RAD51 (control [MIM 179617]) was per-
formed on a Roche LC480-1536 with QIAGEN Quantitect primer
assays in triplicate. Expression levels relative to PGK1 (MIM
311800) or PP1A, used as reference genes, were determined with
qbase Plus software (Biogazelle) and were then compared with
the Pearson test.The American JouIn lymphoblasts from individuals FSP445-4 and FSP445-6, we
analyzed the effect on mRNA splicing of a variant affecting the
last codon of exon 7 of DDHD1 and predicted to alter splicing
by the Splice Site Prediction by Neural Network. This was done
on polyAþ RNA that was reversely transcribed with the 1st Strand
cDNA Synthesis Kit (Roche) according to the manufacturer’s
random primer protocol and was followed by subcloning and
direct sequencing of the PCR products with specific primers (avail-
able upon request).Overexpression Analysis
HeLa cells used for transient transfection of the CYP2U1 cDNA
fused to green fluorescent protein (GFP) (Origen) were maintained
in DMEM (Invitrogen) supplemented with fetal calf serum and
antibiotics (100 UI/ml penicillin and 100 mg/ml streptomycin).
Cells (10,000 cells per well) were transfected with the use of
Fugene Xtreme Gene according to the manufacturer’s instructions
(Promega). After 48 hr, cells were fixed with 4% paraformalde-
hyde, washed, permeabilized with 0.25% Triton/PBS, blocked
for 1 hr with 10% normal goat serum (NGS) before being incu-
bated for 1 hr with primary antibodies at room temperature in
3% NGS/PBS, and then washed in PBS and incubated for
45 min with secondary antibodies in 3% NGS/PBS. Cultures
were mounted with Vectashield HardSet Mounting Medium
(Eurobio) or counterstained with DAPI (1 mg/ml, Sigma) and
mounted with Fluoromount-G (Southern Biotech). Immunocyto-
chemistry was performed with the following primary antibodies:
rabbit anti-SDHA (Abcam), anti-Calregulin (Santa Cruz Biotech-
nology), and mouse anti-FLAG (Sigma). Secondary antibodies
were alexa-fluor 568 and 647 (Invitrogen) anti-mouse and anti-
rabbit. Images of CYP2U1 overexpression were acquired with
a Zeiss VivaTome microscope with a 603 objective. AxioVision
software (Zeiss) was used for analyzing one stack for visualizing
the colocalization. For quantitative colocalization analysis of
CYP2U1 with mitochondria or endoplasmic reticulum (ER), all
images were processed identically with MBF Image J software
and were quantified with Intensity Correlation Analysis plug-in
(ICA) as defined elsewhere.24 For each stack, similar background
signal was subtracted, and images were analyzed as a z-series
projection taken in intervals 0.2 mm deep. Two coefficients
were calculated for each cell: (1) Rr is the Pearson’s correlation
coefficient and ranges from 1 to þ1 (a value of 1 represents
perfect correlation, 1 represents perfect exclusion, and 0 repre-
sents random localization) and (2) ICQ is the intensity correlation
quotient in which colocalization is defined as the synchronous
increase or decrease in fluorescence intensities.24,25 The ICQ is
based on the nonparametric sign-test analysis of the PDM
(product of the differences from the mean) values and is equal
to the ratio of the number of positive PDM values to the total
number of pixel values. The ICQ values are distributed
between 0.5 and þ0.5 (0.5 represents a random staining,
and þ0.5 represents perfect overlap). Each experiment was per-
formed on three independent cells preparations, and 25–30 cells
were quantified for each condition.
Fibroblasts were transfected with a pCMV/mito/GFP vector
(Invitrogen) in which the Myc epitope was deleted26 with the
use of the Neon system (Invitrogen) according to the manufac-
turer‘s instructions. Twenty four hours after transfection, live cells
were observed on a Zeiss Axiovert 200 inverted video-microscope
with a 633 oil objective. Metamorph 7.7.7.0 software was used for
acquiring the image.rnal of Human Genetics 91, 1051–1064, December 7, 2012 1053
Figure 1. Mutations in DDHD1
(A–C) Family trees and segregation analysis of the mutations identified in families FSP445 (A), THI26002 (B) and FSP375 (C). Squares
represent males, circles represent females, diamonds indicate anonymized subjects, filled symbols represent affected individuals, and
a double line indicates consanguinity. The following abbreviations are used: M, mutation; þ, wild-type; and *, sampled individuals.
The electrophoregrams are shown in Figure S2.
(D) A graphical representation of DDHD1 (RefSeq NM_030637.2) on chromosome 14 indicates the DDHD domain (gray boxes) and the
location of the mutations (c.1249C>T [p.Gln417*], c.1766G>A [p.Arg589Gln; r.spl?], c.1874delT [p.Leu625*], and c.2438-1G>T [r.spl?])
(arrows). Black and white boxes represent coding and noncoding exons, respectively. The DDHD1 transcript is 5,603 bp long and is
composed of 12 exons that encode an 872 amino acid protein. There are three known isoforms of DDHD1; isoforms b and c are longer
than isoform a because they include an alternate in-frame coding exon (white box). The sequence contains a lipase consensus domain
and also includes a putative coiled-coil-forming region and a DDHD domain between residues 611 and 858 of isoform a; the four
conserved residues that can form ametal binding site are seen in phosphoesterase domains. This domain is found in retinal degeneration
B proteins, as well as in a family of probable phospholipases.Results
Identification of Mutations in SPG28/DDHD1
We previously described a consanguineous Moroccan
family (with AR inheritance) in which we mapped the
disease locus, SPG28, to chromosome 14q.11We sequenced
all exons of the SPG28 interval in one affected subject
(FSP445-V.3) from the original SPG28-affected kindred by
using a custom Roche-NimbleGen Capture assay and
massively parallel sequencing on a Roche 454-GS-FLX
sequencer. From 239 variants identified, we focused our
analysis on the two homozygous exonic variants not re-
ported as polymorphisms: (1) the c.427G>T (p.Ala143Ser)
transversion in SAMD4A (MIM 610747; RefSeq
NM_015589.4), encoding SMAUG1, an RNA-binding
protein involved in mRNA silencing and deadenyla-
tion in postsynaptic densities, and (2) the c.1766G>A
(p.Arg589Gln) variant located in the last nucleotide of
exon 7 of DDHD1 (encoding an enzyme of lipid metabo-
lism) and affecting correct DDHD1 mRNA splicing (Fig-
ure 1A, Figures S1 and S2, and Table S1, available online).
These two variants cosegregated with the disease and were
absent in controls. The deleterious nature of the DDHD11054 The American Journal of Human Genetics 91, 1051–1064, Decemutation let us focus on this gene. Further screening of
all DDHD1 coding exons by Sanger sequencing and
QMPSF in 96 index cases affected byHSPwith an unknown
genetic cause identified mutations absent in controls in
two individuals (Figures 1B and 1C, Figure S2, and Table
S1). One simplex French case (FSP375-II.1) harbored
heterozygous mutations c.1249C>T (p.Gln417*) and
c.2438-1G>T in exon 4 and intron 11, respectively. DNA
of relatives or mRNA was not available, so we could not
exclude that the mutations were in cis, although this is
unlikely given their rarity (Table S1). One Turkish boy
and his affected brother harbored the homozygous
c.1874del (p.Leu625*) mutation, which was also present
at the heterozygous state in their healthy parents.
Clinical data from the three additional SPG28-affected
subjects identified in this study extended the clinical spec-
trum of this disease compared to the pure phenotype origi-
nally described.11 When examined at 30 years of age, the
twoTurkishbrothers showedprogressive spastic gait (which
had been developing since adolescence), and one had a
cerebellar oculomotor disturbance with saccadic eye pur-
suit. No other signs were noticed, and brain and spineMRI,
sensory-evoked potentials (tibial nerve and median nerve),mber 7, 2012
and nerve-conduction studies were normal. The French
SPG28-affectedwoman, aged 62 years at her latest examina-
tion, had suffered since infancy from HSP with axonal
neuropathy but had unremarkable spinal and brain MRI.
Mapping of an AR-HSP-Associated Locus, SPG49
A genome scan with the Illumina LINKAGE Mapping V
SNP Set was performed in family FSP719, composed of
two nuclear consanguineous kindreds from Saudi Arabia.
Multipoint linkage analysis (Figure S3A) identified on
chromosomes 4, 19, and X three genomic regions with
uninformative multipoint LOD scores between 0 and þ1;
these regions were later excluded with the use of 23 addi-
tional markers (data not shown). A fourth region of 34
consecutive SNPs on chromosome 4 presented a significant
multipoint LOD score of þ3.97 between markers
rs1528381 and rs1525760. Further genotyping of 24 addi-
tional microsatellite markers and haplotype reconstruc-
tions restricted the region and confirmed a 5.9 Mb (6.29
cM) region of homozygosity by descent between markers
D4S3256 and D4S2309 in all four affected individuals of
the family (Figure S4). A maximum and significant multi-
point LOD score of þ4.76 was then reached (Figure S3B).
This locus was named SPG49 according to the Human
Genome Organization. A second Saudi Arabian AR-HSP-
affected family was found to be linked to this locus
with a multipoint LOD score of þ2.4. Both families shared
a portion of the same homozygous haplotype, suggesting
a common ancestry and narrowing down the SPG49 candi-
date interval to the 3.8 Mb (4.42 cM) between markers
D4S3256 and D4S2940 (Figure S4).
Identification of Mutations in SPG49/CYP2U1
In all coding exons of the 23 genes assigned to the SPG49
region, we identified a single CYP2U1 variant, c.947A>T
(p.Asp316Val), which segregated with the disease at the
homozygous state in the two SPG49-affected families
(Figure 2A and Figure S2) and was not detected in healthy
controls (Table S1). This variant affected an amino acid
highly conserved during evolution among orthologs of
CYP2U1 (Figure 2B) but also among other cytochrome
P450 proteins (data not shown), including CYP7B1
(SPG5).15 The mutation was localized in the cytochrome
P450 functional domain and was predicted to be
damaging.18,19 Sanger sequencing and QMPSF analysis
of all exons of CYP2U1 in 94 index cases affected by
HSP with an undetermined genetic basis identified four
mutations predicted to be damaging and absent in
controls (Figures 2C–2E, Figure S2, and Table S1). A homo-
zygous missense mutation affecting a conserved amino
acid (c.1139A>G [p.Glu380Gly]) was detected in an
Italian simplex case (ITAP9-II.1) with suspected consan-
guinity. A homozygous 13 bp deletion (in exon 1) leading
to a frameshift (c.61_73del [p.Leu21Trpfs*19]) segre-
gated with the disease in two Egyptian brothers (from
family HSP1363). Finally, two heterozygous mutations
(c.784T>C [p.Cys262Arg] and c.1462C>T [p.Arg488Trp])The American Jousegregated in trans in two siblings with Spanish and
Vietnamese ancestry.
Phenotype Associated with the SPG49 Clinicogenetic
Entity
The overall SPG49 phenotype (Table 1) was an early-onset
(2.55 2.5 SD years; range ¼ birth to 8 years) spastic para-
plegia frequently involving the upper limbs (7/11 cases)
and rarely associated with dystonic postures (n ¼ 2) and
cognitive alterations (n ¼ 3). Among eight tested subjects,
all had normal conduction velocities of the median and
peroneal nerves, but the facts that five of them had a slight
reduction in the amplitude of compound muscle action
potentials and that three of them had a reduction in the
amplitude of sensory-nerve action potential indicate the
presence of infraclinical axonal neuropathy, predomi-
nantly in the lower limbs (data not shown). On brain
MRI, thinning of the corpus callosum (n ¼ 1) and white-
matter lesions (3/8) were observed but were not inaugural
MRI features in two affected subjects (Figure S5). Interest-
ingly, globus pallidus hypointensities were detected during
follow-up analysis of two siblings and were confirmed
as calcifications by CT scans; they were reminiscent of
the familial idiopathic basal-ganglia calcification (Fahr
syndrome) (see GeneReviews inWeb Resources). Therefore,
SPG49 can be added to the growing number ofmixed forms
(pure and complex) of HSP, such as SPG5 or SPG7.12,13 The
severity of symptoms varied widely among affected sub-
jects, even in the same family, and independently of the
nature of the mutation; two individuals (FSP719-V.5 and
HSP1363-IV.4) never walked, and a third (FSP719-IV.3)
was limited in his running capacities, although he had
otherwise fully conserved autonomy at 30 years of age.
Expression Profiles of CYP2U1 and DDHD1 mRNA
DDHD1 andCYP2U1 transcripts have been shown to be ex-
pressed in the brain.27–29 To identify a possible relationship
between these two genes, we explored their expression pro-
files in multiple CNS and non-CNS mouse tissues by quan-
titative RT-PCR. We observed that DDHD1 and CYP2U1
mRNA levels increased during development in all tested
tissues, including the cerebral cortex, but not in peripheral
tissues in the case of DDHD1 (Figure S6). Moreover, we
showed that their expression levels were significantly core-
gulated at the embryonic and adult stages in the CNS (Fig-
ure S6), but not innon-neuronal tissues, a result compatible
with a concomitant need for the two proteins in the CNS.
Subcellular Localization of CYP2U1 and DDHD1 and
Exploration of Mitochondrial Functions and Network
Organization
We then investigated how these mutations affect cell phys-
iology in HSP. At a subcellular level, DDHD1 fused with a
FLAG tag displayed a diffuse distribution pattern almost
exclusively in the cytosol (data not shown), but it has also
been observed partially in microsomes and mitochon-
dria.30Becauseof its PLA1activity,DDHD1must transientlyrnal of Human Genetics 91, 1051–1064, December 7, 2012 1055
Figure 2. CYP2U1 Mutations in SPG49-Affected Subjects
(A) Segregation analysis of the c.947A>T mutation in two Saudi Arabian families. Their corresponding electrophoregrams are in
Figure S2.
(B) Conservation of the amino acids affected by missense variations with the use of ALAMUT software.
(C–E) Pedigrees and segregation ofmutations in AR-HSP-affected families HSP1363 (C), ITAP9 (D), and FSP544 (E). A T1-weighted sagittal
cerebral MRI from individual HSP1363-IV.4 shows a thin corpus callosum (C, red arrow). A CT scan of individual FSP544-III.1 (E, top
view) shows bilateral globus pallidus calcifications (E, green arrow), and a brain MRI (E, bottom view) shows white-matter abnormalities
(E, blue arrow), including the ‘‘ear of the lynx’’ aspect of frontal horns of the lateral ventricles (E, orange arrow).
(F) Schematic representation of CYP2U1 (coding exons are represented by blue boxes). The locations of the identified mutations
(c.61_73del [p.Leu21Trpfs*19], c.784T>C [p.Cys262Arg], c.947A>T [p.Asp316Val], c.1139A>G [p.Glu380Gly], and c.1462C>T
[p.Arg488Trp]) are shownwith red arrows, and the cytochrome P450 domain is indicated by red boxes. The five exons of CYP2U1 (RefSeq
NM_183075.2) cover 1,635 bp and encode a 544 amino acid protein with potential transmembrane domains and a heme binding site in
the cytochrome P450 domain.interact withmembranes from the cytosolic pool to process
its substrates. We also showed that CYP2U1 fused with
enhanced GFP partially colocalized with ER andmitochon-
dria (Figure S7), as previously reported.31
Given the partial mitochondrial localization of both
proteins and the implication of this organelle in other
HSPs,12,32 we investigatedmitochondrial functions in lym-
phoblasts. At steady state in growth medium, the mean
routine respiration was significantly lower in SPG49 and
SPG28 cells than in controls (Figure 3A; controls versus
SPG49: p ¼ 0.053, which is very close to the limit of sig-1056 The American Journal of Human Genetics 91, 1051–1064, Decenificance; controls versus SPG28: p ¼ 0.011). No cell death
was observed (trypan-blue staining and count), suggesting
that mitochondrial alterations were not a consequence
of a reduction in cell viability. As expected from the res-
piratory data, total and mitochondrial ATP contents were
significantly reduced in SPG49 and SPG28 lymphoblasts
(Figure 3B). Furthermore, a concomitant increase of the
concentration of cytosolic hydrogen peroxide as mea-
sured by CM-H2DCFDA fluorescence (Figure 3C) was also
observed in SPG49 and SPG28 cells when compared to
controls. No major difference in mitochondrial content,mber 7, 2012
Table 1. Clinical Phenotypes in 11 SPG49-Affected Individuals
SPG49-Affected Subject
FSP719-IV.3 FSP719-V.2 FSP719-V.3 FSP719-V.5 FSP1015-IV.2 FSP1015-IV.3 HSP1363-IV.1 HSP1363-IV.4 ITAP9-II.1 FSP544-II-1 FSP544-II-2
Gender male female female female female male male male male female male
Age (years) 33 21 18 11 25 21 12 5 31 29 27
Duration of
follow up (years)
3 12 13 10 12 13 2 2 4 9 9
Age at onset 3 years 5 years 1.5 years 8 months birth 5 years 1.5 years birth 8 years 13 months 16 months
Symptoms at
onset
delayed
walking,
spastic gait
unsteadiness,
spastic gait
delayed
walking,
unsteadiness
delayed
walking,
spasticity
delayed
walking,
toe walking
toe walking unsteady gait,
tip-toe walking
spasticity since
birth
cannot run,
frequent falls
delayed walking,
spastic gait
spastic gait
Age at walking 3 years 1.5 years 1.5 years never walked 6 years (after
surgery)
1 year 2 years never walked 2 years delayed normal
Cognitive delay
or mental
retardation
no no no yes no no no no speech no yes yes
Lower-limb
hyperreflexia and
positive extensor
response (Babinski)
yes yes yes yes yes yes yes yes yes yes yes
Upper-limb
hyperreflexia
no no no yes yes yes no yes yes yes yes
Dysarthria no no no no no no no no speech no yes, mild yes, mild
Extrapyramidal
signs
no no no dystonia in
upper limbs
no no no dystonia in
upper limbs
no no no
Other signs no no no no no no no no no maculopathy no
Disability stagea
(at age)
2 (30 years) 2 (21 years) 2 (18 years) 6 (11 years) 5 (25 years) 2 (21 years) 4 4 2 (28 years) 6 (16 years) 5
MRI cerebral
(at age)
ND normal
(20 years)
normal
(17 years)
normal
(10 years)
ND ND; CT
normal
normal
(5 years)
TCC, WMLs,
mild cortical
changes
(2.5 years)
normal
(28 years)
normal (14 years),
then WMLs and
globus pallidus
hypointensities
(26 years)
WMLs and
globus pallidus
hypointensities
(26 years)
MRI of spine
(at age)
ND normal
(20 years)
normal
(17 years)
normal
(10 years)
ND normal normal (4 years) ND normal
(28 years)
normal normal
(19 years)
Nerve-conduction
studies (at age)
ND subclinical
axonal
neuropathy
(21 years)
subclinical
axonal
neuropathy
(18 years)
subclinical
axonal
neuropathy
(10 years)
subclinical
axonal
neuropathy
(25 years)
subclinical
axonal
neuropathy
(21 years)
normal normal normal
(28 years)
ND ND
None of the affected persons presented with muscle wasting, dysphagia, cerebellar signs, superficial sensory loss, or auditory loss. Muscle biopsy in one subject was unremarkable. The following abbreviations are used: CT,
computed tomography; ND, not done; TCC, thin corpus callosum; and WML, white-matter lesion.
aDisability scale: 1, minimal disability (slight stiffness of the legs); 2, mild disability (unable to run but full autonomy); 3, moderate disability in walking (reduced perimeter and frequent falls); 4, severe disability (unilateral
assistance required for walking); 5, bilateral assistance required for walking; 6, wheelchair bound; and 7, bedridden.
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Figure 3. Mitochondrial Dysfunctions in Lymphoblasts from
SPG28- and SPG49-Affected Individuals
(A) Mitochondrial respiration rate in SPG28-affected subjects
(FSP445-V.3 [SPG28-1] and FSP445-V.1 [SPG28-2] aged 44 and
42 years, respectively, at sampling), SPG49-affected subjects
(FSP719-V.3 [SPG49-1] and FSP1015-IV.3 [SPG49-2] aged 18 and
21 years, respectively, at sampling), and three control lymphoblas-
toid cell lines (aged 34, 37, and 40 years at sampling). The routine
respiration data are shown. These measurements were taken after
trypan-blue staining and a count for the exclusion of the presence
of massive cell death.
(B) Total cellular (light gray bar) and mitochondrial (black bars)
ATP content expressed as relative light unit (RLU) measured in
SPG28, SPG49, and control lymphoblasts.
(C) H2DCFDA fluorescence gives a measure of the concentration
of cytosolic hydrogen peroxide in control cells (white bar) and
in CYP2U1 (light gray bar) and DDHD1 (black bars) mutant cells.
The p values comparing mutant cells to control cells are indicated
above each histogram (Student’s t test). Error bars represent
the SD.
1058 The American Journal of Human Genetics 91, 1051–1064, Decemeasured by the comparison of the level of mitochondrial
TOM20, was detected in lymphoblasts of affected cases
(data not shown), suggesting that the observed reduction
in mitochondrial energy fluxes results from a functional
oxidative-phosphorylation-system alteration caused by
mutations in SPG28/DDHD1 and SPG49/CYP2U1.
Reduced oxygen consumption could be confirmed in
skin fibroblasts of an SPG49-affected individual compared
to controls (Figure S8A). Given that respiration originates
from the activity of the respiratory chain and the consecu-
tive buildup of an electrochemical gradient of protons, we
measured those two parameters. As seen in Figure S8B,
the transmembrane electric potential (Dc) measured with
TMRM was 30% lower in the SPG49 fibroblasts than in
the three controls (respective p values of 0.0011, 0.0010,
and 0.0033). To take into account the nonspecific fluores-
cence due to TMRM (data not shown), we obtained the
same results with the Dc dissipating agent FCCP (uncou-
pler, p-trifluoromethoxy carbonyl cyanide phenyl hydra-
zone). However, the catalytic activities of each of the
respiratory-chain complexes assayed in vitro were not
altered in the SPG49 fibroblasts or in the lymphoblasts
obtained from subjects with SPG28 and SPG49 mutations
(Figure S9). This spectrophotometric assay of complexes
I–IV was performed in experimental conditions of a so-
called ‘‘isolated enzyme’’ with mechanical disruption of
mitochondrialmembranes and the addition of excess exog-
enous substrates. In contrast, mitochondrial respiration,
ATP synthesis, and Dc were measured in cells with intact
mitochondrial membranes, so alteration in membrane
properties could be responsible for the observed bioener-
getic failure in cells of affected individuals. Interestingly,
we observed structural abnormalities of the mitochondrial
membrane, given that the mitochondrial network pre-
sented with unusual signs of tubule self-fusions in the
SPG49 fibroblasts. These abnormalities included the pres-
ence of numerous (1) ‘‘donut-like’’ vesicles 800 nm in diam-
eter within the mitochondrial tubules and (2) circular
subnetworks 5 mm in diameter (Figure 4). These features
were observed with either outer-membrane TOM20
labeling (Figure 4) ormitochondrial-matrix dyes such asmi-
totracker (data not shown) or mito-GFP (Figure S10). All
together, our findings indicate mitochondrial-membrane-
organization alteration associated with a reduction of
energy production. Previous studies revealed that such re-
modeling of mitochondrial tubules could influence the
internal diffusion of energy metabolites, the sequestration
and conduction of the electric membrane potential (DJ),
the stability of the respirasome, the efficiency of oxidative
phosphorylation, the diffusion of proteins, or the delivery
of newly synthesized ATP to various cellular areas.33Discussion
We have described a clinicogenetic entity, SPG49, associ-
ated with a wide range of phenotypes from pure tomber 7, 2012
Figure 4. Abnormal Structures in the Mitochondrial Network of SPG49-Affected Skin Fibroblasts
Mitochondrial-network morphology was analyzed by confocal microscopy of skin fibroblasts obtained from control individuals (A) and
from individual HSP1363-IV.1 (B). The images on the right are high magnifications (53 zoomed in) of the images on the left. The mito-
chondrial network was labeled by immunocytochemistry with specific antibodies directed against TOM20, an outer-membrane mito-
chondrial protein, and fluorescence confocal imaging on a Zeiss Vivatome microscope followed. Three-dimensional stacks were
obtained, and the projection images are shown here. We observed two types of abnormal structures on the mitochondrial network of
SPG49 cells: small ‘‘donut-like’’ vesicles (800 nm in diameter) suggestive of self-fused mitochondrial filaments (D) and larger circular
subnetworks (5 mM in diameter) (C). Counting of these two types of abnormal structures was performed on 50 control cells and 50 cells
from the tested subject (right panels). Mean values and p values (Student’s t test) are shown, and error bars represent the SD.complex forms causing a thin corpus callosum and mental
impairment, as in SPG11 and SPG15,34,35 or basal-ganglia
calcification (see GeneReviews in Web Resources). Second,
the identification of the causative mutations in SPG28-
and SPG49-affected families highlights lipid metabolism
as a critical pathway in HSP given that CYP2U1 andThe American JouDDHD1 encode fatty-acid- and/or phospholipid-metabo-
lizing enzymes.
DDHD1 was previously identified as a PA-preferring
phospholipase A1 (PA-PLA1) but is also known to
serve as a substrate for phosphatidylinositol to form
2-arachidonoyl lysophosphatidylinositol.27,36 DDHD1 isrnal of Human Genetics 91, 1051–1064, December 7, 2012 1059
ubiquitously expressed in human tissues such as the brain
and testis, but the physiological role of this enzyme has
not been fully established. DDHD1 orthologs, p125 and
DDHD2 (KIAA0725p), are involved in the maintenance
of the ER and/or Golgi structures.37,38 Therefore, DDHD1
might also be involved in similar functions in the
maintenance of organelle membranes and intracellular
trafficking.
CYP2U1 is one of the oldest identifiable vertebrate cyto-
chrome P450 proteins implicated in u- and u-1 fatty-acid
(C16–C22) hydroxylation.28 In vitro, CYP2U1 is able to
catalyze the hydroxylation of arachidonic acid and related
long-chain fatty acids such as eicosapentaenoic (EPA) and
docosahexaenoic (DHA) acids. Two known metabolites,
19- and 20-hydroxyeicosatetraenoic (HETE) acids, are local
mediators of signal transduction.28,39–41
These two enzymes most likely act in the same
pathway related to phospholipid degradation and fatty-
acid metabolism, which is in agreement with (1) the
coregulation of the expression of DDHD1 and CYP2U1,
specifically in the CNS, (2) the identification of muta-
tions in both genes in affected subjects with relatively
similar clinical presentations, and (3) similar conse-
quences of these mutations for mitochondrial physi-
ology. In addition, other enzymes involving the metabo-
lism of fatty acids and phospholipids have been implicated
in neurodegeneration.8,42–44 PA and phosphatidylinositol,
as well as the bioactive lipids resulting from their
metabolism, modulate membrane properties and play
a role in signal-transduction pathways.45,46 Alterations of
this pathway (Figure 5) in individuals with HSP could
thus have various consequences leading to the observed
phenotypes.
First, phospholipids and fatty acids can serve as precur-
sors of a wide variety of bioactive lipid messengers45,46
that exhibit hormone- or neurotransmitter-like activity
through membrane receptors. Previously, one of the
authors found that the major molecular species of
phosphatidylinositol (PI), 1-stearoyl-2-arachidonoyl PI,
was able to serve as substrate of DDHD1 to generate
2-arachidonoyl lysophosphatidylinositol, a potent agonist
of GPR55,47,48 considered a cannabinoid receptor,49 like
CB1 or CB2.30,50 Arachinonic acid is metabolized to
various eicosanoids through cyclooxygenase and lipoxyge-
nase pathways. CYP2U1 is known to convert arachidonic
acid into 19- and 20-HETE acids, which are known to regu-
late ion channels and neurotransmitter release.28,51,52 In
particular, 20-HETE acid has recently been reported as
a potent activator of the transient receptor potential vanil-
loid 1 (TRPV1) channel. TRPV1 colocalizes with cannabi-
noid receptors CB1 and CB2 in brain and sensory neurons
and seems to be gated by endocannabinoids, such as anan-
damide and N-arachidonoyl dopamine.51,52 Although the
bioactive lipids synthesized by DDHD1 and CYP2U1
have not been shown to act directly on mitochondria,
their action on receptors might mediate their effect, as
has been demonstrated for the CB1 cannabinoid receptors,1060 The American Journal of Human Genetics 91, 1051–1064, Decewhich can regulate mitochondrial respiration and energy
production.53
Second, mitochondrial-membrane lipid composition
is critical for maintaining proper bioenergetic func-
tions,23,54 and the alteration of phospholipid metabolism
has already been shown to impact mitochondrial func-
tions and trigger secondary cellular dysfunction.54–56
Indeed, maintenance of membrane composition, particu-
larly of the mitochondrial membrane, should be critical
for the functions of the long axons of the corticospinal
tracts. The shape of the mitochondrion is also known to
be linked to mitochondrial functions, including respira-
tion, and the dysregulation of the mitochondria dynamics
causes mitochondrial dysfunction.57 PA, a fusogenic phos-
pholipid at the mitochondrion surface, is postulated to
regulate the fusion of mitochondria.56 Overexpression of
mitochondria phospholipase D (MitoPLD) causes contin-
uous giant perinuclear mitochondria, but the reduced
function of MitoPLD causes noncontiguous mitochondrial
fragments. In the present study, the mutation of DDHD1
(SPG28) was shown to cause mitochondrial dysfunction,
including reduced respiration and ATP production. It is
tempting to postulate that the associated mitochondrial
bioenergetic dysfunction might result from the accumula-
tion of PA in mitochondria given that DDHD1 exhibits
PA-degrading activity (PA-PLA1). SPG28 fibroblasts were
not available for exploring this finding, but the abnormal
mitochondrial organization in SPG49 fibroblasts suggests
that the pathway implicated in SPG28 and SPG49 has
a role in this process. Mitochondrial abnormalities could
also result from other, unknown, mechanisms because
the link between altered mitochondrial morphogenesis
and neuronal impairment has already been shown in other
diseases, including other forms of HSP.12,32,58–63 Further-
more, because these results on mitochondrial-network
disorganization were derived from results from one single
fibroblast culture, additional individuals with CYP2U1
and DDHD1 mutations are required for making firm
conclusions.
Lastly, other mechanisms could also contribute to the
disease. Indeed, in numerous conditions of mitochondrial
respiratory impairment, increased reactive oxygen species
(ROS) were observed, as in SPG28 and SPG49 cells. Such
ROS overproduction could play a role in neuronal degener-
ation, as previously suggested for HSP pathophysiology.64
In conclusion, our identification of causative mutations
in two genes demonstrates the importance of combining
systematic gene mapping with large-scale sequencing for
elucidating the molecular basis of HSP. Unraveling the
role of different proteins involved in the same biological
pathway might pave the way for common therapeutic
possibilities for individuals with different gene mutations.
Our results suggest that the membrane itself or membrane-
derived mediators are very important for the neuronal
functions in the corticospinal tracts.
The wide expression of DDHD1 and CYP2U1 sug-
gests that it should be possible to explore metabolicmber 7, 2012
Figure 5. Schematic Representation of the Metabolic Connections between DDHD1 and CYP2U1 Enzymatic Activities
The content of PA on the surface of mitochondria is known to regulate mitochondrial fusion; PA is generated by mitochondrial phos-
pholipase D (MitoPLD) and is further degraded by lipin PA phosphatase. DDHD1 was previously identified as PA-phospholipase A1
(PLA1). The action of DDHD1 might regulate the content of PA on the surface of mitochondria and then be involved in mitochondrial
fusion. The DDHD1mutation causes reduced PA-PLA1 activity, and the resultant increased PA content on the surface of mitochondria
might cause the impairment ofmitochondrial fusion and lead to the dysfunction ofmitochondria. In contrast, phosphatidylinositol (PI)
serves as a substrate of DDHD1 to form 2-arachidonoyl lysophosphatidylinositol (LPI). 2-arachidonoyl LPI is known to act on GPR55,
which is assumed to be a cannabinoid receptor. 2-arachidonoyl LPI might be hydrolyzed by lysophospholipase C into 2-arachidonoyl-
glycerol, which is an endogenous agonist for cannabinoid receptors CB1 and CB2. Arachidonic acid can be released from PI through
phospholipase A2, which includes PLA2G6 (iPLA2 and PNPLA9), and can also be generated from 2-arachidonoyl LPI by neuropathy
target esterase (NTE, PNPLA6) given that this enzyme exhibits high lysophospholipase activity. Arachidonic acid is converted to various
eicosanoids through the cyclooxygenase and lipoxygenase pathways. In addition, arachidonic acid is known to be the preferred
substrate of CYP2U1 to form 19- or 20-HETE acids. Among these, 20-HETE acid is reported as a potent activator of the TRPV1 cation
channel, which is a receptor of endocannabinoids, including anandamide and N-arachidonoyl dopamine. CYP2U1 can also metabolize
esterified forms of arachidonic acid (EPA and DHA). These common arachidonic-acid metabolites can have effects on the endocannabi-
noid system through the CB1, GPR55, and TRPV1 receptors.dysregulation in peripheral tissues, as in SPG5,65 and
develop biomarkers for potential treatment outcome. In
particular, the probable implication of mitochondria in
the pathophysiology of SPG28 and SPG49 could allow
the development of innovative therapeutic strategies
focused on organelle dynamics and bioenergetics, as well
as ROS scavenging.Supplemental Data
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Loss of Function of Glucocerebrosidase GBA2
Is Responsible for Motor Neuron Defects
in Hereditary Spastic Paraplegia
Elodie Martin,1,2,3,4,19 Rebecca Schu¨le,5,19 Katrien Smets,6,7,8,19 Agne`s Rastetter,1,2,3,4 Amir Boukhris,9,10
Jose´ L. Loureiro,11,12 Michael A. Gonzalez,13 Emeline Mundwiller,1,2,3,14 Tine Deconinck,6,8
Marc Wessner,15 Ludmila Jornea,1,2,3 Andre´s Caballero Oteyza,5 Alexandra Durr,1,2,3,16
Jean-Jacques Martin,8 Ludger Scho¨ls,5,17 Chokri Mhiri,9 Foudil Lamari,18 Stephan Zu¨chner,13
Peter De Jonghe,6,7,8 Edor Kabashi,1,2,3 Alexis Brice,1,2,3,14,16,* and Giovanni Stevanin1,2,3,4,14,16,*
Spastic paraplegia 46 refers to a locus mapped to chromosome 9 that accounts for a complicated autosomal-recessive form of hereditary
spastic paraplegia (HSP).With next-generation sequencing in three independent families, we identified four differentmutations inGBA2
(three truncating variants and one missense variant), which were found to cosegregate with the disease and were absent in controls.
GBA2 encodes a microsomal nonlysosomal glucosylceramidase that catalyzes the conversion of glucosylceramide to free glucose and
ceramide and the hydrolysis of bile acid 3-O-glucosides. The missense variant was also found at the homozygous state in a simplex
subject in whom no residual glucocerebrosidase activity of GBA2 could be evidenced in blood cells, opening the way to a possible
measurement of this enzyme activity in clinical practice. The overall phenotype was a complex HSP with mental impairment, cataract,
and hypogonadism inmales associatedwith various degrees of corpus callosum and cerebellar atrophy on brain imaging. Antisensemor-
pholino oligonucleotides targeting the zebrafish GBA2 orthologous gene led to abnormal motor behavior and axonal shortening/
branching of motoneurons that were rescued by the human wild-type mRNA but not by applying the same mRNA containing the
missense mutation. This study highlights the role of ceramide metabolism in HSP pathology.Hereditary spastic paraplegias (HSPs) are heterogeneous
inherited neurodegenerative disorders. Affected individ-
uals suffer from pyramidal motor neuron dysfunction
such as spasticity, brisk reflexes, and pyramidal weakness
of the lower limbs primarily caused by dysfunction or
degeneration of upper motor neurons.1,2 These clinical
symptoms are sometimes associated with additional neu-
rological or extraneurological signs and structural abnor-
malities of the central nervous system (CNS) observed on
brain magnetic resonance imaging (MRI), such as thin
corpus callosum (TCC), cortical atrophy, and cerebellar
atrophy. This clinical heterogeneity partially reflects the
large genetic heterogeneity of this group of disorders
with ~50 loci mapped to date and accounting for all modes
of inheritance.3
We mapped SPG46 to chromosome 9 (MIM 614409) in
a consanguineous Tunisian family (TUN35) (Figure 1A)
with autosomal-recessive (AR) HSP, mental impairment,
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238 The American Journal of Human Genetics 92, 238–244, Februarygenomic rearrangements in affected individual V.33 by
comparative genomic hybridization (NimbleGen chromo-
some 9-specific 385K array, data not shown). We then
sequenced all coding exons of the SPG46 candidate
interval (n ¼ 1,727 exons and their flanking splice sites
in 183 genes, including 1 kb of their UTRs) by targeted
next-generation sequencing (custom NimbleGen capture
and sequencing in a Roche 454-FLX) in affected subjects
V.32 and V.33 (Table S1 available online). After exclusion
of variants reported as validated polymorphisms in public
(1000 Genomes, dbSNP) and local databases, a total of 52
homozygous variants remained common to both individ-
uals, including 48 synonymous or intronic changes or
variants in pseudogenes. In the absence of nonsense or
intronic/exonic splice-site mutations, we focused our anal-
ysis on the four missense variants. Three of them cosegre-
gated with the disease, were predicted to be damaging by
various online software packages (PolyPhen-2, Muta-
tion Tasting), and affected conserved amino acids. Twoet de la Moelle Epinie`re, Pitie-Salpeˆtrie`re Hospital, Universite´ Pierre et Marie
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Figure 1. Mutations in GBA2
(A–D) Family trees and segregation analysis of the mutations iden-
tified in individuals of families TUN35 (A), Ng121 (B), F18310 (C),
and FSP824 (D). The following symbols are used: squares formales,
circles for females; filled symbols for affected individuals; gray
symbols for subjects not clinically assessed; double line for
consanguinity; m, mutation; þ, wild-type; *, sampled individuals.
Sequencing chromatograms of mutations c.518G>A (p.Trp173*),
c.700C>T (p.Arg234*), c.1888C>T (p.Arg630Trp), and c.1471_
1474dupGGCA (p.Thr492Argfs*9) are in Figure S1.
(E) Graphic representation of the exon organization of GBA2 on
chromosome 9 (gray boxes) and the location of the mutations
(black arrows). The GBA2 transcript is 3,611 bp long (CDS
2,784 bp) and is composed of 17 exons that encode a 927 amino
acid protein. White boxes show the exons encoding the glucosyl-
ceramidase domain.were excluded as the cause of the disease either because of
the frequency in controls (c.88C>T [p.Arg30Trp],
rs75679360, in FAM166B [RefSeq accession number
NM_001164310.1], found in 8/182 chromosomes of North
African controls, including at the homozygous state in
one subject) or because the corresponding gene hadThe Americpreviously been involved, when mutated, in another
autosomal-recessive disease not overlapping with HSP
(c.2909T>C [p.Val970Ala] in NPR2 [MIM 108961, RefSeq
NM_003995.3]). Indeed, we did not detect segregating
variants in NPR2 in 68 AR-HSP index subjects and 44
simplex individuals subjected to exome sequencing. The
remaining variant, c.1888C>T (p.Arg630Trp), found in
exon 12 of GBA2 (MIM 609471, RefSeq NM_020944.2),
segregated with the disease in the family (Figures 1A and
S1) and was detected neither in 1,038 control chromo-
somes of 519 French, West Indian, Brazilian, and North
African healthy subjects nor among 6,500 exomes on
the Exome Variant Server. The variant affected an amino
acid conserved from Caenorhabditis elegans and located
in the six-hairpin-glucosidase-like domain of the enzyme
(Figure 1E).
In parallel, exome capture via the SureSelect Human All
Exon 50Mb kit (Agilent) followed by sequencing on aHiseq
2000 sequencer (Illumina) was performed on the genomic
DNA of two index HSP individuals of Belgian and Turkish
ancestry, Ng121-II.2 and F18310-V.16484, respectively
(Figures 1B and 1C). The Burrows-Wheeler algorithm5
was used to align 100 bp length paired-end reads to the
hg19 version of the human genome (Ensembl); variants
were called with the Genome Analysis Toolkit (GATK)
software package.6,7 Data were then imported into the
Genomes Management Application (GEM-app) database
and its associated toolset for further analysis. On average,
110.4 million reads were produced per sample, 95%
of which could be aligned to the targeted sequence.
Mean coverage of the targeted sequence was 97-fold. On
average, 87,591 single-nucleotide variations (SNV) and
8,876 indels were called per sample. Variants were filtered
for occurrence in the normal population (minor allele
frequency < 1% in dbSNP135 and at the Exome Variant
Server), conservation (Genomic Evolutionary Rate Pro-
filing [GERP] score > 3.5 or PhastCons score > 0.7), and
quality (GATK QUAL score > 100, GATK GQ score > 75).
Variants occurring and segregating in more than two unre-
lated families in GEM-app were removed. Compound
heterozygous variants in eight genes, in the absence of
homozygous variants, were identified in the index subject
of family Ng121. In family F18310, 23 homozygous
changes and compound heterozygous variants in three
genes were identified in the sequenced subject. Among
all variants detected in both families, three were truncating
mutations and cosegregated with the disease (Figures 1B,
1C, and S1), all located in GBA2: c.700C>T (p.Arg234*)
at the homozygous state in exon 4 of individual F18310-
V.16484, and the heterozygous variants c.518G>A
(p.Trp173*) and c.1471_1474dupGGCA (p.Thr492Argfs*9)
in exons 3 and 9 of subject Ng121-II.2.
Direct Sanger sequencing (Table S2) of the 17 coding
exons of GBA2 in 95 index HSP subjects with an AR com-
patible inheritance (study approved by the Paris-Necker
ethics committee; approval No. 03-12-07 granted to A.B.
and A.D.), identified one simplex subject of Portuguesean Journal of Human Genetics 92, 238–244, February 7, 2013 239
Figure 2. Brain Imaging in SPG46-Affected Individuals
(A) Sagittal brain magnetic resonance imaging (MRI) in subject
FSP824-V.14 after 14 years of disease duration, showing a very
slight thinning of the corpus callosum (red arrow).
(B and C) Sagittal and transversal flair MRI of individual F18310-
V.16484 after 39 years of disease duration. The atrophy of the
corpus callosum (B, red arrow) and of the cerebellar (B, blue arrow)
and cerebral (B, white arrow) cortex are evident in the absence of
relevant white matter disease (C).
(D and E) Sagittal T1- and transversal axial T2-weighted MRI
images of subject Ng121-II.2 after 65 years of disease duration,
showing severe atrophy of her cerebellum (D, blue arrow) and
cerebrum (white arrows) with mesencephalon atrophy (D,
hummingbird/colibri sign, green arrow) and pronounced white
matter lesions (E, black arrowhead).ancestry (FSP824-V.14) harboring the samemissense muta-
tion (c.1888C>T [p.Arg630Trp]) as in family TUN35,
although with a different associated haplotype (Figures
1D and S1). The mutation, which was homozygous, was
detected at the heterozygous state in her parents.
The GBA2 protein encoded by GBA2 is an enzyme of
sphingolipid metabolism that is the source of a variety of
mediators of cell signaling responses and of structural
components of the plasma membrane involved in its
dynamics.8 GBA2 was initially identified as a microsomal
bile acid b-glucosidase or b-glucosidase 2,9,10 but it is also
a nonlysosomal glucosylceramidase, a ubiquitous enzyme
that catalyzes the conversion of glucosylceramide to
free glucose and ceramide as well as the reverse reaction
consisting in the transfer of glucose to different lipid
substrates.11,12 The primary catabolic pathway for gluco-
sylceramide involves the lysosomal enzyme glucocerebro-
sidase GBA1 (MIM 606463), which is defective in persons
with Gaucher disease, the most common inherited lyso-
somal storage disorder.13 GBA1 is located in the lysosomal
compartment and ceramides generated by this enzyme are
degraded into sphingosine and fatty acids.11,14 In contrast,
GBA2 has been localized in the endoplasmic reticulum
(ER)12 and at the cell surface,11 and ceramides formed
by this enzyme are rapidly converted into sphingomye-
lin.11,12,15 With a published protocol,16,17 we assessed the
GBA2 glucosylceramidase enzymatic activity in lympho-
blasts and leukocytes of affected persons harboring the
missense c.1888C>T (p.Arg630Trp) mutation in presence
of specific inhibitors of the GBA1 enzyme, which is respon-
sible for the vast majority of the glucosylceramidase
activity.18 No detectable GBA2 activity could be observed
in the cells of subject FSP824-V.14 compared to healthy
controls (p ¼ 0.001, Figure S2), indicating a complete loss
of function by the mutation. Complete loss of function
was also evidenced in nontransformed leukocytes of indi-
viduals TUN35-V.27 and V.33 (data not shown).
The neurological phenotype of the 11 affected individ-
uals was similar (Table S3). Onset occurred in infancy or
childhood (range 1–16 years) with disturbances that pro-
gressed slowly to the need for a cane at 22–32 years and
the need for a wheelchair at the age of 54–60. During the
course of the disease, cerebellar ataxia and cataract were
observed in all individuals. All affected subjects also had
mild tomoderate mental impairment; two explored during
their 50s showed an IQ level equivalent to that of 6-year-
old. In the oldest affected subjects, disease course was
complicated by a memory deficit in their 60s and they
died in a demented state aged 61, 63, and 72 years. The
initial phenotypic description4 was enriched by other
frequently observed signs, such as hearing loss (n ¼ 3)
and axonal neuropathy evidenced at electroneuromyogra-
phy (ENMG, n ¼ 5) and sural nerve biopsy (n ¼ 3). Brain
MRI showed cerebral, cerebellar, and corpus callosum
atrophy in all seven subjects tested, which seemed to
worsen with disease duration (Figure 2). Interestingly, the
two affected men presented a bilateral testicular hypotro-240 The American Journal of Human Genetics 92, 238–244, Februaryphy in the absence of hormonal dysfunctions. Semen
analysis of subject TUN35-V.27 revealed extremely severe
spermatozoid head abnormalities with necrospermia and
severe reduction in velocity (Table S4). Hormonal and
genital exploration of affected woman FSP824-V.14 did
not reveal abnormalities but woman Ng121-II.2 was re-
ported to have few pubic hairs. The infertility highlighted
in SPG46 males is reminiscent of the consequences of
the pharmacological inhibition of glucosylceramidases in
mice19,20 or observed in the Gba2 knockout (KO) mice
in which an abnormal glucosylceramide accumulation in
Sertoli cells is observed.12 This infertility together with
the neurological symptoms in our SPG46 subjects points
to the critical role of this enzyme in multiple tissues,
including testis and brain. Indeed, even if no overt neuro-
logical signs, liver dysfunction, or reduced viability were
observed in the Gba2 KO mice at 4 months of age, an7, 2013
Figure 3. zGba2 Inactivation Induces Morphological Phenotypes and Abnormal Motoneuronal Outgrowth in Zebrafish Larvae
(A–D)Whereas 48 hpf embryos injected with 0.1 pmol of the control AMOmmzGba2aug (B) were phenotypically indistinguishable from
noninjected controls (A), injection of 0.1 pmol zGba2aug (D) impaired embryonic development of the caudal region, with some mor-
phants showing shortened and/or twisted tails. Most of the injected morphants were normal looking even when they showed abnormal
locomotion (C). Magnification 344.
(E) Classification of morphant phenotypes observed after injection of AMOs with or without mRNA. The numbers of noninjected
controls and different zGba2 morphants are indicated in parentheses. *p < 0.002, **p < 0.001.
(F–I) Noninjected and zGba2 morphants were analyzed for Znp-1 staining in spinal neurons. In contrast to noninjected larvae and to
morphants injected with mmzGba2 (F) or zGba2aug þ hGBA2 WT mRNA (H), morphants injected with the zGba2aug AMO in presence
(I) or absence (G) of the mutated c.1888C>T RNA showed dramatically impaired axonal outgrowth leading to truncated axons (arrow-
heads). Axon trajectories are disturbed; ectopic and aberrant motor axon branches can be seen (arrows). Scale bar represents 50 mm.accumulation of glycolipid species in the brain, liver, and
testis was observed by mass spectrometry.12 Longer times
may be required in mouse as shown in other HSP mouse
models in which signs are very subtle during the first
months of life.21,22 The neurological phenotype may also
be obscured by the different structure of corticospinal
tracts in mice or by compensation by other GBA enzymes
early during development. Such compensation in GBA1
mutated individuals by GBA2 activity has been shown
and may explain the absence of notable glucosylceramide
accumulation in some Gaucher disease subjects.17 The
reverse situation was not true because, in our study, no
difference in GBA1 activity could be observed between
lymphoblasts of the Portuguese subject and five controls
(data not shown). This compensation may, however, differ
between tissues and between different species.20
To validate the functional phenotype of the GBA2
mutations in vivo, and in particular in the CNS, we usedThe Americthe zebrafish model and antisense morpholino oligonucle-
otide (AMO) technology to knock down the unique GBA2
ortholog (zGba2; RefSeq NM_ENSDARG00000061472)
by using classical methodologies.23 To inactivate zGba2,
we used an AMO targeting the initiation codon of the
mRNA (zGba2aug). As a control for our results, we designed
a mismatch zGba2aug AMO, mmzGba2aug, comprising five
mismatched bases, whose injection did not significantly
lead to the appearance of phenotypes in injected embryos
compared to uninjected ones (p > 0.05). We determined
that microinjection of 0.1 pmol of zGba2aug did not cause
significant lethality of injected embryos compared to un-
injected (p > 0.05) or mmzGba2aug-injected (p > 0.05)
embryos. This AMO dose induced a curly tail phenotype
in 12.5% of morphants (Figures 3D and 3E) although
73.8% had no visible phenotype (Figure 3C). To further
characterize the phenotype of normal-looking embryos
(Figure 3C), we assessed their motor behavior byan Journal of Human Genetics 92, 238–244, February 7, 2013 241
performing a touch-response test on 2 day postfertilization
morphants (Figure S3). We clearly observed that a substan-
tial proportion of the normal-looking zGba2aug-injected
morphants showed significant motility defects (24%),
characterized by slower movements and shorter touch-
induced escape distances, when compared to control
embryos injected with mmzGba2aug (5.6%, p < 0.001)
(Figure 3E). We next investigated the conservation of the
GBA2 protein functions between human and zebrafish
by coinjecting zGba2aug with the wild-type (WT) human
GBA2 mRNA. When double injected, the number of
normal-looking morphants with no locomotor impair-
ment increased significantly (68.4% versus 49.8%)
compared to zGba2aug-injected larvae (Figure 3E, p <
0.001), suggesting that, in zebrafish, human GBA2 mRNA
can compensate, at least partially, for the loss of endoge-
nous zebrafish mRNA. Indeed, the orthologous genes
have a 65.8% identity and an 86.5% similarity. In contrast,
no significant difference (p > 0.05) was observed after the
coinjection of the zGba2aug AMO with the human GBA2
mRNA containing the c.1888C>T missense mutation
(Figures 3E and 3S), meaning that the mutated mRNA
failed to compensate the zebrafish mRNA decrease. Injec-
tion of WT or mutant mRNA alone, without morpholinos,
did not lead to a curly-tail or a locomotor phenotype and
did not influence lethality in embryos compared to
mmzGba2aug-injected control embryos (p > 0.05). Histo-
chemical analyses were then performed on zGba2aug-in-
jected morphant embryos showing a motor phenotype
without visible anomalies. The Znp-1 antibody, which
labels the synaptic protein synaptotagmin 2 in motor
neuron axons,24 showed abnormal development of the
spinal motoneurons, observed at mid-distance between
head and tail (Figure 3G). We observed and evaluated the
morphology of motor neuron axons in embryos injected
with zGba2aug, which appeared to be shorter and presented
with more terminal branches in contrast to the proper
axonal outgrowth observed in embryos injected with
the mmzGba2aug control (Table S5, p < 0.00001). This
abnormal outgrowth was totally rescued when zGba2aug
was coinjected with the WT human mRNA (Figure 3H
and Table S5, p ¼ 0.87), supporting the specificity of
our model. In contrast, we did not observe any rescue
when the coinjection was performed with the mutated
human c.1888C>T mRNA (Figure 3I and Table S5, p <
0.00001). These observations suggest that, in SPG46, as
in other HSPs,23,25–29 the neuronal tract formation is
defective and they confirm the role of GBA2 in the CNS
development.
Could treatments in use for Gaucher disease, due to
GBA1 mutations, be useful in GBA2 mutated individuals?
Enzyme replacement with imiglucerase (Cerezyme, Gen-
zyme; Velaglucerase alpha, Shire; etc.) will not be effective
because it does not cross the blood-brain barrier and has
been optimized to target lysosomes, which is not the local-
ization of GBA2. Another therapy, called substrate reduc-
tion therapy, uses the iminosugar-based inhibitor N-butyl-242 The American Journal of Human Genetics 92, 238–244, Februarydeoxynojirimycin (miglustat or Zarvesta, Actelion) or a
structural analog (Gen 529448, Genzyme) that decrease
glucosylceramide biosynthesis in vitro and have been re-
ported to increase survival and motor functions of mice
models of Niemann Pick type C1 (MIM 257220) and
Sandhoff (MIM 268800) diseases.20,30–32 However, these
inhibitors also acted on GBA2 enzymatic activity,32
making them unsuitable for SPG46 subjects. Moreover,
a pharmacological chaperone strategy, such as isofago-
mine used in Gaucher disease, may be an interesting
therapeutic option in SPG46 subjects due to missense
mutations, if adapted to the GBA2 protein, because it
was shown to increase GBA1 activity in GBA1 mutant
fibroblasts, reduce glucosylceramide and glucosylsphingo-
sine accumulations in mouse models, and improve neuro-
logical symptoms in subjects with type III Gaucher disease
(MIM 231000).33,34
In conclusion, we have identified mutations in GBA2
leading to a specific phenotype that connects glucosylcer-
amidemetabolism and HSP. Lipid metabolism defects have
already been implicated in other forms of HSP,35 including
SPG35 (MIM 612319), SPG28 (MIM 609340), or SPG49
caused by mutations in FA2H (MIM 611026), DDHD1
(MIM 614603), and CYP2U1 (MIM 610670), respec-
tively.36,37 Interestingly, measurement of specific activities
of enzymes involved in HSP could be useful to facilitate
diagnosis in clinical practice and to monitor drug response
in future therapeutic trials, even when done in the periph-
eral blood cells as in SPG5A (MIM 270800)38 or in SPG46
subjects in our study. Measurement of GBA1 activity is
already in use in Gaucher disease assessment.Supplemental Data
Supplemental Data include three figure and five tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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Alteration of Ganglioside Biosynthesis
Responsible for Complex Hereditary Spastic Paraplegia
Amir Boukhris,1,2,3 Rebecca Schule,4 Jose´ L. Loureiro,5 Charles Marques Lourenc¸o,6
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Hereditary spastic paraplegias (HSPs) form a heterogeneous group of neurological disorders. Awhole-genome linkagemapping effort was
made with three HSP-affected families from Spain, Portugal, and Tunisia and it allowed us to reduce the SPG26 locus interval from 34 to 9
Mb. Subsequently, a targeted capture was made to sequence the entire exome of affected individuals from these three families, as well as
from two additional autosomal-recessive HSP-affected families of German and Brazilian origins. Five homozygous truncating (n¼ 3) and
missense (n ¼ 2) mutations were identified in B4GALNT1. After this finding, we analyzed the entire coding region of this gene in 65
additional cases, and three mutations were identified in two subjects. All mutated cases presented an early-onset spastic paraplegia,
with frequent intellectual disability, cerebellar ataxia, and peripheral neuropathy as well as cortical atrophy and white matter hyperin-
tensities on brain imaging. B4GALNT1 encodes b-1,4-N-acetyl-galactosaminyl transferase 1 (B4GALNT1), involved in ganglioside
biosynthesis. These findings confirm the increasing interest of lipid metabolism in HSPs. Interestingly, although the catabolism of gan-
gliosides is implicated in a variety of neurological diseases, SPG26 is only the second human disease involving defects of their biosyn-
thesis.Hereditary spastic paraplegias (HSPs) constitute a clinically
and genetically heterogeneous group of neurodegenerative
conditions. They are characterized by a slowly progressive
spasticity of the lower extremities resulting from the
axonal degeneration and/or dysfunction observed in
long axons of the corticospinal tracts.1,2 HSPs are classified
according to the following criteria: (1) absence (uncompli-
cated or pure HSP) or presence (complicated or complex
HSP) of additional neurological signs and symptoms,
including intellectual disability, cerebellar ataxia, periph-
eral neuropathy, retinopathy, cataract, epilepsy, and ich-
thyosis; and (2) mode of inheritance in the case of familial
forms, which can be autosomal-dominant, autosomal-
recessive (AR), mitochondrial, or X-linked.3 To date, more
than 55 HSP loci (denoted SPG) have been mapped.
Among them, mutations have been found in ~33 genes;
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drial functions.2,4–8
In 2005, Wilkinson et al. mapped the SPG26 locus (MIM
609195) to a 22.8 cM region flanked by markers
D12S59 and D12S1676 (34.2 Mb) on chromosome
12p11.1–12q14 in a Kuwaiti family with AR complicated
HSP.9 In the present study, we linked additional HSP fam-
ilies to the SPG26 locus, refined the locus region, identified
the segregating mutations in seven of these families, and
described the associated phenotype.
We selected three families in which diagnosis of AR HSP
was established according to Harding’s criteria and careful
exclusion of alternative disorders.10 Blood samples and
clinical assessments were performed after informed con-
sent and after local ethics approvals. The disease was not
caused by mutations in any of the frequently involved
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Figure 1. SPG26 Pedigrees and Segregation of the Mutations Detected in B4GALNT1
Square symbols indicate males and circles indicate females. Filled symbols indicate affected individuals. The numbers are an internal
reference for each sampled individual. Stars indicate sampled subjects. Abbreviations are as follows: M, mutation; þ, wild-type.(n ¼ 4) and unaffected (n ¼ 5) members of a Tunisian fam-
ily (TUN34) were subjected to a genome-wide linkage map-
ping that used 6,090 SNP markers (LINKAGE_24 Illumina)
and an additional 30 microsatellite markers, as previously
described.11 All four affected individuals shared a single re-
gion of homozygosity of 22.5 cM (24 Mb) on chromosome
12 flanked by markers D12S1632 (56,415,415 bp) and
D12S2074 (80,431,457 bp) (Figure S1 available online).
Pairwise LOD scores reached the significance value of þ3
at 19 consecutive markers with a multipoint LOD score
of þ4.45 (data not shown). In three affected and three un-
affected subjects of a Spanish family (FSP112), the genome-
wide scan was performed with 428 microsatellite markers,
including the ABI Mapping set (Applied Biosystems), as
described.12 In a single homozygous region of 33 cM
(41 Mb), a maximal multipoint LOD score of þ2.53
reached the maximal expected value in this pedigree,
flanked by markers D12S1617 and D12S1686 (Figure S1).
Both homozygous regions in families TUN34 and FSP112
overlapped with the SPG26 candidate interval and allowed
its reduction from 34.2 Mb (27 cM) to 9.3 Mb (6.9 cM) be-
tween D12S1632 and D12S1686 (Figure S1). In a third fam-
ily, of Portuguese origin without known consanguinityThe Am(FSP995), the same strategy was employed using the Illu-
mina SNP panel and identified 10 regions with positive
LOD score values ranging from þ0.2 to þ2.25, including
a large portion of chromosome 12 containing SPG26.
Exome sequencing was performed on affected subjects
of families FSP112, FSP995, and TUN34 as well as in two
additional families, IHG25297 from Brazil and THI26004
from Germany (Figure 1). Coding exons and flanking
intronic sequences were enriched with the SureSelect Hu-
man All Exon 50 Mb kit (Agilent) according to the manu-
facturer’s standard protocol. Enriched samples were pre-
pared for the Hiseq2000 instrument (Illumina) and
paired-end reads of 100 bp length were produced. The Bur-
rows-Wheeler algorithm was applied to align sequence
reads to the UCSC Genome Browser hg19 version of the
human genome and variants were called via the GATK soft-
ware package.13 Data were then imported into dedicated
analysis toolsets, including the online GEnomes Manage-
ment application (GEM.app)14 and Eris (Integragen), for
further analysis. In families TUN34, FSP995, and FSP112,
the variants were filtered according to their quality, func-
tional class (nonsynonymous and/or affecting splicing),
presence in chromosomal regions with putative orerican Journal of Human Genetics 93, 118–123, July 11, 2013 119
Figure 2. Schematic Representation of B4GALNT1/SPG26 and Location of the Mutations
(A) Exon-intron structure of B4GALNT1, with positions of mutations identified in seven SPG26-affected families. Exons are indicated as
black boxes. The region encoding a functional domain is indicated by blue bars.
(B) Phylogenetic conservation of three amino acids mutated in SPG26-affected individuals.
(C) Electropherograms of the mutations identified. Mutation nomenclature is in agreement with ALAMUT 2.2 and Mutalyzer software
with transcript NM_001478.3.nonexcluded linkage, and frequency %1% in publically
available genomic databases. Together, these criteria
helped to reduce the list of variants to two to five variants
per family (Table S1). Based on conservation and variant
class, we restricted this list to single mutations for each
family that were all in the same gene, B4GALNT1 (MIM
601873; RefSeq accession number NM_001478.3):
c.898C>T (p.Arg300Cys), c.358C>T (p.Gln120*), and
c.395delC (p.Pro132Glnfs*7), respectively. In family
IHG25397, filtering of exome variants under a recessive
model identified three candidate variants, one being a
homozygous stop mutation in B4GALNT1 (c.682C>T
[p.Arg228*]). Similarly, a single homozygous variant in
B4GALNT1 remained under the same filters in family
THI26004 (c.1298A>C [p.Asp433Ala]) (Table S1).120 The American Journal of Human Genetics 93, 118–123, July 11, 2We then screened a series of 65 index cases of HSP fam-
ilies compatible with an ARmode of inheritance and found
three other mutations in two simplex cases. One homo-
zygous truncating mutation was identified in a consan-
guineous Algerian subject (FSP1007-8: c.263dupG
[p.Leu89Profs*13]). A French HSP case harbored com-
pound heterozygote changes: one codon deletion affecting
a conserved amino acid and one in-frame duplication of
two codons (FSP852-1: c.1315_1317delTTC [p.Phe439del]
and c.917_922dup [p.Thr307_Val308dup]). For the latter
case, it was not possible to verify whether they segregated
in cis or in trans (Figures 1 and 2).
These mutations all segregated with the disease in their
respective pedigree, when it could be tested (Figure 1),
and they were also absent from the Exome Variant Server013
Figure 3. Simplified Representation of
Ganglioside Metabolism and Their
Related Disorders
Arrows indicate the orientation of the
enzymatic reactions and the correspond-
ing enzymes are indicated in black. Meta-
bolic diseases are indicated in blue at the
corresponding altered reaction. Ganglio-
side formation is performed in the endo-
plasmic reticulum and Golgi by successive
glycosylations. Their degradation takes
place in lysosomes. Abbreviations are as
follows: hex, hexosaminidase; Gb3, globo-
trioaosylceramide; GBA, glucocerebrosi-
dase; GD, disialic ganglioside; GALC, gal-
actosylceramide-beta-galactosidase; GLA,
alpha galactosidase; GLB, beta galac-
tosidase; GM, monosialic ganglioside;
GT, trisialic ganglioside; GT3 synthase,
alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase; MLD, metachromatic
leukodystrophy; Sap, saposin.(EVS; 13,006 chromosomes) and our local databases
(>3,340 chromosomes). The two missense variants and
the codon deletion affected strongly conserved amino
acids (Figure 2) in B4GALNT1 and they were all predicted
to be pathogenic when examined with algorithms de-
signed to assess the impact of genetic variations (Polyphen,
MutationTaster, Sift).
B4GALNT1 encodes b-1,4-N-acetyl-galactosaminyl trans-
ferase 1 (GM2/GD2 synthase; EC 2.4.1.92), an enzyme
involved in the biosynthesis of complex gangliosides (G),
which aremono- (M), di- (D), and tri- (T) sialic acid-contain-
ing glycosphingolipids generated by sequential glycosyla-
tions (Figure 3).15 Gangliosides are part of the larger family
of glycosphingolipids and are components of the synaptic
plasma membrane involved in synaptic plasticity, signal
transduction, and endocytosis and then are critical for
CNS development. B4GALNT1 catalyzes the transfer of
N-acetyl-galactosamine into GM3, GD3, and globotriaosyl-
ceramideby ab-1,4 linkage (Figure 3). The reverse reaction is
performed by b-hexosaminidase and its cofactor (GM2 acti-
vator). Molecular defects in the degradation of glycosphin-
golipids led to well-known lysosomal storage diseases,
including Gaucher disease caused by GBA (MIM 606463)
mutations,16,17 Fabry disease (MIM 301500), metachro-
matic leukodystrophy (MIM 250100 and 249900), Tay-
Sachs AB variant/GM2 gangliosidosis (MIM 272750),
Sandhoff disease (MIM 268800), and GM1 gangliosidosis
(MIM 230500) (Figure 3). Conversely, to our knowledge, a
single proven case of a human disorder resulting from
disruption of ganglioside biosynthesis has been
described.18 Mutations in ST3GAL5 (also known as SIAT9
[MIM 604402]) coding for GM3 synthase, also called lacto-
sylceramide a-2,3 sialyltransferase, resulted in infantile
epileptic encephalopathy (MIM 609056) with severe devel-
opmental delay and blindness. ST3GAL5-mutated individ-
uals displayed a complete lack of plasmaGM3and its down-
stream biosynthetic derivatives but had increased levels of
plasma lactosylceramideand increasedflux throughtheglo-The Amboside and paragloboside pathways.18 Therefore, SPG26 re-
sulting from B4GALNT1 mutations is the second ganglio-
side biosynthesis defect and is expected to lead to the
accumulation of globotriaosylceramide and gangliosides G
[M/D/T]3. Of note, another complex AR HSP, SPG46 (MIM
614409), is caused by loss-of-function mutations in GBA2
(MIM609471), coding for an enzyme acting on glucosylcer-
amides, substrates of lactosylceramides (Figure 3).8
The clinical features of 18 affected individuals from the
7 SPG26 families identified in this study are summarized
in Table S2. Gait difficulties occurred early, from 2 to 19
years of age. All subjects had predominant spasticity of
the lower limbs (with variable spastic involvement of
the upper limbs in 33%), increased reflexes, and bilateral
Babinski sign. Pseudobulbar dysarthria was present in
47% (7/15). After a mean disease duration of 32.2 5
19.5 years (range 1–60), four subjects were confined to a
wheelchair or bedridden. Severity was variable: one was
bedridden after 13 years (TUN34-11) whereas another
was confined to a wheelchair after 47 years of disease evo-
lution (FSP995-17). Lower motor neuron involvement was
variably present, indicated by lower limb muscle wasting
(11/18, 61%) at later disease stages, decrease or absence
of lower limb tendon reflexes (11/18, 61%) during the
course of the disease (as in family THI26004), and periph-
eral neuropathy predominantly of the axonal type in
four families (7/11, 64%). Mild to moderate cognitive
impairment and developmental delay was noted in all in-
dividuals, often preceding motor deficits. Cognitive
dysfunction was noted to worsen with time in some sub-
jects. Cerebellar signs (10/18, 55%) and extrapyramidal
signs (8/18, 44%), such as facial dyskinesia and dystonia,
were also noted. Further commonly observed signs and
symptoms included bladder disturbances (6/18, 33%),
peripherally decreased vibration sense (9/15, 60%), scoli-
osis (10/15, 67%), pes cavus (9/16, 56%), and strabismus
(4/18, 22%). Four subjects had psychiatric features (the
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addition, several signs were confined to one family: mild
dysmorphic features in the Brazilian subjects and congen-
ital posterior capsular cataract in the three Spanish indi-
viduals. Brain magnetic resonance imaging (MRI) was
either normal or, after long disease durations, showed
cortical atrophy (n ¼ 5/10), subcortical atrophy (n ¼ 1/
10), and/or white matter hyperintensities (WMHs) on
FLAIR sequence (n ¼ 4/10) (Figure S2). In subject
FSP995-19, WMHs worsen with time, as observed in two
brain MRIs performed 12 years apart. We noted a slightly
enlarged corpus callosum in 4/10 subjects; some of them
with otherwise unremarkable MRIs. Finally, serum testos-
terone was reduced or at the lower limit in four of the six
young men tested (67%), and one of them (IHG25297-
105) had hypogonadism and delayed puberty.
Interestingly, the B4galnt1/ mouse19 shows progres-
sive gait disorder reminiscent of clinical features of
SPG26. This phenotype could result from decreased central
myelination in dorsal spinal cord and increased numbers
of unmyelinated fibers,20,21 increased astrocyte/microglia
proliferation, or alteration of lipid content in glycolipid-
enrichedmembrane (raft) domains.22,23 Cerebellar granule
cells of B4galnt1/ mice are also more prone to degenera-
tion in depolarizing conditions, very probably due to an
alteration of calcium homeostasis.24 In addition, knockout
males have progressive testicular atrophy with the pres-
ence of diffuse vacuoles in Sertoli cells and, despite almost
normal testosterone levels per mg of testis, a severe reduc-
tion of serum testosterone.25 All these phenotypes could
be due to the accumulation of globotriaosylceramide and
simple gangliosides and/or the lack of complex ganglio-
sides.19,24 Interestingly, GM3 accumulation has been re-
ported in a simplex case with liver and brain disease.26,27
Whether the disease in this subject is the result of a muta-
tion in B4GALNT1 remains unknown.
In conclusion, we used a combined mapping and exome
sequencing approach to identify B4GALNT1 variants as the
cause of an AR complicated form of HSP. This was achieved
with18SPG26-affected individuals that belonged to7unre-
lated families from Europe, South America, and North
Africa (indicating theworld-wide distribution of this partic-
ular formofHSP). In accordancewith previous reports,9 the
phenotype of SPG26 consisted in early-onset and slowly
progressive spastic paraparesis and cognitive impairment,
complicated by cerebellar ataxia. We extended this clinical
spectrum to include extrapyramidal involvement and pe-
ripheral neuropathy as well as cortical atrophy with white
matter hyperintensities at brain MRI and low levels of
testosterone in males. Disease progression seemed slow:
most affected subjects were still able to walk after long dis-
ease durations but heterogeneity in disease progression
was frequent among families. Altogether, SPG26 is the sec-
ondhumandisorder of ganglioside biosynthesis. Abnormal
glycosphingolipid profile may be detectable in peripheral
samples from SPG26 subjects: this would hasten clinical
diagnosis and facilitate monitoring in therapeutic trials as
for other HSPs, such as SPG5A (MIM 270800) associated122 The American Journal of Human Genetics 93, 118–123, July 11, 2with 25- and 27-hydroxycholesterol accumulation28 and
X-linked adrenoleukodystrophy (MIM 300100).
Supplemental Data
Supplemental Data include two figures and two tables and can be
found with this article online at http://www.cell.com/AJHG/.
Acknowledgments
The authors are grateful to the familymemberswhoparticipated in
this study, toM.A.M. Salih andM. Koenig for family referral, and to
S. Trefouret and P. Ribai as well as the DNA and cell Bank of CRICM
and the Centre National de Genotypage (Evry, France) for their
help. This work was financially supported by the French-Tunisian
Cooperation Project (to A. Brice and C.M.) led by INSERM (France)
and DGRSRT (Tunisia), the VERUM Foundation (to A. Brice), the
French Agency for Research (ANR) (to G.S. and A.D.), the Associa-
tion Franc¸aise contre les Myopathies (‘‘LIGENAX’’ to G.S.), the
Strumpell-Lorrain association (to the SPATAX network), the
Deutsches Zentrum fu¨r Neurodegenerative Erkrankungen (to
L.S.), the Interdisziplina¨ren Zentrums fu¨r Klinische ForschungUni-
versity of Tu¨bingen (grant 1970-0-0 to R.S.), and the European
Community with the ANR (‘‘Eurospa’’ project to A. Brice and
L.S.; 7th Framework ProgrammeNeuromics to A. Brice). This study
also benefited from funding from the program ‘‘Investissements
d’avenir’’ ANR-10-IAIHU-06 (to the Brain and Spine Institute,
Paris), a Canadian Institutes of Health Research grant (#119191)
entitled ‘‘Emerging Team to identify and characterize novel and
existing Hereditary Spastic Paraplegia (HSP) disease genes,’’ and a
National Institutes of Health grant (R01NS072248 to S.Z.).
Received: April 7, 2013
Revised: May 6, 2013
Accepted: May 8, 2013
Published: June 6, 2013Web Resources
The URLs for data presented herein are as follows:
1000 Genomes, http://browser.1000genomes.org
Alamut, http://www.interactive-biosoftware.com/
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/
Ensembl Genome Browser, http://www.ensembl.org/index.html
ERIS, http://eris.integragen.com/
GEM.app, https://genomics.med.miami.edu
Mutalyzer, https://mutalyzer.nl/index
MutationTaster, http://www.mutationtaster.org/
NHLBI Exome Sequencing Project (ESP) Exome Variant Server,
http://evs.gs.washington.edu/EVS/
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org/
PolyPhen-2, http://www.genetics.bwh.harvard.edu/pph2/
RefSeq, http://www.ncbi.nlm.nih.gov/RefSeq
SIFT, http://sift.bii.a-star.edu.sg/
UCSC Genome Browser, http://genome.ucsc.eduReferences
1. Behan, W.M., andMaia, M. (1974). Stru¨mpell’s familial spastic
paraplegia: genetics and neuropathology. J. Neurol. Neuro-
surg. Psychiatry 37, 8–20.013
2. Stevanin, G., Ruberg, M., and Brice, A. (2008). Recent ad-
vances in the genetics of spastic paraplegias. Curr. Neurol.
Neurosci. Rep. 8, 198–210.
3. Fink, J.K. (2006). Hereditary spastic paraplegia. Curr. Neurol.
Neurosci. Rep. 6, 65–76.
4. Schu¨le, R., and Scho¨ls, L. (2011). Genetics of hereditary spastic
paraplegias. Semin. Neurol. 31, 484–493.
5. Finsterer, J., Lo¨scher, W., Quasthoff, S., Wanschitz, J., Auer-
Grumbach, M., and Stevanin, G. (2012). Hereditary spastic
paraplegias with autosomal dominant, recessive, X-linked, or
maternal trait of inheritance. J. Neurol. Sci. 318, 1–18.
6. Tesson, C., Nawara, M., Salih, M.A.M., Rossignol, R., Zaki,
M.S., Al Balwi, M., Schule, R., Mignot, C., Obre, E., Bou-
houche, A., et al. (2012). Alteration of fatty-acid-metabolizing
enzymes affects mitochondrial form and function in heredi-
tary spastic paraplegia. Am. J. Hum. Genet. 91, 1051–1064.
7. Schuurs-Hoeijmakers, J.H.M., Geraghty, M.T., Kamsteeg, E.-J.,
Ben-Salem, S., de Bot, S.T., Nijhof, B., van de Vondervoort,
I.I.G.M., van der Graaf, M., Nobau, A.C., Otte-Ho¨ller, I.,
et al.; FORGE Canada Consortium. (2012). Mutations in
DDHD2, encoding an intracellular phospholipase A(1), cause
a recessive form of complex hereditary spastic paraplegia.
Am. J. Hum. Genet. 91, 1073–1081.
8. Martin, E., Schu¨le, R., Smets, K., Rastetter, A., Boukhris, A.,
Loureiro, J.L., Gonzalez, M.A., Mundwiller, E., Deconinck, T.,
Wessner, M., et al. (2013). Loss of function of glucocerebrosi-
dase GBA2 is responsible for motor neuron defects in heredi-
tary spastic paraplegia. Am. J. Hum. Genet. 92, 238–244.
9. Wilkinson, P.A., Simpson, M.A., Bastaki, L., Patel, H., Reed,
J.A., Kalidas, K., Samilchuk, E., Khan, R., Warner, T.T., and
Crosby, A.H. (2005). A new locus for autosomal recessive
complicated hereditary spastic paraplegia (SPG26) maps to
chromosome 12p11.1-12q14. J. Med. Genet. 42, 80–82.
10. Harding, A.E. (1983). Classification of the hereditary ataxias
and paraplegias. Lancet 1, 1151–1155.
11. Boukhris, A., Feki, I., Elleuch, N., Miladi, M.I., Boland-Auge´,
A., Truchetto, J., Mundwiller, E., Jezequel, N., Zelenika, D.,
Mhiri, C., et al. (2010). A new locus (SPG46) maps to
9p21.2-q21.12 in a Tunisian family with a complicated auto-
somal recessive hereditary spastic paraplegia with mental
impairment and thin corpus callosum. Neurogenetics 11,
441–448.
12. Stevanin, G., Bouslam, N., Thobois, S., Azzedine, H., Ravaux,
L., Boland, A., Schalling, M., Broussolle, E., Du¨rr, A., and Brice,
A. (2004). Spinocerebellar ataxia with sensory neuropathy
(SCA25) maps to chromosome 2p. Ann. Neurol. 55, 97–104.
13. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis,
K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly,
M., and DePristo, M.A. (2010). The Genome Analysis Toolkit:
a MapReduce framework for analyzing next-generation DNA
sequencing data. Genome Res. 20, 1297–1303.
14. Gonzalez, M.A., Lebrigio, R.F., Van Booven, D., Ulloa, R.H.,
Powell, E., Speziani, F., Tekin, M., Schule, R., and Zuchner, S.
(2013). GEnomes Management Application (GEM.app): A
New Software Tool for Large-Scale Collaborative Genome
Analysis. Hum. Mutat. 34, 860–863.
15. Xu, Y.-H., Barnes, S., Sun, Y., and Grabowski, G.A. (2010).
Multi-system disorders of glycosphingolipid and ganglioside
metabolism. J. Lipid Res. 51, 1643–1675.The Am16. Tsuji, S., Choudary, P.V., Martin, B.M., Stubblefield, B.K.,
Mayor, J.A., Barranger, J.A., and Ginns, E.I. (1987). A mutation
in the human glucocerebrosidase gene in neuronopathic
Gaucher’s disease. N. Engl. J. Med. 316, 570–575.
17. Cox, T.M. (2001). Gaucher disease: understanding the molec-
ular pathogenesis of sphingolipidoses. J. Inherit. Metab. Dis.
24(Suppl 2 ), 106–121, discussion 87–88.
18. Simpson, M.A., Cross, H., Proukakis, C., Priestman, D.A.,
Neville, D.C.A., Reinkensmeier, G., Wang, H., Wiznitzer, M.,
Gurtz, K., Verganelaki, A., et al. (2004). Infantile-onset symp-
tomatic epilepsy syndrome caused by a homozygous loss-of-
function mutation of GM3 synthase. Nat. Genet. 36, 1225–
1229.
19. Takamiya, K., Yamamoto, A., Furukawa, K., Yamashiro, S.,
Shin, M., Okada, M., Fukumoto, S., Haraguchi, M., Takeda,
N., Fujimura, K., et al. (1996). Mice with disrupted GM2/
GD2 synthase gene lack complex gangliosides but exhibit
only subtle defects in their nervous system. Proc. Natl. Acad.
Sci. USA 93, 10662–10667.
20. Sheikh, K.A., Sun, J., Liu, Y., Kawai, H., Crawford, T.O., Proia,
R.L., Griffin, J.W., and Schnaar, R.L. (1999). Mice lacking com-
plex gangliosides develop Wallerian degeneration and myeli-
nation defects. Proc. Natl. Acad. Sci. USA 96, 7532–7537.
21. Ma, Q., Kobayashi, M., Sugiura, M., Ozaki, N., Nishio, K., Shir-
aishi, Y., Furukawa, K., Furukawa, K., and Sugiura, Y. (2003).
Morphological study of disordered myelination and the
degeneration of nerve fibers in the spinal cord of mice lacking
complex gangliosides. Arch. Histol. Cytol. 66, 37–44.
22. Ohmi, Y., Tajima, O., Ohkawa, Y., Yamauchi, Y., Sugiura, Y.,
Furukawa, K., and Furukawa, K. (2011). Gangliosides are
essential in the protection of inflammation and neurodegen-
eration via maintenance of lipid rafts: elucidation by a series
of ganglioside-deficient mutant mice. J. Neurochem. 116,
926–935.
23. Ohmi, Y., Ohkawa, Y., Yamauchi, Y., Tajima, O., Furukawa, K.,
and Furukawa, K. (2012). Essential roles of gangliosides in the
formation and maintenance of membrane microdomains in
brain tissues. Neurochem. Res. 37, 1185–1191.
24. Wu, G., Xie, X., Lu, Z.H., and Ledeen, R.W. (2001). Cerebellar
neurons lacking complex gangliosides degenerate in the pres-
ence of depolarizing levels of potassium. Proc. Natl. Acad. Sci.
USA 98, 307–312.
25. Takamiya, K., Yamamoto, A., Furukawa, K., Zhao, J., Fuku-
moto, S., Yamashiro, S., Okada, M., Haraguchi, M., Shin, M.,
Kishikawa, M., et al. (1998). Complex gangliosides are essen-
tial in spermatogenesis of mice: possible roles in the transport
of testosterone. Proc. Natl. Acad. Sci. USA 95, 12147–12152.
26. Max, S.R., Maclaren, N.K., Brady, R.O., Bradley, R.M., Rennels,
M.B., Tanaka, J., Garcia, J.H., and Cornblath, M. (1974). GM3
(hematoside) sphingolipodystrophy. N. Engl. J. Med. 291,
929–931.
27. Fishman, P.H., Max, S.R., Tallman, J.F., Brady, R.O., Maclaren,
N.K., and Cornblath, M. (1975). Deficient Ganglioside Biosyn-
thesis: a novel human sphingolipidosis. Science 187, 68–70.
28. Schu¨le, R., Siddique, T., Deng, H.-X., Yang, Y., Donkervoort, S.,
Hansson, M., Madrid, R.E., Siddique, N., Scho¨ls, L., and
Bjo¨rkhem, I. (2010). Marked accumulation of 27-hydroxycho-
lesterol in SPG5 patients with hereditary spastic paresis.
J. Lipid Res. 51, 819–823.erican Journal of Human Genetics 93, 118–123, July 11, 2013 123
ARTICLE
Mutations in phospholipase DDHD2 cause autosomal
recessive hereditary spastic paraplegia (SPG54)
Michael Gonzalez1, Sheela Nampoothiri2, Cornelia Kornblum3, Andre´s Caballero Oteyza4, Jochen Walter3,
Ioanna Konidari1, William Hulme1, Fiorella Speziani1, Ludger Scho¨ls4,5, Stephan Zu¨chner1
and Rebecca Schu¨le*,4
Hereditary spastic paraplegias (HSP) are a genetically heterogeneous group of disorders characterized by a distal axonopathy
of the corticospinal tract motor neurons leading to progressive lower limb spasticity and weakness. Intracellular membrane
trafficking, mitochondrial dysfunction and myelin formation are key functions involved in HSP pathogenesis. Only recently
defects in metabolism of complex lipids have been implicated in a number of HSP subtypes. Mutations in the 23 known
autosomal recessive HSP genes explain less than half of autosomal recessive HSP cases. To identify novel autosomal recessive
HSP disease genes, exome sequencing was performed in 79 index cases with autosomal recessive forms of HSP. Resulting
variants were filtered and intersected between families to allow identification of new disease genes. We identified two
deleterious mutations in the phospholipase DDHD2 gene in two families with complicated HSP. The phenotype is characterized
by early onset of spastic paraplegia, mental retardation, short stature and dysgenesis of the corpus callosum. Phospholipase
DDHD2 is involved in intracellular membrane trafficking at the golgi/ endoplasmic reticulum interface and has been shown to
possess phospholipase A1 activity in vitro. Discovery of DDHD2 mutations in HSP might therefore provide a link between
two key pathogenic themes in HSP: membrane trafficking and lipid metabolism.
European Journal of Human Genetics (2013) 21, 1214–1218; doi:10.1038/ejhg.2013.29; published online 13 March 2013
Keywords: Hereditary spastic paraplegia; exome sequencing; neurodegenerative disease
INTRODUCTION
The genetically diverse group of hereditary spastic paraplegias (HSP)
is clinically defined by a progressive spasticity and weakness of the
lower limbs, caused by distal axonopathy of the long motor axons
of the corticospinal tract. Identification of more than 39 HSP1
genes highlights intracellular membrane trafficking, mitochondrial
metabolism and myelin formation as key functions involved in
HSP pathogenesis.2 Only recently lipid metabolism has emerged as
another main theme in HSP pathophysiology, backed by the discovery
of mutations in a number of genes involved in lipid metabolism and
signaling including CYP2U1,3 CYP7B1,4 DDHD1,3 FA2H,5 GBA26 and
PNPLA6.7
In this study, we have identified deleterious mutations in phos-
pholipase DDHD2, the sister enzyme of PA-PLA1/DDHD1 in two
families with complicated HSP.
MATERIALS AND METHODS
Exome sequencing was performed in 79 index patients with familial forms of
autosomal recessive HSP. The SureSelect Human All Exon 50Mb kit (Agilent,
Santa Clara, CA, USA) was used for in-solution enrichment; exome sequencing
was performed using the Hiseq2000 instrument (Illumina, San Diego, CA,
USA). Paired-end reads of 100 bp length were produced. BWA and GATK
software packages8,9 were used to align sequence reads to the reference and call
variant positions. The data were then imported into Gem.app, a web-based
database and analysis tool for next generation sequencing data developed
by the group of S Zu¨chner (https://secureforms.med.miami.edu/hihg/
gem-app/)10 for further analysis. An average of 82 613 347 sequence reads
was produced per sample, 98.7% of which could be aligned to the targeted
sequence. Mean coverage was 75.9-fold; 85.5% of the targeted sequence was
covered by at least 10 reads. Variants were filtered for impact on the coding
sequence, presence of either one homozygous or two heterozygous variants in
one gene, frequency in public databases (minor allele frequency in dbSNP135
and NHLBI ESP6500o0.5%), conservation (GERP score42 or PhastCons
score40.6) and genotyping quality (GATK quality index430 and genotype
quality GQ430). Additionally, variants segregating in more than two families
in Gem.app were removed. In addition to 79 families with complex HSP,
Gem.app contained B130 families with pure HSP and B450 families with
non-HSP phenotypes at the time of analysis.
Informed consent was obtained from all individuals and the Institutional
Review Boards at the participating medical centers approved the study.
RESULTS
Gene identification
In family THI26003, seven homozygous SNVs and one homozygous
Indel were present; two of the SNVs as well as the Indel didn’t
segregate with the disease. Segregating homozygous missense variants
were found in C14orf166 (NM_016039.2: c.311C4T, p.Pro104Leu;
rs149288575), FUT10 (NM_032664.3: c.473T4C, p.Leu158Pro),
IMPA1 (NM_001144879.1: c.542C4T, p.Thr181Ile) and OTOGL
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(NM_173591.3: c.3461A4G, p.Asp1154Gly); a homozygous nonsense
variant in DDHD2 (NM_001164234: c.859C4T, p.Arg287*) was the
only truncating change present. Details on all the five segregating
variants in family THI26003 are given in Supplementary Table 1. As it
was not possible to further narrow down the list of candidate genes in
family THI26003 alone based on the available in silico parameters, the
resulting list of five candidate genes was used as a seed and intersected
with the resulting candidate gene lists obtained by exome sequencing
in the remaining 78 autosomal recessive HSP families. Another
deleterious DDHD2 variant was identified in family IHG25194
(NM_001164232.1: c.1982_1983delAT, p.Tyr661Cysfs*8) that segre-
gates with the disease (Figure 1). Parents of the two affected siblings
of this family were not available for genetic analysis, therefore a
genomic deletion of one DDHD2 allele cannot be ruled out with
certainty. Independent analysis of the exome data of family IHG25194
did not yield any nonsense or truncating variants other than the
above described DDHD2 mutation.
In none of the other four candidate genes additional variants were
found in the remaining autosomal recessive HSP families.
Both DDHD2 mutations will destroy the integrity of the DDHD
domain and thereby affect catalytic function, membrane localization,
phosphoinositide binding and homo-oligomerization (Figure 1). Both
mutations therefore likely lead to a complete loss of phospholipase
DDHD2 function.
Clinical description
The two siblings of family THI26003 originating from Azerbaijan
(Iran) from a consanguineous family background (first degree
cousins) developed a progressive spastic gait disorder since early
childhood. At the time of examination (disease duration 22–13 years)
they were still able to walk unsupported. Due to mental retardation
both had attended a special school for mentally disabled children and
were working in a sheltered workshop. Spastic paraplegia was further
complicated by short stature, high arched palate and dysgenesis of the
corpus callosum especially in the dorsal parts (Figures 2a and b).
The two brothers of family IHG25194 were of Indian origin and
had spastic paraplegia from early childhood. No consanguinity was
reported, but both parents originated from the same village and were
part of the Muslim community, explaining a possible founder effect.
Additional clinical signs and symptoms in both the siblings included
mental retardation, mild facial dysmorphism, short stature and
dysgenesis of the corpus callosum (Figures 2c and d).
Considering the usually high phenotypic variability in HSP, the
phenotype between the two unrelated DDHD2 families is astonish-
ingly similar. Key features of DDHD2-related HSP appear to be spastic
paraplegia, mental retardation, short stature and dysgenesis of the
corpus callosum (Table 1).
DISCUSSION
Phospholipids are a key component of biological membranes. They
are metabolized by the large family of phospholipases that can be
classified according to their site of cleavage. The phospholipase
A1 family, consisting of extracellular and intracellular enzymes,
hydrolyzes the ester bond at the sn-1 position of phospholipids,
producing 2-acyl-lysophospholipids and fatty acids. In contrast to
most eukaryotic organisms, mammals have three different intracel-
lular phospholipase A1s: phosphatidic acid preferring phospholipase
A1 (PA-PLA1/iPLA1a; DDHD1), the SEC23-interacting protein p125
(iPLA1b; SEC23IP) and phospholipase DDHD2 (iPLA1c; DDHD2).
The biological function of phospholipase DDHD2 is not fully
understood. DDHD2 is ubiquitously expressed; a cytosolic and a
membrane-associated pool, localizing to the cis-Golgi and the
ER-Golgi intermediate compartment (ERGIC) are in a dynamic
equilibrium.11–13 Overexpression of DDHD2 leads to dispersion of
the Golgi and enlargement of the perinuclear ERGIC.12,14 Conflicting
data exists about the effect of DDHD2 depletion. Morikawa et al13
report a specific defect of retrograde transport from the Golgi to the
ER; this defect is not confirmed by Sato et al11 who instead postulate a
anterograde transport defect from the Golgi to the plasma membrane.
The authors contribute these differences to their use of different
oligonucleotides for the knockdown of DDHD2 in HeLa cells and
possible off-target effects. In spite of these contradictions, the role of
DDHD2 in intracellular membrane trafficking is further supported by
its homology to another member of the PLA1 family – p125 – that
has been shown to be involved in vesicular transport from the ER to
the Golgi by interacting with Sec23p, a component of the COP II
complex.15
Figure 1 Pedigrees and mutations. (a) Pedigrees and sequence traces of the
DDHD2 families. The c.859C4T mutation segregates in family THI26003
and leads to the formation of a preterminal stop signal at codon 287. The
c.1982_1983delAT mutation segregates in family IHG25194; it results in a
frameshift at amino acid position 661. (b) Schematic of the DDHD2 gene.
The DDHD2 gene contains three known protein domains. The WWE domain
is predicted to mediate protein interactions in ubiquitin and ADP ribose
conjugation systems. The tandem SAM (sterile alpha motif domain) – DDHD
domain is required for phosphoinositide binding.14 Integrity of the family-
defining DDHD domain, present in DDHD2 as well as its homolog DDHD1,
is necessary for the PLA1 catalytic activity and homo-oligomerization of
DDHD2. Catalytic function as well as a positively charged cluster in the
SAM domain (Arg434-Lys435-Lys436) also required for phosphoinositide
binding are necessary to promote membrane localization.11,14 Mutations
previously described28 are indicated in black, novel mutations in red.
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Changes in morphology and dynamics of Golgi and ER function-
ally connect several subtypes of HSP: Atlastin-1 (SPG3), the CNS
expressed member of the atlastin family of GTPases, localizes
predominantly to the tubular ER and to a lesser extent to the ERGIC
and the cis-Golgi. It is required for the formation of three-way
junctions of the ER.16 Receptor expression-enhancing proteins
(REEPs) and reticulons form large oligomeric complexes in the ER
membrane that are involved in curving the ER membrane, thereby
forming the characteristic tubular structure of the smooth ER.
Mutations in REEP1 (SPG31) as well as reticulon 2 (RTN2, SPG12)
genes cause autosomal dominant forms of HSP.17 Point mutations in
BSCL2, causing SPG17, lead to upregulation of ER stress markers.18
The long isoform of spastin mutated in the most common autosomal
dominant subtype of HSP (SPAST, SPG4) forms a protein complex
with atlastin-1 and REEP1 in the tubular ER network and is thought
to coordinate microtubule regulation and membrane modeling.2,17
The identification of mutations in the gene encoding DDHD2,
another protein acting at the ER-to-Golgi interface therefore comes
as no surprise.
In addition to its involvement in membrane trafficking, DDHD2
has been shown to possess phospholipase A1 catalytic activity towards
phosphatidic acid and other phospholipids,12,19 a function shared also
by DDHD1. Phosphatidic acid has diverse biological functions.
It is a precursor for the biosynthesis of triacylglycerols and phos-
phoglycerols. In addition to its structural functions in biological
membranes,20 it is also involved in lipid signaling.21 This
phospholipase A1 catalytic activity puts DDHD2 into context
with a number of recently discovered HSP genes involved in lipid
metabolism. Both seipin (SPG17)22 and spartin (SPG20)23 are
involved in formation and regulation of lipid droplets. These
dynamic organelles consist of a core of neutral lipids that are
covered by a monolayer of amphiphatic lipids containing
cholesterol and phospholipids. Phosphatidic acid, preferred
substrate for DDHD1 and DDHD2, is essential for lipid droplet
assembly.24 The acetyl-CoA transporter SLC33A1 located in the ER
membrane and required for the formation of O-acetylated
gangliosides is mutated in SPG42. Defects in the metabolism of
complex lipids cause at least four more HSP subtypes: in SPG39 the
deacetylation of phosphatidylcholine, the major membrane
phospholipid, is defective due to mutations in phospholipase
B/neuropathy target esterase (PNPLA6),7 mutations in fatty acid-2
hydroxylase (FA2H) affect synthesis of 2-hydroxysphingolipids in
Figure 2 Cranial MRI/CT scans of DDHD2 patients. MRI/CT scans of DDHD2 patients show dysgenesis of the corpus callosum as well as some paucity of
the periventricular white matter (d). (a): coronal MRI (T1 inversion recovery) of THI26003-4. (b): axial CT-scan of THI26003-3. (c): sagittal MRI (T1)
of IHG25194-3. (d): axial MRI (T1) of IHG25194-3.
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SPG3525 and CYP2U1 mutations in SPG49 lead to disturbed o- and
w-1 fatty acid hydroxylation.3 In GBA2, mutated in autosomal
recessive HSP SPG46, the conversion of glucosylceramide to free
glucose and ceramide by the non-lysosomal glucosylceramidase
is deficient.6 In SPG5 mutations in the 7a-hydroxylase gene
CYP7B1 not only lead to accumulation of oxysterols in SPG5
patients26 but may also influence neurosteroid metabolism.27
During preparation of this manuscript Schuurs-Hoeijmakers et al28
reported mutations in DDHD2 in four families with autosomal
recessive HSP. The phenotype in these families is strikingly similar to
the clinical features reported in families THI26003 and IHG25194
with early onset spasticity, mental retardation and TCC being the
overlap between all affected family members. The seven DDHD2
mutations described in Schuurs-Hoeijmakers et al28 and our study
comprise four frameshift, two nonsense and only one missense
mutation so far (Figure 1). Of note, most mutations cluster in the
DDHD domain, located in the C-terminal half of the protein.
Further studies will have to clarify whether a toxic gain of function
of potentially expressed truncated or mutant DDHD2 protein
contributes to the phenotype. The nonsense mutation Arg287* that
we identified in the Iranian family THI26003 has been described by
Schuurs-Hoeijmakers et al28 in another Iranian family; a founder
effect is therefore possible.
The identification of mutations in DDHD2, which is involved in
Golgi-/ER membrane trafficking and lipid metabolism further
demonstrates the critical roles of these essential cellular processes in
motor neuron function and helps to understand the molecular
mechanisms underlying the pathogenesis of HSPs.
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Motor protein mutations cause a new form
of hereditary spastic paraplegia
ABSTRACT
Objective: To identify a novel disease gene in 2 families with autosomal recessive hereditary spas-
tic paraplegia (HSP).
Methods: We used whole-exome sequencing to identify the underlying genetic disease cause in 2
families with apparently autosomal recessive spastic paraplegia. Endogenous expression as well
as subcellular localization of wild-type and mutant protein were studied to support the pathoge-
nicity of the identified mutations.
Results: In 2 families, we identified compound heterozygous or homozygous mutations in the kinesin
gene KIF1C to cause hereditary spastic paraplegia type 58 (SPG58). SPG58 can be complicated by
cervical dystonia and cerebellar ataxia. The same mutations in a heterozygous state result in a mild or
subclinical phenotype. KIF1C mutations in SPG58 affect the domains involved in adenosine triphos-
phate hydrolysis and microtubule binding, key functions for this microtubule-based motor protein.
Conclusions: KIF1C is the third kinesin gene involved in the pathogenesis of HSPs and is char-
acterized by a mild dominant and a more severe recessive disease phenotype. The identification
of KIF1C as an HSP disease gene further supports the key role of intracellular trafficking pro-
cesses in the pathogenesis of hereditary axonopathies. Neurology® 2014;82:2007–2016
GLOSSARY
ATP 5 adenosine triphosphate; BICDR-1 5 bicaudal-D-related protein 1; DMEM 5 Dulbecco’s modified Eagle medium;
FCS 5 fetal calf serum; HSP 5 hereditary spastic paraplegia; HSP60 5 heat shock 60kDa protein 1; KIF1C 5 kinesin
family member 1C; p-loop 5 phosphate-binding loop; SPG58 5 hereditary spastic paraplegia type 58; WB 5Western blot;
WES 5 whole-exome sequencing.
Hereditary spastic paraplegias (HSPs) are among the most heterogeneous mendelian diseases.1 The
pathologic hallmark of HSPs is a length-dependent distal axonopathy of the upper motor neurons.
To maintain their high degree of polarization, corticospinal tract motor neurons critically depend
on efficient mechanisms to selectively distribute proteins and membrane components throughout
the cell. It is therefore not surprising that a large number of HSP proteins interfere with membrane
trafficking pathways in various ways: by affecting membrane curvature and/or the morphology of
the endoplasmic reticulum (Reep1, RTN2, spastin, atlastin-1), by modifying vesicle sorting and
trafficking along the secretory or endosomal pathway (adapter protein complexes, strumpellin, vcp,
vps37a), or by disturbing axonal transport (KIF5A, spastin) (reviewed in reference 2).
In this study, we used whole-exome sequencing (WES) to identify the genetic cause of a novel
form of complicated HSP, termed hereditary spastic paraplegia type 58 (SPG58).
METHODS Exome sequencing.WESwas performed on the index patients of families THI26001 (P3) and IHG25215 (P5) (figure 1A).
After exome capture via the SureSelect Human All Exon 50 Mb kit (Agilent, Santa Clara, CA), samples were sequenced on HiSeq2000
instruments (Illumina, SanDiego, CA). An average of 70,811,663 sequence reads of 100–base pair length were produced per sample, 98.8% of
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which could be aligned to the target sequence. Mean coverage was
57-fold. Data were analyzed using the browser interface of the
Genomes Management Application GEM.app.3 Candidate variants
were confirmed with conventional Sanger sequencing.
Cell culture. Fibroblast lines were established from skin biop-
sies using standard procedures. Cells were grown in Dulbecco’s
modified Eagle medium (DMEM) plus 10% fetal calf serum
(FCS) and maintained at 37°C and 5% CO2. Lymphocytes
were isolated from blood samples and immortalized by expo-
sure to Epstein-Barr virus. Cells were cultivated in Roswell Park
Memorial Institute medium plus 20% FCS and maintained
at 37°C and 5% CO2. The motor neuron–like hybrid cell
line NSC-34 and the fibroblast-like cell line COS-7 were
cultured in DMEM plus 10% FCS at 37°C, 5% CO2.
Quantitative PCR. RNA was extracted and transcribed using
standard protocols. Control fibroblasts and lymphoblasts were
matched to patient cells for age (65 years), sex, and cell passage
(62 passages). Quantitative PCR was run on a LightCycler 480
device (Roche Applied Science, Penzberg, Germany).
Western blot. Protein was isolated from primary fibroblast and
lymphoblast cell lines using standard protocols. After sodium
dodecyl sulfate–polyacrylamide gel electrophoresis, samples were
Figure 1 Pedigrees and mutations in the KIF1C gene
(A) The KIF1C variants c.[305G.C];[527C.T], p.[Gly102Ala];[Pro176Leu], and c.[901A.G];[901A.G], p.[Arg301Gly];[Arg301Gly] segregate in families
THI26001 and IHG25215, respectively. Severely affected family members are depicted by black boxes and are homozygous or compound heterozygous for
the respective mutations. Mildly or subclinically affected family members are depicted by gray boxes and are carriers of one mutant allele each. Electro-
pherograms are shown on the right. (B) All 3 KIF1C mutations (red) affect amino acids that are highly conserved across species as well as among kinesin-3
and -1 families. Gly102Ala is located within the Walker A motif (GxxxxGKT/S) of the so called p-loop, essential for nucleotide binding, and therefore likely
renders KIF1C catalytically inactive. Both Pro176Leu (loop 8) and Arg301Gly (loop 12) affect the microtubule binding interface of KIF1C. KIF5Amutations
causing autosomal dominant SPG10 are shown in green. The uniprot alignment tool was used to generate alignments with the following protein identifiers:
KIF1C_human: O43896; KIF1C_chimpanzee: K7BP32; KIF1C_mouse: O35071; unc104_d.m.: A1ZAJ2; unc104_C elegans: P23678; KIF1A_human:
Q12756; KIF1B_human: O60333; and KIF5A_human: Q12840. (C) Domain structure of the KIF1C gene. Known interaction partners and putative binding
regions of KIF1C are depicted by horizontal lines. Mutations detected in this study are indicated in red, mutations published by Dor et al.26 in gray.
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transferred onto a polyvinylidene difluoride membrane, washed 3
times with 1x Tris-buffered saline/Tween 20, and blocked with
1x Tris-buffered saline/Tween 20 1 5% skimmed milk. The
membrane was incubated with the primary antibody overnight
in blocking buffer and with the secondary antibody for 1 hour at
room temperature. Detection was performed using ECL reagent
(Thermo Fisher Scientific, Waltham, MA).
Cloning. The KIF1C ORF was amplified from a complementary
DNA clone4 and transferred into a pcDNA3.1/CT-GFP-TOPO
expression vector (Invitrogen, Carlsbad, CA). Site-directed
mutagenesis was performed on the resulting pTOPO-GFP-
KIF1Cwt, using QuikChange II XL (Agilent), introducing the
human mutations c.305G.C (pTOPO-GFP-KIF1CGly102Ala),
c.527C.T (pTOPO-GFP-KIF1CPro176Leu), and c.901A.G
(pTOPO-GFP-KIF1CArg301Gly). Identity with the reference
sequence (NM_006612.5) and introduction of the desired
mutations was confirmed by conventional sequencing.
Restriction enzyme digest was used to transfer the inserts to
pmCherry-N1 (Clontech Laboratories, Mountain View, CA).
Immunofluorescence. Cells were fixed in 4% paraformalde-
hyde and stained with specific primary antibodies and Alexa-
conjugated secondary antibodies. Cells were mounted on
coverslips with Prolong Gold Antifading Reagent with DAPI
(4’,6-diamidino-2-phenylindole) (Invitrogen). Pictures were
taken with a Zeiss LSM 710 inverted confocal microscope
using the ZEN2010 software (Carl Zeiss Corporation,
Oberkochen, Germany). Finally, images were processed with
the ImageJ software (http://rsbweb.nih.gov).
Antibodies. The following antibodies were used: rabbit polyclonal
anti-KIF1C (AKIN11; Cytoskeleton Inc., Denver, CO), dilution
1:250 (immunofluorescence) and 1:500 (Western blot [WB]);
mouse monoclonal anti-a-tubulin (A-11126; Invitrogen), dilution
1:200 (immunofluorescence); mouse monoclonal anti-a-tubulin
(T6074; Sigma-Aldrich, St. Louis, MO), dilution 1:5,000
(WB); and mouse anti-GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) (clone 6C5; Millipore Corporation, Billerica, MA),
dilution 1:5,000 (WB).
Statistics. Statistical analyses were performed using SPSS software
version 20 for Mac (IBM Corporation, Armonk, NY). Two-sided
t tests were used to compare KIF1C levels between groups.
Standard protocol approvals, registrations, and patient
consents. Informed consent was obtained from all individuals
involved in the study, and the institutional review boards of the
participating medical centers approved the study.
RESULTS Exome sequencing and identification of the
KIF1C gene (SPG58).We performedWES in the index
patient of a German family with apparently autosomal
recessive HSP (THI26001, figure 1A) and filtered the
resulting variants for allele frequency (EVS6500
,0.5%), genotype frequency in the GEM.app database
(number of families with segregating variant#10), con-
servation across species (GERP score.1 or PhastCons
score .0.4), effect on protein function (Polyphen-2
score .0.3), and quality (GATK QUAL score .50,
genotype quality GQ .50). None of the known HSP
genes contained any variants matching the filter criteria.
Only 5 potentially novel candidate genes remained on
the hit list, containing either 2 heterozygous (n5 4) or
1 homozygous (n 5 1) variant: KIF1C, LYST,
TENM1, SAMD11, and OVOS. To narrow down this
candidate gene list, we analyzed all variants for cosegre-
gation with the disease. Only the 2 variants in the
KIF1C gene (NM_006612.5) cosegregated completely:
c.[305G.C];[527C.T], p.[Gly102Ala];[Pro176Leu]
(figure 1A, table e-1 on the Neurology® Web site at
Neurology.org).
To further support the role of KIF1C as a disease
gene, we revisited the exomes of 186 index patients with
genetically unresolved HSP (n5 126), ataxia (n5 30),
or spastic ataxia (n 5 30) compatible with autosomal
recessive modes of inheritance. One additional family
(IHG25215) carried a highly conserved unknown
homozygous KIF1C variant: c.[901A.G];[901A.G],
p.[Arg301Gly];[Arg301Gly]. This variant cosegregated
with disease (figure 1A).
Clinical description of SPG58 families. THI26001. All 3
affected siblings presented with adult-onset (18–30
years) spastic ataxia with predominant lower limb
spasticity and weakness. Cerebellar ataxia was pre-
sent in all 3 with cerebellar oculomotor disturbance
(2/3) and upper . lower limb ataxia (3/3). Dorsal
column sensory deficits (3/3) were rather pro-
nounced compared with most other HSP subtypes.
Although not formally tested, none of the family
members showed an indication of cognitive involve-
ment. Details on the phenotype are given in table 1.
Neurophysiologic studies indicated a widespread
demyelinating process with central and peripheral
involvement. Motor evoked potentials showed increased
central motor conduction times at early disease stages
and were later absent when recorded from the upper
and the lower limbs. The long sensory tracts were simi-
larly involved with prolonged or absent cortical poten-
tials. Increased latencies were also observed for visual
(2/3) and auditory (1/3) evoked potentials. One sibling
showed peripheral involvement with a demyelinating
sensory-motor peripheral neuropathy.
MRIs revealed signs of widespread T2 hyperinten-
sities primarily affecting the pre- and postcentral
white matter, pyramidal tracts, superior cerebellar pe-
duncles, and the occipital white matter with relative
sparing of the optic radiations (figure 2).
Both parents are carriers of one of the KIF1C muta-
tions. The father had consulted a neurologist a few
weeks prior because of a subjective limping and some
sensory deficits in his legs. The mother reported no gait
problems. Closer clinical examination revealed a carrier
phenotype in both of them, consisting of lower limb
weakness with central distribution (proximal . distal,
hip abductors . hip adductors) and demyelinating
sensory-motor neuropathy in the father (Gly102Ala)
and mild signs of pyramidal involvement (brisk reflexes,
extensor plantar response) in the mother (Pro176Leu).
The MRIs of both parents also showed T2
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Table 1 Phenotypes and characteristics of the families
THI26001-3 THI26001-4 THI26001-5 THI26001-1 THI26001-2 IHG25125-5 IHG25125-3
Origin Germany Germany Germany Germany Germany Turkey Turkey
Sex Male Male Female Male Female Male Male
Genotype Gly102Ala/Pro176Leu Gly102Ala/
Pro176Leu
Gly102Ala/Pro176Leu Gly102Ala/wt Wt/Pro176leu Arg301Gly/
Arg301Gly
Arg301Gly/wt
Age at onset, y 18 30 18 69 NA 10 16
Age at last
examination, y
48 45 42 69 67 48 46
Severity SPRS 30 26 27 7 3 ND ND
UL
Spasticity 2 2 1 2 2 2 2
Reflexes Normal Normal Increased Decreased Increased Normal
Weakness 2 2 2 2 2 2 2
Amyotrophy 2 2 2 2 2 2 2
LL
Spasticity 111 11 111 - - 111 11
Reflexes Increased Increased Increased Normal Increased Increased Increased
Weakness 1 (distal predominant) 1 11 (distal predominant) 1 (proximal
predominant)
2 11 (distal
predominant)
1 (distal
predominant)
Amyotrophy 2 2 2 2 2 2 2
Extensor
plantar sign
1 1 1 2 1 1 1
Cognition Normal Normal Normal Normal Normal Normal Normal
Oculomotor
disturbance
Upward vertical gaze
palsy
Cerebellar
(saccadic pursuit,
gaze-evoked
nystagmus)
Cerebellar (saccadic
pursuit, gaze-evoked
nystagmus, dysmetric
saccades)
2 2 2 2
Cerebellar
ataxia
UL . LL limb ataxia, UL
intention tremor
UL . LL limb
ataxia, UL
intention tremor
UL . LL limb ataxia, UL
intention tremor
2 2 2 2
Dysarthria Mild Mild Moderate Mild 2
Dystonia 2 2 Mild cervical dystonia 2 2 2 2
Vibration
sense
LL distal absent LL distal reduced LL distal reduced LL distal
reduced
LL distal absent LL distal
absent
LL distal absent
Urinary
symptoms
2 2 2 2 2 2 2
Other
symptoms
Irregular head tremor 2 2 2 2 2 2
Nerve
conduction
studies
Normal Demyelinating
sensory-motor
neuropathy
Normal Demyelinating
sensory-motor
neuropathy
ND ND Sensory-motor
neuropathy
Evoked
potentials
VEP: increased latency;
AEP: normal; MEP: not
possible because of head
tremor; Tib-SEP: no
cortical potential
VEP: increased
latency; AEP:
increased latency
over brainstem;
MEP: UL/LL no
potential; Tib-SEP:
no cortical
potential
VEP: normal; AEP:
normal; MEP: UL/LL no
potential (at age 34
prolonged CMCT); Tib-
SEP: increased latency
cortical potential
ND ND ND VEP: normal;
AEP: normal;
MEP: ND; Tib-
SEP: no cortical
potential
Imaging MRI: T2 hyperintensities
(pre-/postcentral/occipital
white matter, pyramidal
tract, superior cerebellar
peduncles), mild global
cerebral atrophy,
pronounced tegmental and
vermian cerebellar atrophy
ND MRI: T2 hyperintensities
(pre-/postcentral/
occipital white matter,
pyramidal tract, superior
cerebellar peduncles),
mild vermian cerebellar
and spinal atrophy
MRI: mild T2
hyperintensities
(pyramidal tract,
optic radiation),
mild cerebellar
atrophy
MRI: mild T2
hyperintensities
(pyramidal tract,
superior
cerebellar
peduncles)
ND MRI: mild T2
hyperintensities
(pyramidal tract)
Abbreviations: AEP5 auditory evoked potentials; CMCT5 central motor conduction time; LL5 lower limbs; MEP5motor evoked potentials; ND5 not done; Tib-
SEP 5 tibial sensory evoked potentials; SPRS 5 Spastic Paraplegia Rating Scale; UL 5 upper limbs; VEP 5 visual evoked potentials; wt 5 wild-type.
2010 Neurology 82 June 3, 2014
hyperintensities with a similar pattern, albeit less intense
than in the affected offspring (figure e-1).
IHG25215. The 2 affected siblings of consanguine-
ous descent (parents first-degree cousins) of family
IHG25215 both reported an unsteady gait since their
adolescence, but with different disease course. While
the disease progressed insidiously in the younger
brother (IHG25215-5), leading to loss of the ability
to walk and caregiver dependency in his early 40s,
the disease was apparently stable in the older brother
(IHG25215-3) who is working full-time and displays
only mildly spastic gait not interfering with his daily
activities at age 46.
On examination, both brothers exhibited a lower
limb spastic paraparesis, mild in IHG25215-3 and
severe in IHG25215-5. In the latter, additionally mild
cervical dystonia and loss of vibration sense in the lower
extremities were noted. The mother of the 2 siblings
(IHG25215-2) reported no gait problems at the age
of 67 and her neurologic examination was normal.
Cognition appeared normal in all family members.
IHG25215-2 and -3 received a neurophysiologic
examination. While normal in the mother, the mildly
affected sibling showed absence of somatosensory evoked
cortical potentials and sensory-motor neuropathy.
Localization of mutations. KIF1C is a kinesin-type
microtubule-dependent motor protein that belongs
to the kinesin-3 subfamily. It contains an N-terminal
conserved kinesin motor domain with several
characteristic features: the phosphate-binding
loop (p-loop) responsible for adenosine triphosphate
(ATP) hydrolysis and propagation of nucleotide-
dependent conformational changes from the ATP
binding pocket to the microtubule binding region.
The latter is often called switch-2 cluster and is
formed by helix a4, loop L12, helix a5, and
supporting structures5 (figure 1C). In addition,
members of the kinesin-3 subfamily contain a stretch
of positively charged lysine residues thought to enhance
microtubule binding6 (k-loop). The SPG58 mutations
are found in the p-loop and the switch-2 cluster.
Gly102 is located within the highly conserved
Walker A motif of the nucleotide binding p-loop.
Mutation of this glycine residue to alanine presum-
ably renders KIF1C catalytically inactive, as noted
for the neighboring Lys103Ala mutation.7 The
mutant may no longer be capable of binding nucleo-
tide, and is possibly less stable (see below).
Pro176 is part of loop 8 of the kinesin’s motor
domain and thus close to the microtubule interaction
domain. Functional studies are lacking. Arg301 lies at
the core of a highly conserved motif in the L12 loop,
involved in microtubule interaction. The homologous
amino acid in KIF5A (Arg280) is a mutational hotspot
in the autosomal dominant HSP subtype SPG10.8,9
The Arg280Ala mutant has been shown to reduce
microtubule affinity in vitro, suggesting impaired
transport rates.10
Impact of identified mutations on KIF1C expression. To
check whether the mutations affect expression levels of
Figure 2 Brain MRI of family THI26001
Brain T2-weighted imaging (B, C, E, fluid-attenuated inversion recovery) of THI26001-3 (age 48 years) reveals symmetrical
T2-hyperintense cerebral and mild cerebellar demyelination affecting the pre- and postcentral white matter (Δ in B), the
pyramidal tracts (# in C–E), the occipital white matter with relative sparing of the optic radiations (* in C and F), and the
superior cerebellar peduncles († in E). The midsagittal view (A) shows mild tegmental (black arrow) and vermian cerebellar
(white arrow) atrophy.
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KIF1C, we compared messenger RNA and protein levels
between lymphoblasts and fibroblasts of family
THI26001 with age- and sex-matched controls. KIF1C
messenger RNA levels among those affected,
heterozygous carriers, and controls (figure e-2A)
were not significantly different applying quantitative
real-time PCR to lymphoblasts. In contrast, protein
levels of KIF1C in lymphoblasts of affected persons
were reduced to 45% in WBs. These results were
confirmed in patient-derived fibroblasts, in which
KIF1C protein was reduced to a level of 58%
(figure e-2, B and C). The polyclonal antibody used
is directed against the KIF1C neck domain and
does not specifically recognize wild-type or mutant
KIF1C. Of note, the heterozygous carrier of the
Gly102Ala mutation (father, P1) showed KIF1C
protein levels comparable to his affected offspring
(P3-5), whereas KIF1C protein levels in the carrier
of the Pro176Leu mutation (mother, P2) were
comparable to the control probands’ levels. This
pattern indicates that the Gly102Ala mutation
renders the KIF1C protein less stable, leading to
significantly reduced protein levels.
Subcellular localization of endogenous KIF1C protein.We
have studied the localization of KIF1C in several cell
lines, including human primary fibroblasts (data not
shown), a fibroblast-like cell line (COS-7), a human
Figure 3 Subcellular localization of endogenous and overexpressed KIF1C
(A, B) Endogenous KIF1C. In the mouse motor neuron–like spinal cord cell line NSC-34, endogenous KIF1C is found through-
out the cell body with an accumulation in the pericentrosome and along the neurites, and strong accumulation at the neurite
tips (A). In fibroblast-like COS-7 cells, endogenous KIF1C is sparsely distributed throughout the cell and accumulates
perinuclear in a reticular pattern (B). In COS-7 cells displaying cellular processes, accumulation at the tips of these pro-
cesses can be seen (not shown). (C) Overexpressed, mCherry-tagged KIF1C accumulates at the tips of cellular processes in
the COS-7 monkey fibroblast cell line (left). The same localization pattern can be observed for mCherry-tagged KIF1C-
Pro176Leu (middle). In contrast, mCherry-tagged KIF1CGly102Ala (right) fails to reach cellular processes and instead is
observed in a reticular pattern around the nucleus. 200-mm scale bar.
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neuroblastoma cell line (SH-SY5Y, data not shown),
and a mouse spinal cord motor neuron cell line
(NSC-34). As described in the literature,7,11,12 KIF1C
was located mainly in the perinuclear area with an
accumulation in the pericentrosomal region. In cells
forming cellular processes, i.e., NSC-34 cells or a
subset of COS-7 cells, KIF1C was additionally
localized along cellular processes and enriched at
their tips (figure 3, A and B).
Subcellular localization of overexpressed wild-type
and mutant KIF1C protein. Similarly, we found
overexpressed wild-type KIF1C (pmCherry-
KIF1Cwt) in the perinuclear region and strongly
accumulating in the cellular processes of COS-7
cells (figure 3C). Overexpressed KIF1CPro176Leu
(pmCherry-KIF1CPro176Leu) showed a localization
pattern indistinguishable from wild-type. Overexpressed
KIF1CGly102Ala (pmCherry-KIF1CGly102Ala) as well as
KIF1CArg301Gly, however, failed to reach the tips of
cellular processes and instead accumulated in a reticular
pattern in a wide area around the nucleus of COS-7 cells
(figure 3C, data for KIF1CArg301Gly not shown).
In family THI26001, severely affected subjects carry
a mixture of 2 mutant alleles, whereas the very mildly
affected heterozygous mutation carriers possess only
one of the mutant copies in a wild-type background.
Two kinesin-3 motors closely related to KIF1C have
been studied in vitro, mouse KIF1A and Caenorhabditis
elegans Unc104.13–15 Both appear to be active in vivo as
dimers. To mimic the human situation more closely,
we simultaneously overexpressed each of the mutants
together with wild-type and a combination of both
mutants together. As expected from the mono-
overexpression experiments, simultaneous overexpres-
sion of KIF1CPro176Leu and KIF1Cwt led to colocaliza-
tion of both alleles in a distribution indistinguishable
from wild-type (figure 4B). Of note, upon co-
overexpression of KIF1CGly102Ala and KIF1Cwt, the
normal distribution pattern could partially be restored
and both KIF1CGly102Ala and KIF1Cwt colocalized at
the tips of cellular processes (figure 4C). Overexpression
of KIF1CPro176Leu together with KIF1CGly102Ala, how-
ever, failed to restore the localization at the tips of cel-
lular processes. Moreover, KIF1CPro176Leu, which
shows a normal localization pattern when overexpressed
alone or together with KIF1Cwt, also became trapped in
the reticular perinuclear localization pattern typical for
the KIF1CGly102Ala mutant (figure 4D).
DISCUSSION HSPs are genetically highly heteroge-
neous. However, despite at least 38 known HSP genes,
approximately one-third of dominant and at least half of
recessive cases still cannot be explained by mutations in
known genes. In this study, we uncovered the genetic
basis for a new subtype of HSP with autosomal
dominant and recessive inheritance—termed SPG58.
Our approach exemplifies the power of exome
sequencing to identify novel disease genes even in small
families, especially when combined with classic segrega-
tion analysis and access to a “validation cohort” of cases
with similar phenotypes. Considering the long lists of
candidate genes typically generated by exome sequenc-
ing of single families, the latter is absolutely essential to
gain additional evidence for the pathogenic relevance of
a novel disease gene. Collection of these “exome repos-
itories,” however, can be challenging, especially for rare
diseases, and requires large collaborative efforts.3
KIF1C belongs to the large family of kinesin motor
proteins and represents the third kinesin gene involved
in the pathogenesis of HSP: mutations in the kinesin
heavy chain gene KIF5A, encoding the main neuronal
motor for long-range axonal transport, cause autosomal
dominant SPG10,16,17 and mutations in KIF1A cause
autosomal recessive SPG30.18,19 Kinesins are a large
family of microtubule-dependent motor proteins that
are involved in intracellular transport and organization
of the mitotic spindle. KIF1C was first identified as a
binding partner of tyrosine phosphatase PTPD1 and
recognized, together with KIF1A, as a member of the
so-called kinesin-3/KIF1 family based on sequence
homology and the presence of a forkhead-associated
domain.7 Endogenous KIF1C is localized at the peri-
centrosome, in the region of the Golgi apparatus,7 and
in the cell periphery with accumulation at the tips of
cellular processes, colocalizing with microtubule plus-
ends.12,20 Although the precise function of KIF1C still
is not clear, it has been implicated in retrograde vesic-
ular transport between Golgi and endoplasmic reticu-
lum,7 maintenance and reformation of podosomes in
macrophages,20 and stabilization of trailing adhesions
in migrating cells.12 Knockdown of KIF1C in hippo-
campal neurons leads to defective neurite outgrowth.11
Most known protein interactions of KIF1C require the
C-terminus (figure 1C); known interaction partners
comprise 14-3-3 family proteins,21 the nonmuscle myo-
sin II A,20 bicaudal-D-related protein 1 (BICDR-1),11
and kinesin binding protein KBP.22 Notably, some of
these interaction partners are themselves associated with
hereditary disorders: mutations in the myosin II A
MYH9 cause sensorineural deafness, mutations in the
bicaudal D homolog 2 (BICD2) gene, a close homolog
of BICDR-1, have recently been shown to cause a spec-
trum of motor neuron disorders including HSP,23 and
KBP mutations are responsible for autosomal recessive
Shprintzen-Goldberg syndrome.
The 3 mutations we describe in this study are all
located within the highly conserved KIF1C motor
domain. The p-loop mutation Gly102Ala affects the
ATP binding site of the motor. Mutations of this
amino acid in KIF1A and other kinesins have been
shown to impair ATP hydrolysis, lead to “rigor” bind-
ing of the immobilizedmotor on microtubules,24,25 and
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have a dominant negative effect when expressed in
wild-type background.25 Similar to the Arg301Gly
mutation for which we have demonstrated reduced
microtubule binding affinity and consequently reduced
transport rates in the corresponding amino acid in
KIF5A (Arg278),10 the position of the Pro176Leu
mutation suggests a microtubule binding defect.
While overexpression of wild-type KIF1C can rescue
the perinuclear mislocalization of KIF1CGly102Ala,
the KIF1CPro176Leu protein does not rescue this
defect, supporting the pathogenicity of both variants.
The phenotype of SPG58 is—as is typical for HSP—
variable, ranging from seemingly pure HSP to a spastic
ataxia phenotype with signs of widespread
Figure 4 Double overexpression of mCherry- and GFP-tagged mutant and wild-type KIF1C alleles
In double transfections of COS-7 cells with 2 wild-type alleles (A) or one Pro176Leu and one wild-type allele (B), the normal local-
ization pattern consisting of a slight cytoplasmic staining combinedwith accumulation in cellular processes can be seen. The local-
ization defect observed in KIF1CGly102Ala mono-overexpression experiments can be partially rescued by simultaneous
overexpression of KIF1Cwt (C), but not by simultaneous overexpression of KIF1CPro176Leu (D). 200-mm scale bar.
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demyelination in neurophysiologic examinations and
T2 hyperintensities compatible with demyelination
on MRI. While this report was under review, another
report of KIF1C mutations in 2 consanguineous fam-
ilies of Palestinian/Moroccan origin was published.26
The phenotype was very similar to that of our fami-
lies, with an early-onset spastic ataxia, normal cogni-
tive function, and a similar pattern of T2
hyperintensities on MRI. Cervical dystonia, neurop-
athy, and reduced visual acuity were variably present.
Notably, 3 of 4 heterozygous mutation carriers that
were available for examination in our study expressed a
mild clinical disease phenotype as well as mild MRI
changes. This dual mode of inheritance with a mild
dominant disease phenotype and a more severe recessive
disease expression has been previously described for at
least 2 HSP subtypes. In autosomal recessive SPG7, a
mild carrier phenotype mimicking autosomal dominant
inheritance has been described in some families.27 While
heterozygous mutations in the heat shock protein 60
gene, HSP60, cause autosomal dominant pure HSP,28
homozygousHSP60mutations cause an early-onset fatal
hypomyelinating leukodystrophy.29 In many ways,
SPG58 exemplifies the diagnostic and counseling chal-
lenge rare hereditary diseases pose: phenotypic variability
that impedes pattern recognition strategies for diagnosis,
a phenotype overlapping with other disorders (hereditary
ataxias and spastic paraplegias), and a mode of inheri-
tance that blurs the lines between traditional mendelian
inheritance patterns.
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Abstract 
Hereditary spastic paraplegias (HSPs) are highly heterogeneous neurodegenerative disorders 
characterized by lower limb spasticity and weakness. All HSPs share a common trait – a progressive 
length-dependent degeneration of the motor axons that compose the corticospinal tract. However, 
many underlying mechanisms of the pathology still remain unknown. In the present study we aim to 
elucidate the pathological mechanism of spastic paraplegia type 58 (SPG58), an autosomal recessive 
subtype of HSP complicated by ataxia, which is caused by mutations in the Kinesin-like protein 1C 
(KIF1C) gene. Here we demonstrate that KIF1C functions as an RNA-binding protein (RBP), that it 
interacts with other RBPs such as the polyadenylate binding protein cytoplasmic I (PABP), the heat-
shock 70KDa protein 8 isoform 1 (HSPA8) and the insulin-like growth factor II mRNA binding 
protein I (IMP-1); and that the KIF1C-PABP mutual interaction is RNA-mediated. We report that 
KIF1C-bound transcripts are involved in pathways such as gene expression, cell cycle, RNA 
processing and RNA splicing, and that ribosomal RNAs are strongly enriched among these transcripts. 
Finally, we show that immobilizing mutations in KIF1C lead to a dramatic re-distribution of 
ribosomes. These findings suggest KIF1C as an axonal transporter for ribosomes. 
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Introduction 
Hereditary spastic paraplegias (HSPs) are a group of inherited neurodegenerative disorders 
characterized by a progressive spasticity and weakness of the lower limbs. With a prevalence of 1,3 to 
9,6 in 100.000 individuals (1, 2). HSPs are rare, yet they rank among the clinically and genetically 
most heterogeneous Mendelian diseases. HSPs can be inherited in autosomal dominant, autosomal 
recessive and X-linked manner. To date, at least 76 different loci and 59 corresponding spastic 
paraplegia genes (SPG) have been identified (3, 4). Despite this diversity all forms of HSP share a 
common pathology, a length-dependent distal axonopathy of the upper motor neurons, which compose 
the corticospinal tract. 
Corticospinal tract motor neurons critically depend on efficient transport mechanisms throughout the 
axons to deliver vesicles and other organelles such as mitochondria, RNA-granules and polyribosomes 
to their respective target sites (5, 6). Polyribosomes - complexes of ribosomes linked to messenger 
RNA (mRNA) molecules - are transported as stably paused complexes from the nucleus to the synapse 
to allow rapid on-site translation (6). Local protein translation is essential for synaptic plasticity (6), 
dysregulation of which can cause common neurological disorders such as Alzheimer’s disease (AD) 
(7), Parkinson’s disease (PD) (8), and Huntington’s disease (HD) (9). RNA-binding proteins (RBPs) 
play a critical role in translational control of mRNA and dysfunction of RBPs such as TDP-43, FMRP 
or SMN can lead to Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia (FTLD) (10), 
Fragile X syndrome (FXS) (11), or Spinal muscular atrophy (SMA) (12) respectively.  
Corticospinal tract axons are among the longest in the central nervous system (CNS) and therefore are 
arguably most vulnerable to disturbances of axonal transport (13). Thus it is not surprising that several 
HSP-associated proteins are directly involved in axonal transport, including kinesin heavy chain 5A 
(KIF5A), kinesin-like protein 1A (KIF1A) and spastin (SPAST) (14–16). We have recently discovered 
that loss-of-function mutations in KIF1C, encoding the kinesin-like protein 1C (KIF1C), cause 
autosomal recessive HSP type 58 (SPG58) (17). The biological function of KIF1C as well as the 
molecular mechanism of SPG58 pathogenesis, however, are still incompletely understood. 
Endogenous KIF1C is expressed ubiquitously and can be spotted around the centrosome and Golgi 
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apparatus (18, 19). It also accumulates in the cell periphery and verges of cellular extensions (20, 21). 
Functionally, KIF1C has been shown to be involved in retrograde vesicular transport between Golgi 
and endoplasmic reticulum (ER) (19), in Golgi membrane organization (22), formation and 
maintenance of podosomes in macrophages (21, 23) and stabilization of trailing focal adhesions in 
migrating cells (20).  
In the present study, we set out to elucidate the molecular function of KIF1C. We demonstrate that 
KIF1C directly binds RNA and RNA-binding proteins. Ribosomal components are strongly enriched 
among KIF1C-bound transcripts. We speculate that KIF1C might be an axonal transporter for 
ribosomes and show that immobilizing mutations in KIF1C lead to a dramatic re-distribution of 
ribosomal components.  
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Results 
Identification of KIF1C interacting partners 
Specific cargoes as well as cargo adapters and regulators of KIF1C are still unknown. To identify 
interaction partners we immunoprecipitated protein complexes bound to wildtype KIF1C (KIF1CWT) 
or pathogenic KIF1C (KIF1CG102A and KIF1CP176L) isoforms overexpressed (17) in the monkey 
fibroblast-like COS-7 cell line as well as in the human kidney HEK293T line. Silver staining of SDS-
PAGE gels (Figure S1) loaded with the respective precipitates, demonstrated the enrichment of a 
specific protein band of approximately 70 KDa in both wildtype and mutant KIF1C samples in 
comparison to controls (proteins pulled down with an IgG antibody). Mass spectrometry indicated the 
presence of several proteins (Table S1) including the polyadenylate binding protein cytoplasmic I 
(PABP), the heat-shock 70KDa protein 8 isoform 1 (HSPA8), the insulin-like growth factor II mRNA 
binding protein I (IMP-1), and the insulin-like growth factor II mRNA binding protein III (IMP-3).  
Validation of KIF1C interactions 
We then performed co-immunoprecipitation (Co-IP) assays and co-localization analysis by 
immunofluorescence (IF) to validate the potential new KIF1C interaction partners PABP, IMP-1 and 
HSPA8.  
a) Protein interaction was confirmed by Co-IP by overexpression of the HA-tagged fusion proteins 
KIF1CWT, KIF1CG102A, KIF1CP176L or KIF1CR301G in HEK293T cells. All three candidate interactors - 
PABP, IMP-1 and HSPA8 - could be detected by western blot after being pulled down with an anti-
HA antibody (Figure 1A). Quantification of the relative ratio of the respective candidate interactor 
over KIF1C in three independent experimental repetitions revealed that mutant KIF1C isoforms bind 
to interactors with the same affinity as wildtype KIF1C (Figure 1B). The same results were observed 
with a reverse Co-IP, when an anti-PABP antibody was used to pull down the protein complex, instead 
of an anti-HA antibody (Figure 1C), thus confirming the specificity of the interaction. As expected 
none of the candidate interactors could be immunoprecipitated with an IgG control antibody (Figure 
1A,C). 
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The dynein motor adaptor Bicaudal D Homolog 2 (BICD2), which has been implicated in the 
pathogenesis of spinal muscular atrophy and HSP (24), has been previously reported to interact with 
KIF1C (25). However, we were not able to confirm a KIF1C-BICD2 interaction through 
immunoprecipitation (Figure 1A).  
b) Co-localization by confocal microscopy of endogenous KIF1C with its respective candidate 
interaction partners: PABP, IMP-1 and HSPA8 were observed in the human neuronal SH-SY5Y cell 
line (Figure 2). KIF1C is sparsely distributed throughout the cell with a propensity to accumulate at 
the centrosome and at the tips of cellular processes where it co-localizes with PABP. KIF1C also co-
localizes with HSPA8 at the edge of cellular protrusions, and with IMP-1 at the periphery of cellular 
extensions and partially around the nucleus. Similar results were obtained in the monkey fibroblast-
like COS-7 cell line (Figure S2), although both the staining pattern of endogenous KIF1C as well as 
the co-localization pattern between KIF1C and its interaction patterns are less distinct than in the 
neuronal SH-SY5Y cell line.  
In line with our results obtained with immunoprecipitation, we observed no co-localization between 
BICD2 and KIF1C, when overexpressing KIF1CWT or KIF1CG102A (Figure S3, Figure S4).  
Impact of pathogenic p.G102A mutation on KIF1C interactions 
To test whether immobilizing mutations in the motor domain of KIF1C affect the co-localization 
pattern with the candidate interaction partners, we proceeded to overexpress KIF1CWT and mutant 
KIF1CG102A in COS-7 cells. As previously described in (17), overexpressed KIF1CWT accumulates at 
the cell periphery or tips of cellular protrusions. We observed almost complete co-localization of 
endogenous PABP with overexpressed KIF1CWT; both proteins accumulate at the tips of cellular 
processes (Figure 3). The extent of KIF1CWT:PABP co-localization is near complete and comparable 
to co-localization of GFP- and mCherry-tagged KIF1CWT fusion proteins (control). HSPA8 co-
localizes with KIF1CWT at sites of KIF1CWT accumulation while maintaining a strong cytoplasmic 
staining pattern seemingly independent of KIF1CWT. IMP-1 shows a predominantly cytoplasmic 
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staining pattern in COS-7 cells and co-localizes with KIF1CWT in a few small spots in the cell 
periphery. 
We have previously shown that the p.G102A mutation in the motor domain of KIF1C completely 
abolishes the peripheral staining pattern observed for overexpressed KIF1CWT (17). Interestingly, 
KIF1CG102A also recruits PABP to the cytoplasm, preventing its localization at the verge of cellular 
processes (Figure 4). Similarly, IMP-1 and HSPA8 lose their predilection for peripheral accumulation 
and display a more homogeneous cytoplasmic distribution while retaining a limited co-localization 
with KIF1CG102A. 
Further analysis looking at Pearson’s co-localization coefficient of KIF1CWT or KIF1CG102A with each 
of the respective interactors showed no relevant differences in the ratio interactor/KIF1C between 
wildtype and mutant KIF1C isoforms (Data not shown). This observation supports our hypothesis that 
pathogenic p.G102A mutation alters the distribution of KIF1C complexes without affecting its binding 
affinity to interactors.  
Study of KIF1C distribution 
For a better understanding of KIF1C localization and function we also studied its distribution in 
relation to different subcellular compartments such as the Golgi apparatus, the endoplasmic reticulum 
(ER) and the mitochondrial network. Previous publications have associated KIF1C with Golgi-ER 
transport or Golgi compartment organization (19, 22). Also the kinesin-like protein 1B (KIF1B), a 
strong homolog of KIF1C, is known to be involved in mitochondrial transport (26). However, in COS-
7 cells KIF1C did not co-localize with any of the tested markers for the ER (pmKate2-ER), Golgi 
(GM130), or the mitochondrial network (TRAK2). These results were consistent for endogenous 
KIF1C (Figure S5), overexpressed KIF1CWT (Figure S3) as well as KIF1CG102A (Figure S4).  
In a previous study about the role of KIF1C in podosome dynamics in macrophages, the motor protein 
had been reported to interact indirectly with the actin cytoskeleton (21). Thus we decided to employ 
immunofluorescent imaging to evaluate the effects of KIF1CG102A overexpression on actin 
cytoskeleton architecture. However, the actin cytoskeleton looked unaltered compared to cells 
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overexpressing KIF1CWT (Figure S6). Additionally, we also observed that pathogenic p.G102A 
mutation caused no apparent disturbance on the microtubule architecture when compared to cells 
overexpressing the wildtype form or cells with endogenous protein levels (Figure S7). 
KIF1C-PABP interaction is RNA-mediated 
PABP, IMP-1 and HSPA8 are known RNA-binding proteins that are involved in RNA metabolism in 
various functions (27–29). This suggested that KIF1C might also be involved in RNA metabolism 
through regulation and/or transport. To test whether KIF1C binds to its interactors directly or 
indirectly by mutual interaction with RNA, we performed an “RNAse-COIP” experiment. We focused 
on KIF1C-PABP interaction because it had proven to be the strongest (Figure 1). We added increasing 
concentrations of RNAse I to the lysis buffer before pulling down protein complexes with an anti-HA 
antibody in HEK293T cells transiently overexpressing KIF1C-HA. The interaction between KIF1C 
and PABP was markedly reduced by addition of RNAse I in a dose-dependent manner (Figure 5A,B). 
This could also be confirmed when pulling down protein complexes using an anti-PABP antibody 
(Figure 5A,B). To control for the relative excess of KIF1C due to transient overexpression, we 
repeated the experimental setup overexpressing both KIF1C (HA-tagged) and PABP (GFP-tagged). 
Again, a reduced interaction between KIF1C and PABP after addition of RNAse I was confirmed 
using either an anti-HA or anti-GFP antibody for the precipitation of complexes (Figure 5C,D). Lastly, 
the dependence of the KIF1C-PABP interaction on the presence of RNA was confirmed under 
endogenous conditions (Figure 5E,F). The latter experiment was carried out in HeLa cells as they 
express rather strong endogenous levels of both KIF1C and PABP compared to other cell types 
(Figure S8A). 
The results of these three similar approaches suggest that KIF1C and PABP interact indirectly and that 
the interaction is mediated through mutual binding of RNA. 
Identification of transcripts bound to KIF1C 
Given that the interaction between KIF1C and PABP is RNA-mediated we hypothesized that KIF1C 
might be an RBP itself. To test this hypothesis and identify KIF1C-bound transcripts, we performed 
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individual-nucleotide resolution UV crosslinking immunoprecipitation (iCLIP) in HEK293T cells 
transiently overexpressing either KIF1C-mCherry or mCherry encoded by the empty pmCherry-N1 
plasmid. We applied the protocol detailed in (30) with slight modifications (see material and methods). 
In short, RNA-protein binding sites were crosslinked (CL) by irradiation with UV light (254nm), 
allowing for subsequent rigorous purification of RNA-protein complexes. Lysates were 
immunoprecipitated with anti-mCherry, separated using SDS-PAGE, transferred to a nitrocellulose 
membrane and visualized with Ponceau staining. Complexes ranging between 150-250 kDa in size 
were retrieved from the membrane (blue box in Figure S9A) and proteins were removed by proteinase 
K treatment. Then the remaining RNA (tagged with small peptides at CL sites) was reverse transcribed 
with a specific “Rclip” primer. Resulting cDNA was loaded on a TBE-Urea gel (not shown), where we 
artificially defined three different cutting fractions of 120-200 nt (high), 85-120 nt (medium) and 70-
85 nt (low). cDNA fragments of all fractions were purified from the gel and circularized, linearized 
again and amplified with specific primers. Finally, a quality control of amplified cDNA fragments 
(Figure S9B) revealed that only lanes 7 and 8, which represent the high and medium size fraction of 
the KIF1C-mCherry crosslinked sample, contained significant amounts of amplified DNA. 
Consequently, a cDNA library was generated from the mix of lanes 7 and 8 together. Four different 
concentrations of this library were prepared in duplicates to obtain eight separate replicates which 
were subjected to next generation sequencing. In the two negative controls, i) overexpression of empty 
mCherry plasmid and ii) overexpression of KIF1C-mCherry without cross-linking, no DNA could be 
amplified in any of the size fractions.  
Analysis of next generation sequencing data 
An average of about 157 million read-pairs of ~100bp in length were produced per sample (8 
replicates).  About 48 million read-pairs could be mapped to the hg19 reference genome (Figure 6A).  
Consecutively, mapped reads were processed with the PIPE-CLIP analysis tool (31). Filtering for 
minimum read length and maximum base mismatch retrieved a mean of about 500 thousand reads per 
sample. Aggregation of adjacent reads overlapping by at least one nucleotide identified a mean of 
1.065 ± 141 enriched clusters per sample. Clustering of all cDNA truncations (indicating RNA-protein 
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crosslinking sites) found at a given genomic location identified a mean of 3.017 ± 167 reliable 
truncation sites (Figure 6A). Finally, the mapping of the truncation sites to the enriched clusters 
allowed us to identify a mean of 1.858 ± 116 crosslinking mutations clustered in 602 ± 70 CL sites, 
which matched to 427 ± 52 genes per sample (Table S2). These values were within the expected range 
for PIPE-CLIP analysis as shown in the summary table for the Nova iCLIP data (31).  
The crosslinking sites across all 8 replicates mapped to a total of 515 unique genes (Table S3). The 
candidate gene lists resulting from the 8 replicates were highly correlated (correlation coefficients > 
0.997); 86% of genes were represented in at least four samples and 57% of genes were present in all 8 
replicates (Table S3). The genes present in three or less samples without exception had low peak 
scores (number of reads per cluster), 40fold lower than average peak scores in genes present in ≥4 
lanes. We therefore decided to pool all replicates for further analysis and include only genes detected 
in at least four samples (n=441) in the joint analysis. 99.1% of genes had peak scores below 5.000 
with a median of 133. Among the four genes represented by transcripts with the highest peak scores 
were two ribosomal DNA genes: RNA45S5 from which the ribosomal 28S, 5.8S, and 18S subunits are 
transcribed, and RNA5-8S5 that encodes the ribosomal 5S subunit (Figure S9C). Very high peak scores 
were further observed for KIF1C and HYDIN (hydrocephalus inducing protein homologue) (Figure 
S9C). 
Confirmation of RNA transcripts 
To validate the iCLIP results, we performed an RNA-immunoprecipitation (RIP) assay in HEK293T 
cells, either untransfected or transiently overexpressing KIF1C-HA. In short, after 
immunoprecipitation of the RNA-protein complex, recovered RNA was retro-transcribed and 
amplified with specific primers to verify presence and relative abundance of a specific transcript in the 
immunoprecipitated sample. Preliminary RNA quality control addressed by a Bioanalyzer showed 
rRNA and mRNA present in the sample immunoprecipitated with an anti-HA but absent in the IgG 
control (Figure S10). We selected five genes - KIF1C, HYDIN, HFM1, PDE3 & RAPGEF – all of 
which were among the 10 highest scoring genes in the iCLIP analysis (Table S3). As expected all 
these transcripts were not only present in the IP sample (under endogenous or overexpressing 
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conditions) but also overrepresented in comparison to the RNA from the input sample (Figure 6B). 
GAPDH ranked the 330
th
 position in the list and therefore was used to show a case of low 
representation, whereas amplification of RPLP0 (absent in the list, Table S3) served as a negative 
control. 
Pathway enrichment analysis 
To determine cellular pathways and components that the transcripts bound to KIF1C play a role in, we 
used the DAVID Bioinformatics Database (32) to functionally annotate the genes (n=441) whose 
RNA we found to interact with KIF1C. 420/441 could be mapped by DAVID; the 21 genes that could 
not be mapped by DAVID included 16 RNA genes (ncRNA, miRNA, lncRNA, mt-rRNA) (Figure 6c), 
4 pseudogenes and 1 fusion protein gene. We performed functional annotation using several pathway 
tools (BBID, BIOCARTA, KEGG pathway, Panther pathway, REACTOME, GO terms) and then 
created a pathway enrichment map using the Cytoscape pathway enrichment plugin. Significant 
enrichment was demonstrated for genes involved in RNA/DNA metabolism, gene expression, cell 
cycle, RNA processing and RNA splicing pathways (Figure 6C). This analysis suggests that KIF1C 
has a clear prevalence for transcripts involved in a certain aspect of RNA metabolism. This hypothesis 
is further supported by the presence of two ribosomal genes: RNA45S5 and RNA5-8S5, which are 
among the transcripts with highest peak scores in (Table S3).  
KIF1C interacts with Ribosomes 
The strong over-representation of RNA-related functional pathways among the interactions of KIF1C 
suggested that KIF1C might cooperate with ribosomes. We therefore studied the interaction between 
the ribosomal protein RPS6 and the KIF1C motor through IF and IP. Immunofluorescent imaging of 
COS-7 cells overproducing KIF1CWT demonstrates strong co-localization between RPS6 and 
KIF1CWT in the cell periphery accumulating at the tip of cellular processes (Figure 7A). 
Overexpression of the immobile motor KIF1CG102A on the other hand leads to cytoplasmic 
redistribution of kinesin and recruitment of RPS6 from the cell periphery to the cytoplasm. Under 
endogenous conditions the KIF1C-RPS6 co-localization is not complete but is clearly detected at the 
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cell edges in COS-7 cells (Figure 7A) and it is even more clearly perceptible in SH-SY5Y cells 
(Figure 7B). 
The interaction between KIF1C and the ribosomal protein RPS6 could also be confirmed in HEK293T 
cells transiently overexpressing KIF1CWT-HA and immunoprecipitated with an anti-HA or anti-RPS6 
antibody (Figure 7C); in both cases the two proteins, as well as PABP, were co-immunoprecipitated, 
thus proving to be part of the same complex.  
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Discussion 
Previous studies have implicated KIF1C in anterograde transport of α5β1-integrins, retrograde Golgi 
to ER transport (19, 20) or Golgi membrane shaping (22). However, it is currently unclear, how these 
different functions may be related and which properties of KIF1C may be critical for its role in HSP 
disease pathology. Therefore we hypothesized that identification of KIF1C interaction partners might 
reveal previously unrecognized functional connections. Peptide identification (Table S1) in KIF1C 
complexes indeed revealed novel interactions with the proteins PABP, IMP-1 and HSPA8, all of 
which were successfully confirmed by co-immunoprecipitation and co-localization studies. 
Interestingly, PABP is a protein that binds to the 3' poly(A) tail of messenger RNAs to regulate mRNA 
stability, splicing, translation and nonsense-mediated decay (NMD) (33, 34). Moreover, when PABP 
binds to the adenine-rich auto-regulatory sequence (ARS) in the 5’UTR of its own mRNA to repress 
translation, it is assisted by IMP-1 forming an auto-regulatory complex (ARC) in vitro (35). In 
addition, IMP-1 binds to the 3’UTR of β-actin (ACTB) mRNA forming and mRNP complex that is 
responsible to deliver ACTB mRNA to leading edges of cells as seen for chicken fibroblasts and 
neurons and for growth cones of Xenopus laevis. This localization is essential for growth cone motility 
and guidance (36–38). Lastly, HSPA8 is a component of the PRP19-CDC5L complex in the 
spliceosome, which is required to activate mRNA splicing (39). The fact that all three novel 
interactors are known RNA-binding proteins (27–29), strongly suggested a role of KIF1C in RNA 
metabolism and/or transport. And indeed, RNA-immunoprecipitation in HEK293T cells transiently 
overexpressing KIF1C-HA confirmed presence of messenger and ribosomal RNA in KIF1C 
complexes (Figure S10). 
However, neither the protein- nor the RNA-immunoprecipitation experiments we had initially 
performed were suitable to discriminate between direct and indirect interactions. We first speculated 
that the RBPs might mediate interaction between KIF1C and RNA. We were however surprised to 
find that instead, the interaction between KIF1C and the other RBPs is seemingly mediated by their 
mutual capacity to bind RNA, as shown exemplarily for PABP (Figure 5). This hypothesis is 
supported by two independent studies in which high-throughput screenings had previously identified 
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KIF1C as a candidate RBP as one of 860 and 800 identified candidate proteins respectively (40, 41). 
To validate these findings we used iCLIP, a state-of-the-art technique that allows identification of 
RNA transcripts covalently bound to a specific protein (30). Compared to normal RNA-
immunoprecipitation, crosslinking-immunoprecipitation (CLIP) allows for more stringent purification, 
thus reducing unspecific interactions (42). In none of the negative controls (overexpression of an 
‘empty’ pmCherry vector; overexpression of KIF1C-mCherry without crosslinking) RNA transcripts 
were present (Figure S9B). Analysis of the 441 transcripts consistently present in our dataset 
consolidated the role of KIF1C in RNA metabolism and/or transport. For one, pathway analysis - 
using the DAVID bioinformatics tool - revealed a strong enrichment of genes related to RNA/DNA 
metabolism, gene expression, cell cycle, RNA processing and RNA splicing pathways (Figure 6C). 
Secondly, 46% of all reads represented the ribosomal genes RNA45S5 and RNA5-8S5 (Table S3). As 
no ribosomal contamination was present in the negative controls we consider these reads to be specific 
to our dataset. The abundance of ribosomal RNA, overrepresentation of transcripts related to RNA 
metabolism in the broader sense, and presence of known RNA-binding proteins in the KIF1C complex 
suggested an interaction of KIF1C with ribosomes. This hypothesis was tested by studying KIF1C 
interaction with a representative ribosomal protein such us RPS6 by IF and IP assays (Figure 7). 
Ribosomal protein S6 has been used as a marker to measure dendritic mRNA transport as RNA 
granules in hippocampal neurons (43). Judging by RPS6-KIF1C co-localization, overexpression of 
KIF1CWT induces a ribosomal recruitment to the cell periphery and accumulation at the tips of cellular 
processes. However, this localization pattern is lost after overexpression of KIF1CG102A; the 
cytoplasmic phenotype reflects how pathogenic p.G102A mutation in KIF1C alters ribosome 
distribution. Immunofluorescence results are supported by the reciprocal co-immunoprecipitation of 
KIF1C and RPS6. Taken together, these observations strongly suggest that KIF1C interacts with 
ribosomes and that it is likely involved in active ribosomal transport.  
Surprisingly little is known about such a basic mechanism as ribosomal transport. We know that in 
neurons, ribosomal subunits are found in RNA granules - large macromolecular structures containing 
RNAs and proteins - (44) however, it is not known how those RNA granules are carried. A few studies 
have described the implication of certain kinesins in the transport of ribosomes. It is known that a 
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member of the human kinesin-5 family: KIF11 is required to link ribosomes to microtubules, and that 
its inhibition causes slowed ribosome transit and affects translation, which is physiologically 
dependent on KIF11’s ATPase activity. Although it is unknown whether KIF11 binds directly or 
indirectly to the ribosome, it has been proposed as a motile microtubule-ribosome linker that enhances 
translation efficiency and that could also play a role in translation elongation and termination (45). 
KIF1C, KIF1B and kinesin-like protein 1A (KIF1A) belong to the kinesin-3 family. A kinesin-3 
homolog in the fungus Ustilago maydis: Kin3, is responsible for the endosome-mediated anterograde 
shuttling of mRNPs that contain the RBP: Rrm4, in the elongated hyphal cell (46). Furthermore, the 
mouse homolog of the Kinesin-4 family in humans: KIF4 interacts with the ribosomal protein P0 
(component of the 60s subunit) in dorsal root ganglia (DGR) neurons; as KIF1C does with RPS6 in 
our cellular models. In addition, as it happens with the p.G102A mutation in KIF1C, mutations in 
KIF4 alter the intracellular distribution of ribosomes, represented by P0 localization. Finally, RNAi 
suppression reveals that KIF4 is essential for the anterograde translocation of ribosomal constituents to 
developing axons (47). 
Implication of these kinesins in ribosomal transport further strengthens our hypothesis that KIF1C 
might be an axonal transporter for ribosomes involved in maintenance and regulation of synaptic 
translation in neurons. However, a more comprehensive live imaging testing will be needed to prove 
the hypothesis. As a next step we will study in vivo ribosomal transport of KIF1C in a more suitable 
neuronal model such as iPS-derived neurons.  
Our study for the first time implicates RNA transport and/or metabolism in the pathogenesis of HSP 
and thus moves HSPs closer to the growing number of related neurodegenerative diseases like ALS 
and FTD (10) in which mutations in RNA-binding proteins are recognized to be intricately involved in 
disease pathology.  
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Methods 
Cloning. KIF1C cDNA was amplified from pRK5-KIF1C kindly provided by Dr. Reiner Lammers 
and cloned into a pENTR/D-TOPO vector (#K2400-20, Invitrogen) accordingly to manufacturer’s 
instructions. Subsequently we introduced the changes c.305G>C (p.G102A); c.527C>T (p.176P>L) 
and c.901A>G (p.301R>G) respectively into pENTR-KIF1CWT, using the Q5 site-directed 
mutagenesis kit (#E0554S, NEB). KIF1C coding sequence was amplified from all resulting constructs: 
pENTR-KIF1CWT, pENTR-KIF1CG102A, pENTR-KIF1CP176L, pENTR-KIF1CR301G, with specific 
primers (Reverse primer containing sequence coding for an HA-tag) to introduce them into a pCS2+ 
vector (kindly donated by Dr. Alexander Abrams), thus obtaining: pCS2+KIF1CWT-HA, 
pCS2+KIF1CG102A-HA, pCS2+KIF1CP176L-HA, pCS2+KIF1CR301G-HA. All plasmids were sequenced 
to confirm changes - primers available in (TableS4) - and no other mutations were found. Additional 
plasmids used such us pTOPO-GFP-KIF1CWT, pTOPO-GFP-KIF1CG102A, pmCherryN1-KIF1CWT and 
pmCherryN1-KIF1CG102A were previously cloned as described in (17). 
Other plasmids. pmCherryN1 (#632523, Clontech Laboratories), pmKate2-ER (#FP324, Evrogen), 
pEGFP-N3-ITGA5 (#15238, Addgene), p.α5-integrin-GFP and pKIF1C-mCherry were provided by 
Dr. Anne Straube, pTOPO-TRAK2-GFP was provided by Dr. Adriana Rebelo and pPABP-eGFP was 
kindly donated by Dr. Matthias Hentze. 
Cell culture. Human Embryonic Kidney (HEK) 293T, HeLa, human glioblastoma U-87 MG, human 
neuroblastoma SH-SY5Y, mouse motoneuron-like NSC-34 and the monkey fibroblast-like kidney 
COS-7 cell lines were all cultured in Dubelco’s modified eagle medium (DMEM) (Biochrom) 
supplemented with 10% Fetal calf serum (FCS) (#10270106, Thermofisher) and maintained at 37°C 
and 5% CO2. 
Transfection. Mammalian cell transfection of COS-7 or HEK293T with any of the above mentioned 
plasmids was done using Turbofect reagent (#R0531, ThermoScientific) dissolved in Opti-MEM 
(#31985047, Thermofisher) following the manufacturer’s instructions. 24 hours after transfection cells 
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were harvested and stored as frozen cell pellets or used directly for WB or IP, or either fixed in-situ for 
immunofluorescent microscopy purposes. 
Cell pellet stocks. All different cell types used: COS-7, HEK293T, HeLa, SH-SY5Y and U-87 MG -
transfected or untransfected- were grown in normal DMEM + 10% FCS medium, harvested when the 
plate was full and re-suspended in PBS (#8537, Sigma Aldrich), aliquoted (2-3 aliquots per 100mm 
culture dish, depending on cell type) and centrifuged at 500g for 10 min at 4°C. After aspiring 
supernatant, resulting cell pellets were snap-frozen on dry-ice and kept at -80°C until further use. 
KIF1C pull-down. Performed in parallel in COS-7 and HEK293T cells, both lines were transfected 
with three different constructs: pCS2+KIF1CWT-HA, pCS2+KIF1CG102A-HA and pCS2+KIF1CP176L-
HA. Cells were harvested and re-suspended in 1 ml of Lysis buffer (#87788, ThermoScientific) and 
centrifuged at maximum speed for 30 min. Following the Crosslink Magnetic IP and Co-IP Kit 
(#88805, ThermoScientific) collected supernatants were incubated with protein A/G magnetic beads 
previously coupled to the respective antibody (HA or IgG) and then protein complexes were eluted 
from beads. Eluted samples were loaded into an SDS-PAGE gel which was later fixed and silver 
stained to detect protein bands. The desired band was cut off the gel and sent to the TSRI Center for 
Mass Spectometry in Miami (FL, USA) for further analysis. 
(CO-) Immunoprecipitation (CO-IP). Was performed following the Classic Magnetic IP and Co-IP 
Kit (#88804, ThermoScientific). Cell pellets were thawed and re-suspended in 0.5 ml of Lysis buffer 
supplemented with Proteinase inhibitor (Sigma) and incubated at 4ºC for 30 min with rotation. Cell 
lysates were then centrifuged at 14.000 r.p.m. for 15 min. 50 µl of supernatant was saved as “input” 
sample and the rest (0.5-1mg protein) was incubated with 2-10 µg of the respective antibody (HA, 
KIF1C, PABP, RPS6 or IgG) overnight at 4°C rotating and then linked to 0.25 mg protein A/G 
Magnetic beads for 1 hour at room temperature (RT). After washings, immunoprecipitated protein 
complexes were finally eluted from the beads in 100µl of loading buffer (10µl 10x DTT, 20µl 5x 
loading dye, 70µl H2O) for 10 min at RT. 
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Western Blot. Either 1/2 or 1/3 of eluted IP samples and 30-50µg of input samples were loaded into 
8% BIS-TRIS gels and run at a constant 20mA per gel for 2 hours in 1x MOPS buffer. Proteins were 
then transferred onto a PVDF membrane (Milipore), or to Nitrocellulose for iCLIP, at 4°C overnight 
and 25V. Blocking was done in TBST + 5% milk and antibodies were incubated at 4°C overnight 
(Primary) and at RT for 1 hour (Secondary) in TBST + 1% milk. ECL detection was done with 10 ml 
of ECL-solution (10% Tris[1M] pH 8,5 + 0,5% Luminol[4,4%] + 0,22% PCA[1,5%] in water) plus 
10µl 30% H2O2. Blots were imaged using the ChemiDoc System (Bio-Rad) and images were 
processed and analyzed with Image Lab 5.1 software (Bio-Rad).  
Immunofluorescent microscopy. Untransfected or transfected COS-7 or SH-SY5Y cells were fixed 
in 4% Paraformaldehyde (PFA) in PBS for 20 minutes, washed once with PBS + 0.1% Triton X-100 
(TPBS) and blocked for 1 hour at RT with TPBS + 5% FCS. Primary and secondary antibodies were 
incubated in TPBS + 1% Bovine serum albumin (BSA) inside a moist chamber at 4°C overnight and 
for 1 hour at RT respectively. Coverslips were mounted into the slides with Dako fluorescent 
mounting media (Dako, Agilent). Cells were imaged using a LSM 510 Confocal Axiovert 200M 
inverted microscope (Zeiss), the resulting images were processed and analyzed with Fiji software and 
employing the “Coloc2” plugin to quantify co-localization through the Pearson’s-R correlation 
coefficient measured above threshold. 
RNAse-COIP. Followed the same procedure as for a CO-IP but adding either RNAse I (RNAse If, 
NEB) or RNAse inhibitor (RNAseOUT, Invitrogen) to the Lysis buffer.  
Individual-nucleotide resolution UV crosslinking immunoprecipitation. Following the method 
described by Huppertz I. and colleagues (30) we used HEK293T cells transfected either with 
pmCherryN1-KIF1CWT or pmCherryN1 empty vector (as a control). Transfected cells were irradiated 
with a pulse of 150 mJ/cm
2
 at 254 nm in a Stratalinker 2400 (Stratagene) and harvested in PBS (a non-
crosslinked control was included). Cells were lysed in lysis buffer containing a low RNAse dilution 
(1:500) and incubated with magnetic beads for overnight immunoprecipitation. IP was followed by 
high-salt buffer washes; dephosphorylation of RNA 3’-ends with polynucleotide kinase (PNK) (NEB); 
ligation to RNA 3’-ends of linker L3 (5’P-AAGATCGGAAGAGCGGTTCAG-3ddC); and a final 
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RNA 5’-end ATP labelling with PNK. Then samples were loaded on a SDS-PAGE and transferred to 
Nitrocellulose membrane which was stained with Ponceau solution to visualize protein bands. Desired 
region was cut off and treated with proteinase K (ThermoScientific) to degrade proteins, leaving just 
small peptides bound to RNA molecules at CL sites. This was followed by phenol/chloroform RNA 
isolation and overnight ethanol (ETOH) precipitation. Recovered RNA was mixed with Rclip13 
primer (5'P-NNTCCGNNNAGATCGGAAGAGCGTCGTGGATCCTGAACCGC) and reverse 
transcribed using Superscript III kit (Invitrogen). Resulting cDNA was precipitated overnight in 
ETOH and then loaded into a 6% TBE-urea gel (Invitrogen) to purify and separate by size. Three 
fractions at 120-200 nt (high), 85-120 nt (medium) and 70-85 nt (low) were cut off from each sample, 
which were later purified and precipitated overnight in ETOH. On the next day a cut_oligo 
(GTTCAGGATCCACGACGCTCTTCaaaa) was annealed to 5’-ends of cDNA fragments and 
molecules were circularized using CircLigase II (Epicentre) to be later again linearized with BamHI 
(Fermentas). After cDNA purification and precipitation, samples were PCR amplified with P5/P3 
solexa primers 
(AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT / 
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATC
T) using Accuprime Supermix enzyme (Invitrogen). Finally, aliquots of the samples were used for 
quality control on the Agilent bioanalyzer (High sensitivity DNA chip) to visualize cDNA bands.  
Library preparation & next generation sequencing. Positive samples on the TBE gel were 
retrieved, purified and prepared for sequencing. A cDNA library was generated pooling lanes 7 and 8 
together (Figure S9B), and then four different concentrations (6, 8, 10 and 12 pM) of this library were 
prepared in duplicates, thus obtaining eight separate replicates. High-throughput sequencing of the 
replicates was carried out by IMGM Laboratories GmbH (Germany) with an Illumina HiSeq 2500 
system. Sequencing was set as a non-stranded paired-end run (2x50bp). Sequencing data containing 
the reads was retrieved and stored as fastq files. 
Analysis of sequencing data. Fastq files were processed with Galaxy (https://usegalaxy.org) (48) as 
follows: all files from each sample (8 repetitions) were uploaded and treated independently and 
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concatenated into 2 files containing either all R1 reads (50bp) or all R2 reads (50bp). Concatenated 
read files were formatted with the FastqGrommer tool, QC read quality was checked and reads were 
finally aligned to the hg19 human genome using the Bowtie2 tool with default settings: Pair-end 
library (fastq file for R1 concatenate and fastq file for R2 concatenate); Minimum fragment length for 
valid pair-end alignment: 0; Maximum fragment length for valid pair-end alignment: 450; 
upstream/downstream mate orientations for a valid paired-end alignment against the forward reference 
strand: --fr; no-mixed behavior: No; no-discordant behavior: No; Allow mate dovetailing: No; Allow 
one mate alignment to contain another: No;  Allow mate alignments to overlap: No. Resulting .BAM 
files were analyzed using the PIPE-CLIP pipeline developed by Dr. Beibei Chen (31) from QBRC 
(TX, USA). Since PIPE-CLIP deals with pair-end as two single fragments, in order to reduce noise 
introduced by the second fragment of each sequenced pair, only the first fragment (R1 reads) 
containing the CLIP site were kept for further analysis. Mapped reads were filtered to exclude reads 
shorter than 20bp and with a maximum mismatch of 2bp. Crosslinking sites were predicted and 
annotated without removing the PCR duplicates and FDR for both enriched clusters and reliable 
mutations were set to 0.05 (-r 0 –M 0.05 –C 0.05). An individual output file was retrieved for each 
sample (8 replicates) containing a list of identified crosslinking sites and their matching transcripts. 
These were later mapped to the respective genes and sorted by descending peak score (number of 
reads). Then all genes identified across the 8 replicates were pooled together, with their respective 
peak score values, into a final list containing unique genes (Table S3). To normalize for peak score, 
genes in the list were given 8 values depending on how they ranked in the respective origin lists and 
then these values were summed up to allow gene sorting by ascending ranking value. Finally the total 
number of genes per replicate was estimated by giving 1-values if a gene was present or 0-values if 
absent and summing numbers up. 
RNA-Immunoprecipitation. We used cell pellets of untransfected HEK293T and HEK293T cells 
transfected with pCS2+KIF1C-HA for the endogenous and overexpressed RIP respectively; and 
followed the above mentioned IP protocol although prior to protein elution we proceeded to the 
purification of RNA:  Samples were washed repeatedly and digested with proteinase K solution, RNA 
was then extracted using the Phenol-Chloroform method and isolated through ethanol precipitation 
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following the Magna RIP protocol (#17-700, Milipore). After RNA recovery, equal amounts of input 
and immunoprecipitated sample were retro-transcribed to cDNA using the High fidelity cDNA 
synthesis kit (#05081955001, Roche), and then used the cDNA as PCR template using different 
primers (Table S4) specifically designed for quantitative PCR amplification and a GoTaq2 polymerase 
(M7801, Promega). PCR products were loaded into a 2% agarose gel and ran at 120V for 30min, 
images were captured with the Bio-Capt software on a UV-light Vilber Lourmat device. 
Functional Annotation.  Only genes (Table S3) detected in at least four of the eight replicates 
(n=441) were included in the joint analysis with DAVID Bioinformatics Resources 6.7, NIAID/NIH 
(david.ncifcrf.gov) (32). Since DAVID does not recognize all HGNC symbols, some were sequentially 
converted to different ID symbols and mapped to other gene lists: 396 IDs were mapped using 
Ensembl’s IDs (GRCH38.p3), 21 IDs mapped with HGNC symbols, 2 IDs mapped to Unigene 
accession symbols, 1 mapped to Ensembl Transcript IDs (GRCH38.p3) and 21 genes couldn’t be 
mapped to DAVID, including 16 RNA genes (ncRNA, miRNA, lncRNA, mt-rRNA), 4 pseudogenes, 
and 1 fusion protein gene. All gene IDs were then combined and submitted to DAVID. Fort the 
creation of the functional annotation chart EASE parameter was set to 0.05 and the rest were set as 
default; and for the Enrichment map we used the Cytoscape 3.2 plugin with the following parameters 
(p-value: 0.0001, FDR Q-value: 0.05, similarity overlap: 0.4). Finally, enrichment map was edited in 
Adobe Illustrator, changing node colors to represent data source: GO-terms: red, Reactome: orange, 
Panther biological process: purple, Panther molecular function: yellow, RNA genes were added 
manually in green. 
Antibodies. Mouse monoclonal PABP(10E10) (NB120-6125, Novus Biologicals), rabbit polyclonal 
PABP (ab21060, Abcam), goat polyclonal IMP-1(E-20) (sc-21026, Santa Cruz Biotechnology), mouse 
monoclonal HSC70(13D3) (MA3-014, ThermoScientific), rabbit monoclonal HSPA8(D12F2) (8444, 
Cell Signaling), mouse monoclonal anti-HA (26183, ThermoScientific), rabbit monoclonal HA-
Tag(C29F4) (3724, Cell Signaling), mouse monoclonal ß-Tubulin (32-2600, Invitrogen), mouse 
monoclonal ß-Actin (A5441, Sigma), rabbit polyclonal anti-BICD2 (HPA023013, Sigma Life 
Science), rabbit polyclonal anti-KIF1C (AKIN11, Cytoskeleton), rabbit polyclonal anti-KIF1C 
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(ab72238, abcam), mouse monoclonal anti-GM130 (610823, BD Biosciences), mouse monoclonal 
GAPDH (H86504M, Meridian Life Science), rabbit polyclonal mCherry (PA5-34974, 
ThermoScientific), mouse GFP-tag (GF28R, ThermoScientific), mouse S6 Ribosomal protein (2317, 
Cell Signaling), rabbit S6 Ribosomal protein (710405, Novex), normal mouse IgG (sc-2025, Santa 
Cruz Biotechnology), normal rabbit IgG (sc-2027, Santa Cruz Biotechnology), Anti-rabbit/mouse IgG 
HRP-linked (7074 & 7076, Cell Signaling), donkey anti-goat IgG-HRP (sc-2020, Santa Cruz 
Biotechnology), goat anti-mouse alexa-488, goat anti-rabbit alexa-488, goat anti-mouse alexa-568, 
goat anti-rabbit alexa-568 (A-11001, A-11008, A-11004, A-11011, Invitrogen). 
Primers. All primers used for the study can be found within Table S4 in the supplement. 
Statistics and Graphics. GraphPad Prism 5 (GraphPad Software Inc., CA, USA) was the software of 
choice for the statistical analysis using 1 way ANOVA with Dunnett's Multiple Comparison Test when 
comparing two or more groups against a control group; or performing an unpaired t-test when 
comparing only two groups against each other. Graphs were also created using GraphPad Prism 5 
software, bars drawn in the graphs represent the mean + SEM.    
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Figures and Figure legends 
 
 
 
Figure 1. Immunoprecipitation of KIF1C protein complexes from lysates of HEK293T cells 
untransfected (Ctrl) or transfected with plasmids encoding KIF1C
WT
-HA, KIF1C
G102A
-HA, 
KIF1C
P176L
-HA or KIF1C
R301G
-HA respectively and co-immunoprecipitated with an anti-HA antibody 
(A) or an anti-PABP antibody (C). Proteins KIF1CWT-HA, PABP, IMP-1 and HSPA8 co-
immunoprecipitate and are positively detected by western blot on both IP and input (50µg) lanes, 
whereas proteins BICD2 and GAPDH are absent on the IP lanes. Dotted lines delimit different blots. 
(B) Quantification of the relative amount of PABP, IMP-1 or HSPA8 bound to KIF1C between 
KIF1CWT and the different mutant isoforms, for the Co-IP seen in (A), using data from 3 independent 
IP experiments. Statistics: 1way ANOVA with Dunnett's Multiple Comparison Test, bars represent 
mean+SEM, p-values given for each comparison. 
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Figure 2. Co-localization of endogenous KIF1C Images show fluorescent immunostainings of SH-
SY5Y cells where endogenous KIF1C co-localizes with PABP mainly around the centrosome and at 
the tips of cellular extensions. KIF1C-HSPA8 co-localization is mainly found at the tip of cellular 
processes. KIF1C-IMP-1 co-localization also happens at the edges of cellular protrusions and partially 
around the nucleus. Fine dotted lines delimit nucleus and cell contours, scale bar: 20µm. 
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Figure 3. Co-localization of overexpressed KIF1C
WT
 Images show distribution of overexpressed 
KIF1C
WT
-cherry in COS-7 cells immunolabelled with endogenous PABP, HSPA8 or IMP-1 or co-
transfected with KIF1C
WT
-GFP (control for co-localization). Co-localization between KIF1CWT and 
PABP is almost complete. KIF1C-HSPA8 co-localization is restricted to sites of KIF1C accumulation, 
and KIF1C-IMP1 co-localization is limited to a few specific spots. Fine dotted lines delimit nucleus 
and cell contours, scale bar: 20µm. 
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Figure 4. Co-localization of overexpressed KIF1C
G102A
 Images show distribution of overexpressed 
KIF1C
G102A
-cherry in COS-7 cells immunolabelled with endogenous PABP, HSPA8 or IMP-1, or co-
transfected with KIF1C
G102A
-GFP (control for co-localization). Mutant KIF1C
G102A 
loses its 
predilection for the cell periphery leading to redistribution of PABP, the co-localization between the 
two proteins is almost complete. HSPA8 is drawn to sites of KIF1C
G102A 
accumulation, while IMP-1 
and KIF1C
G102A 
co-localize in few specific spots. In summary, the distribution of the KIF1C
G102A 
complex is altered compared to KIF1C
WT
, however the extent of interaction with PABP, HSPA8 and 
IMP-1 seems unperturbed. Fine dotted lines delimit nucleus and cell contours, scale bar: 20µm. 
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Figure 5. RNAse-COIP experiment on HEK293T cells untransfected or overexpressing KIF1CWT-
HA. (A) KIF1CWT-HA and PABP co-immunoprecipitate either with anti-PABP or anti-HA antibodies. 
As expected no KIF1CWT-HA was pulled-down in the untransfected sample. Addition of RNAse I to 
the lysis buffer reproducibly led to a reduction in the affinity between KIF1C and PABP; 
quantification of this phenomenom is represented in (B) (n=3). (C) RNAse-COIP of HEK293T co-
expressing KIF1CWT-HA and PABP-GFP fusion proteins; both proteins co-immunoprecipitate with 
anti-GFP and anti-HA antibodies. As expected nothing was pulled-down with an IgG control antibody. 
Addition of RNAse I to the lysis buffer reproducibly led to a reduction in the affinity between 
KIF1CWT-HA and PABP-GFP; quantification of this phenomenom is represented in (D) (n=4). (E) 
Same experiment in HeLa cells using antibodies against endogenous KIF1C and PABP for co-
immunoprecipitation; quantification of this effect is represented in (F) (n=4). Bars in Graphs represent 
mean+SEM. Statistics: 1 way ANOVA with Dunnets test for (B) and unpaired t-tests for (D) and (F). 
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Figure 6. Identification and characterization of transcripts bound to KIF1C (A) Funnel shows the 
filtering of iCLIP sequencing data with PIPE-CLIP tool. (B) Confirmation of RNA transcripts bound 
to KIF1C was done through RIP and later RT-PCR of the recovered RNA. Agarose gels show the 
presence and over-representation on the IP-positive sample of 5 transcripts which were among the first 
10 genes with the highest peak score in the list (Table S3). GAPDH is representative of genes with 
low peak score and RPLP0 is a negative control. Left-side gels show cDNA from immunoprecipitated 
RNA of HEK293T overexpressing KIF1CWT-HA pulled-down with anti-HA or -IgG antibody; right-
side gels show cDNA from immunoprecipitated RNA of untransfected HEK293T. (C) Enrichment 
map of functional pathways in which the transcripts bound to KIF1C are involved. The network 
contains all genes present in at least 4 of the 8 replicates of the iCLIP experiment and annotated with 
DAVID bioinformatic functional tool. Node colors represent data source: GO-terms: red, Reactome: 
orange, Panther biological process: purple, Panther molecular function: yellow, RNA genes were 
added manually in green.  
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Figure 7. KIF1C interacts with Ribosomes (A) Images show fluorescent immunostainings of either 
endogenous KIF1C, overexpressed KIF1C
WT
-Cherry or KIF1C
G102A
-Cherry with the ribosomal protein 
S6 (RPS6) in COS-7 cells. In endogenous conditions KIF1C co-localizes with RPS6 at the tips of 
cellular protrusions, however after KIF1C overexpression almost all RPS6 is sequestered resulting in a 
stronger co-localization pattern. Fine dotted lines delimit nucleus and cell contours, scale bar: 20µm. 
(B) Co-staining of endogenous KIF1C and PABP in SH-SY5Y cells also shows co-localization at the 
cell verges. (C) Membrane shows how KIF1CWT-HA co-immunoprecipitates with RPS6 in HEK293T 
cells transfected with KIF1CWT-HA and pulled down with an anti-HA or anti-RPS6 antibody. As 
previously shown PABP protein also co-immunoprecipitates with KIF1CWT-HA and RPS6; as 
expected nothing was pulled down with the IgG control antibody (30µg of input sample was loaded as 
control). 
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Supplemental data 
Evaluation of other previously reported KIF1C interaction. 
KIF1C has been also implicated in the vesicular transport of α5-integrins (1). Indeed, overexpressed 
α5-integrin (ITGA5) and endogenous KIF1C seem to co-localize in the perinuclear region to some 
extent (Figure S5), however, this could not be confirmed when overexpressing KIF1CWT or 
KIF1CG102A (Figure S3, Figure S4). Moreover, we were not able to reproduce the perinuclear vesicular 
staining pattern for α5-integrin and KIF1C described by Theisen et al. in human retinal pigment 
epithelial cells (1). To exclude that we were missing the vesicular pattern due to artifacts of 
paraformaldehyde cell fixation we repeated the experiment under live cell conditions in COS-7 cells 
co-transfected with plasmids respectively encoding for ITGA5 and KIF1CWT, which were kindly 
provided by Theisen et al., nevertheless we could not reproduce the co-localization pattern described 
by them (1) (data not shown).  
References 
1. Theisen U, Straube E, Straube A. Directional Persistence of Migrating Cells Requires Kif1C-
Mediated Stabilization of Trailing Adhesions. Dev. Cell 2012;23(6):1153–1166. 
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Supplemental figures 
 
Figure S1. KIF1C pull-down Images represent two different silver stained SDS-PAGE gels to detect 
all loaded proteins with high sensitivity. Samples correspond to COS-7 (A) cells overexpressing 
KIF1C
WT
 (Lanes 1,4), KIF1C
G102A 
(2,5) or KIF1C
P176L
 (3,6) lysates of which were co-
immunprecipitated with an anti-HA or an IgG control antibody. (B) Same experiment as in (A) but 
done in HEK293T cells. Arrowheads pinpoint protein bands that were overrepresented in lanes 1-3 
compared to lanes 4-6. These bands were cut and analyzed by Mass Spectometry. 
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Figure S2. Co-localization of endogenous KIF1C Images show fluorescent immunostainings in 
COS-7 cells of endogenous KIF1C co-localizing with PABP at specific peripheral regions and 
partially around the nucleus. KIF1C co-localizes with HSPA8 mostly in a perinuclear manner, and 
with IMP-1 also around the nucleus. Fine dotted lines delimit nucleus and cell contour, scale bar 
20µm. 
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Figure S3. Study of overexpressed KIF1CWT co-localization Images show distribution of 
overexpressed KIF1CWT-cherry in COS-7 cells immunolabelled with markers for endoplasmic 
reticulum (pmKate2-ER), Golgi (GM130), mitochondrial network (TRAK2), α5-integrin (pEGFPN3-
ITGA5) and BICD2 protein. KIF1C does not seem to co-localize with any of the markers displayed 
here. Fine dotted lines delimit nucleus and cell contour, scale bar 20µm.  
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Figure S4. Study of overexpressed KIF1C
G102A
 co-localization Images show distribution of 
overexpressed KIF1C
G102A
-cherry in COS-7 cells immunolabelled with markers for endoplasmic 
reticulum (pmKate2-ER), Golgi (GM130), mitochondrial network (TRAK2), α5-integrin (pEGFPN3-
ITGA5) and BICD2 protein. KIF1C does not seem to co-localize with any of the markers displayed 
here.  Fine dotted lines delimit nucleus and cell contour, scale bar 20µm. 
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Figure S5. Study of endogenous KIF1C co-localization Images show immunofluorescent co-
stainings of endogenous KIF1C with markers for endoplasmic reticulum (pmKate2-ER), Golgi 
(GM130), mitochondrial network (TRAK2) and α5-integrin (pEGFPN3-ITGA5) in COS-7 cells. 
KIF1C does not appear to co-localize with any of the markers for ER, Golgi or mitochondria, although 
it might co-localize in few restricted points with ITGA5 around the nucleus. Fine dotted lines delimit 
nucleus and cell contour, scale bar 20µm. 
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Figure S6. Overexpression of KIF1C
G102A
 does not affect the actin cytoskeleton. Images show 
COS-7 cells either untransfected or transfected with KIF1C
WT
-cherry or KIF1C
G102A
-cherry 
respectively and immunolabelled with ß-actin to visualize the actin cytoskeleton. Fine dotted lines 
delimit nucleus and cell contour, scale bar 20µm. 
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Figure S7. Overexpression of KIF1C
G102A
 does not affect the microtubular architecture. Images 
show COS-7 cells either untransfected or transfected with KIF1C
WT
-cherry or KIF1C
G102A
-cherry 
respectively and immunolabelled with ß-tubulin to visualize microtubular network. Fine dotted lines 
delimit nucleus and cell contour, scale bar 20µm. 
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Figure S8. KIF1C expression and PABP co-immunoprecipitation depending on the cell type. (A) 
Western blot membrane shows co-immunoprecipitation of endogenous KIF1C with PABP performed 
on different cell lines, using an antibody against KIF1C or a control IgG antibody. HeLa cells seem to 
work best for this experiment. (B) Graph shows the relative amount of KIF1C per GAPDH as a way to 
address relative protein expression depending on the cell type (normalized to COS-7 cells), bars 
represent mean + SEM (n = 2-5). 
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Figure S9. iCLIP experiment and analysis (A) Ponceau staining of nitrocellulose membrane reveals 
all loaded proteins. Blue region delimits where KIF1C-RNA complex is located, which was cut out to 
isolate RNA. (B) The high sensitivity Agilent DNA chip shows amplification of high and medium size 
fragments of cDNA for KIF1C-mCherry_crosslinked (CL) sample. As expected nothing is amplified 
on any of the fractions of the negative controls “empty-mCherry_CL” (lanes 1-3) and “KIF1C-
mCherry_non-crosslinked” (lanes 4-6), thus proving the efficiency of the method. (C) Represents the 
peak score distribution of KIF1C-bound gene transcripts extracted from Table S3. 
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Figure S10. Quality control for RNA-immunoprecipitation Bioanalyzer analysis shows presence 
and quality of RNA for the different samples.  
  
 47 
 
Tables 
Protein hits Name Mass Score Matches Peptides emPAI 
gi|11935049 Keratin I 66198 963 39(37) 15(15) 1.27 
gi|547754 Keratin, type II 66110 876 31(29) 14(13) 1.15 
gi|40254834 Kinesin family member 1C 123725 791 25(21) 14(12) 0.51 
gi|28317 Unnamed protein product 59720 796 30(29) 12(12) 1.07 
gi|693937 Polyadenylate binding protein II 58709 511 17(17) 9(9) 0.74 
gi|55956899 Keratin 9 62255 464 12(12) 7(7) 0.59 
gi|5729877 Heat schock 70KDa protein 8 isoform 1 71082 360 15(15) 5(5) 0.43 
gi|56237027 Insulin-like growth factor 2 mRNA binding protein 1 63783 328 8(8) 6(6) 0.4 
gi|386785 Heat shock protein 70110 310 11(11) 5(5) 0.29 
gi|119581150 Keratin 14 44865 237 10(9) 4(4) 0.38 
gi|386850 Keratin 5 54649 185 5(5) 3(3) 0.22 
gi|30795212 Insulin-like growth factor 2 mRNA binding protein 3 64008 113 3(2) 2(1) 0.12 
gi|37460 Unnamed protein product 27329 72 1(1) 1(1) 0.14 
gi|292059 MTHSP75 74019 64 4(4) 1(1) 0.05 
gi|16751921 Dermicidin preprotein 11391 57 2(1) 1(1) 0.35 
gi|51476370 Hypothetical protein 199652 48 2(2) 1(1) 0.02 
gi|114682771 Predicted: similar to ribosomal protein L36 
(P.troglodytes) 
5528 45 1(1) 1(1) 0.78 
gi|20149993 Chain A, structure of Human Trysin IV 24832 43 1(1) 1(1) 0.15 
 
Table S1. Protein hits found by Mass spectrometry  
Proteins followed up functionally are marked in bold font. The remaining peptides mapped mostly to 
keratins, probably due to contamination during handling, and to KIF1C which presence is likely 
attributable to its abundance after KIF1C overexpression. 
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Rep. 
 
sequencing 
paired-reads 
mapped 
pair-end  
(Bowtie2) 
# reads 
after 
filtering 
reliable 
mutations 
clusters 
enriched 
clusters 
CL 
mutations 
CL 
candidate 
sites 
# genes 
1 118680109 38978481 394871 2926 3654 1010 1792 567 405 
2 151318478 48552947 495051 3065 3904 1105 1895 623 439 
3 171310069 55163189 564032 3070 3937 1122 1891 633 450 
4 194101960 62960780 650985 3190 4074 1203 1977 668 472 
5 117122886 21077481 212942 2651 3128 743 1602 444 307 
6 145283635 46230734 469958 3018 3768 1075 1878 609 434 
7 173089145 55665454 570315 3091 3895 1127 1898 630 449 
8 184224256 58944226 611268 3124 3896 1138 1934 645 456 
mean 156891317 48446661 496178 3017 3782 1065 1858 602 426 
stdev 28808260 13425569 140654 167 291 141 116 70 52 
min 117122886 21077481 212942 2651 3128 743 1602 444 307 
max 194101960 62960780 650985 3190 4074 1203 1977 668 472 
Rep.: replicate, #: number of, CL: crosslinking  
Table S2. PIPE-CLIP analysis of iCLIP sequencing data 
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 Sum Peak Score in sample Ranking in sample   
Gene 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 Present in Mean Peak Score 
RNA45S5 82841 104145 120074 135786 44940 99078 119569 127662 1 1 1 1 1 1 1 1 8 104736 
KIF1C 30802 38287 43893 50048 16850 36436 43773 46624 2 2 2 2 2 2 2 2 8 38594 
HYDIN 7678 9899 10513 14022 4035 9431 11825 13525 3 3 3 3 3 3 3 3 8 10051 
RNA5-8S5 4605 5648 6566 7474 2391 5314 6527 7098 4 5 5 4 4 4 4 4 8 5714,6 
HFM1 1554 2066 2391 2710 900 1968 2391 2553 6 6 6 5 6 6 6 5 8 2073,1 
SLC26A3 1193 1360 1461 2005 565 1321 1643 1820 7 7 7 6 7 7 7 6 8 1416,8 
PDE3A 917 1156 1207 1498 472 1067 1280 1363 8 8 8 7 8 8 8 7 8 1124,5 
RAPGEF6 662 882 983 1314 338 809 1088 1343 9 9 9 8 9 9 9 8 8 910,15 
LINC01019 552 758 784 991 283 715 845 1017 10 10 11 9 11 10 10 9 8 736,54 
RPS29 542 704 783 781 283 642 771 865 12 11 12 14 12 11 12 10 8 675,26 
MFSD11 552 677 819 903 299 637 786 826 11 12 10 10 10 12 11 11 8 690,82 
SLCO5A1 502 593 695 785 268 597 685 805 13 14 15 13 14 14 14 12 8 619,87 
MAZ 471 634 727 827 281 603 762 798 14 13 13 12 13 13 13 13 8 639,92 
EFTUD1P1 
 
575 657 835 
 
559 660 762 
 
15 16 11 
 
15 15 14 6 445,08 
MALAT1 382 460 559 656 176 510 511 657 17 18 20 17 21 16 21 15 8 483,9 
GARS 373 534 703 673 208 461 606 613 18 16 14 16 18 17 16 16 8 518,2 
FN1 412 443 628 682 223 437 575 608 16 21 18 15 17 20 17 17 8 503,15 
HSPA1B 318 428 636 631 105 406 546 594 22 22 17 19 83 21 19 18 8 437,99 
CCDC107 415 457 561 642 226 445 553 578 15 19 19 18 15 19 18 19 8 490,82 
DCTN1 352 461 540 544 224 451 531 565 19 17 21 24 16 18 20 20 8 466,23 
RPL23 284 451 467 561 152 355 466 560 31 20 25 22 25 29 23 21 8 405,71 
BRD4 312 390 488 559 182 381 483 541 24 26 24 23 19 24 22 22 8 417,1 
MKNK1 226 342 359 563 106 295 414 536 57 37 47 21 79 50 35 23 8 341,28 
CDH11 347 400 530 588 174 393 443 508 20 24 22 20 22 23 25 24 8 422,76 
PPP1R7 285 370 410 532 182 367 448 507 29 27 31 26 20 27 24 25 8 390,13 
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BYSL 298 396 419 505 149 369 416 476 26 25 27 28 26 25 33 26 8 377,57 
SLC30A10 286 318 349 463 145 312 421 469 28 46 53 34 30 44 32 27 8 345,35 
ZFP64 258 367 417 536 136 347 424 467 40 28 29 25 39 31 31 28 8 363,4 
HIST2H2AA3 315 405 498 514 119 394 440 464 23 23 23 27 54 22 27 29 8 386,53 
IMP4 284 366 426 480 147 345 410 460 30 29 26 31 28 32 36 30 8 363,95 
WDFY3 259 362 400 497 140 340 442 453 39 31 34 29 36 33 26 31 8 358,22 
PIM3 329 356 419 493 157 368 424 438 21 32 28 30 23 26 30 32 8 375,69 
PCNX 269 346 413 411 141 351 416 435 36 34 30 50 35 30 34 33 8 348,23 
PCGF3 276 314 371 449 142 314 372 434 33 49 43 38 33 42 46 34 8 334,86 
TMC7 271 324 383 438 144 315 399 424 35 44 39 43 31 41 38 35 8 338,25 
TACC3 221 261 333 473 132 259 371 419 61 73 57 33 42 67 48 36 8 305,66 
NCBP2 232 319 367 458 111 316 366 418 56 45 46 35 68 40 51 37 8 317,51 
C18orf54 247 308 370 420 113 316 375 415 45 50 44 47 63 39 44 38 8 316,54 
MDK 301 336 386 477 132 358 428 414 25 38 37 32 41 28 28 39 8 352,74 
KNTC1 222 316 373 436 134 300 350 413 60 48 42 44 40 48 57 40 8 316,73 
AKAP13 242 282 388 412 149 316 389 411 48 60 36 49 27 37 41 41 8 325,72 
NUP107 250 336 407 447 132 307 391 404 44 39 33 41 44 45 40 42 8 332,32 
EIF4H 233 304 347 380 70 281 362 389 53 52 54 60 166 54 52 43 8 285,84 
LAMC1 237 331 389 389 140 283 408 388 50 42 35 56 37 52 37 44 8 321,66 
CHAF1A 279 332 410 452 154 317 394 383 32 40 32 37 24 35 39 45 8 343,43 
OAZ1 243 328 333 448 132 301 359 383 47 43 55 40 43 47 53 46 8 315,81 
DENR 253 354 378 448 146 330 374 382 43 33 41 39 29 34 45 47 8 335,19 
HIST2H2BC 257 346 385 445 124 313 385 377 41 35 38 42 48 43 43 48 8 327,09 
GTF2H1 223 332 355 373 138 241 371 375 59 41 50 61 38 76 49 49 8 302,84 
COL1A1 220 304 370 430 110 282 351 371 62 53 45 45 70 53 55 50 8 300,25 
 
Table S3. Gene list resulting from iCLIP data filtering with PIPE-CLIP; only first 50 genes (Total: 515) are represented.
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Primer name Sequence Application 
 kif1c_topo_for  atggctggtgcctcgg Cloning 
 kif1c_topo_nonstop_rev  tcacagctgccccact Cloning 
 kif1c_g305c_for   gcagaccggggctgcgaaatcctataccat Mutagenesis 
 kif1c_g305c_rev  atggtataggatttcgcagccccggtctgc Mutagenesis 
 kif1c_c527t_for  cccatcctgggcctgtacgtgcaggac Mutagenesis 
 kif1c_c527t_rev  gtcctgcacgtacaggcccaggatggg Mutagenesis 
 kif1c_a901g_for  ggattttatcccctacggggactctgtgctcac Mutagenesis 
 kif1c_a901g_rev  gtgagcacagagtccccgtaggggataaaatcc Mutagenesis 
 BamHI-kif1c_for  taggatccatggctggtgcctcggtg Cloning 
 kif1c-ha-XhoI_rev  atctcgagtcaagcgtaatctggaacatcgtatgggtacacagctgccccactctcc Cloning 
 kif1c_seq_1_for  gtgaaagtggcagtgagggt Sequencing 
 kif1c_seq_2_rev  cctccgtcgaagtgtgtgac Sequencing 
 kif1c_seq_2_for  ctcttgaaccccaagagtcg Sequencing 
 kif1c_seq_3_for  gctgctcaaggaaaatttgg Sequencing 
 kif1c_seq_4_for  agaggctgcaggagacagag Sequencing 
 kif1c_seq_5_for  agaaccacgttttccgcttc Sequencing 
 kif1c_seq_6_for  tcgcagggtttatcagatcc Sequencing 
 kif1c_seq_7_for  gatcagaggcagcagaggag Sequencing 
 kif1c_seq_8_for  gcaggaactccctggatg Sequencing 
 kif1c_for_ex16-17  ctccaaagaagactccccacc qPCR 
 kif1c_rev_ex19  ctccgtcacaagcttcccat qPCR 
rna28s5_for acctctcacgtctcttcacc qPCR 
rna28s5_rev aggcgcatgaatggatgaac qPCR 
gapdh_qpcr_for  cctgttcgacagtcagccgcat qPCR 
 gapdh_qpcr_rev  caggcgcccaatacgaccaa qPCR 
actb_qpcr_for cgcgagaagatgacccagat qPCR 
actb_qpcr_rev tcaccggagtccatcacgat qPCR 
 hydin_qpcr2_for  gcggggaatggaggtagaat qPCR 
 hydin_qpcr2_rev  tctgagggtgtaagcattcgg qPCR  
 hfm1_qpcr_for  tgtccgcagggagatttatgac qPCR 
 hfm1_qpcr_rev  agcaggagggagaaaccaatc qPCR 
 pde3a_qpcr_for  tcccggtgtttaagaggagg qPCR 
 pde3a_qpcr_rev  ggttcctgaagactgtgatcct qPCR 
 rapgef6_qpcr_for  cttgcctccttgcagttttgg  qPCR 
 rapgef6_qpcr_rev  aatggtttggcgctctcctt  qPCR 
 rplp0_qpcr_f  acgggtacaaacgagtcctg qPCR 
 rplp0_qpcr_r  cgactcttccttggcttcaa qPCR 
 
Table S4. Primers used in the study 
  
 
 
